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Introduction
Although major advancements have been achieved in prognostication and treatment of 
patients with atherosclerosis, cardiovascular (CV) disease (CVD) remains the number 
one cause of death globally. In Europe alone, every year 3.9 million people die from the 
eff ects of atherosclerosis (Figure 1).1 
Atherosclerosis is an acquired chronic condition, which may cause ischemic heart 
disease (IHD) including stable angina pectoris (SAP) or acute coronary syndrome 
(ACS), the collective term for unstable angina pectoris, non ST-elevation myocardial 
infarction and ST-elevation myocardial infarction. Patients who are diagnosed with IHD 
are at high risk of developing (recurrent) CV events. Moreover, patients who experience 
a recurrent CV event are 2.5 times more likely to die of that event, than fi rst-time expe-
riencers.2 Within the fi rst year after hospital discharge, the death rate in IHD patients is 
as high as 9%.3 Without proper treatment, the annual death rate remains on average 
5% hereafter, resulting in a cumulative death rate of almost 80 percent 15 years post 
hospital discharge in IHD patients (Figure 2).3
 
2 
 
Chapter 1 
 
Introduction 
Although major advancements have been achieved in prognostication and treatment of 
patients with atherosclerosis, cardiovascular (CV) disease (CVD) remains the number one cause 
of death globally. In Europe alone, every year 3.9 million people die from the effects of 
atherosclerosis (Figure 1).(1)  
    Atherosclerosis is an acquired chronic condition, which may cause ischemic heart disease 
(IHD) including stable angina pectoris (SAP) or acute coronary syndrome (ACS), the collective 
term for unstable angina pectoris, non ST-elevation myocardial infarction and ST-elevation 
myocardial infarction. Patients who are diagnosed with IHD are at high risk of developing 
(recurrent) CV events. Moreover, patients who experience a recurrent CV event are 2.5 times 
more likely to die of that event, than first-time experi ncers.(2) Within the first year after 
hospital discharge, the death rate in IHD patients is as high as 9%.(3) Without proper treatment, 
the nnual death rate remains on av rage 5% hereafter, r sulting in a cumulative death rate of 
almost 80 percent 15 years post hospit l discharge in IHD atients (Figure 2).(3) 
 
Figure 1. Causes of deaths in Europe by the European Cardiovascular Disease Statistics 2017 
   
   
    Currently, over 30 million people in Europe have established IHD, and, thus, are prone to 
recurrent CV events and cardiac death.(1) In recent decades, several clinical risk factors have 
been identified that advance pathological progression of atherosclerosis, such as diabetes 
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Figure 1. Causes of deaths in Europe by the European Cardiovascular Disease Statistics 2017
Currently, over 30 million people in Europe have established IHD, and, thus, are 
prone to recurrent CV events and cardiac death.1 In recent decades, several clinical risk 
factors have been identifi ed that advance pathological progression of atherosclerosis, 
such as diabetes mellitus, hy rtensio , hyperlipidaemia and smoking.4 These factors 
may be used to foster tailored treatment and monitoring during clinical follow-up. How-
ever, clinical risk factors do not refl ect the actual coronary atherosclerotic burden of a 
patient, nor are they a proxy for dynamic atherosclerotic changes. To further improve 
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risk stratifi cation of IHD patients, one should aim to eff ectuate a more precision-based 
approach to prognostication, and, eventually, to secondary preventive care in IHD 
patients. In particular, imaging modalities and circulation biomarkers may be of interest 
in this context.
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Figure 2. Cumulative death rate after hospital discharge in patients with IHD*  
*As described in Law et al.(3) 
  
    Atherosclerosis is a lipid driven inflammatory disease. The pathophysiology of the onset and 
progression of atherosclerosis is complex. Although atherosclerosis manifests itself in various 
forms, some key inflammatory processes have been established in the development and 
progression of atherosclerotic plaques in IHD.  
 
Atherosclerotic plaque formation 
In general, atherosclerotic plaques tend to form at coronary artery sites with disrupted blood 
flow, such as in curvatures and bifurcations of branches, where the vascular wall shear-stress is 
distributed irregularly. Constant wall shear-stress is a requisite for well-functioning stable 
endothelial cells and stimulates atheroprotective pathways.(5) In case of disturbed wall shear-
stress, flow-initiated inflammatory factors are activated in the endothelium and may change 
endothelial cells in dysfunctional cells. These cells may induce multiple processes associated 
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Figure 2. Cumulative death rate after hospital discharge in patients with IHD* 
*As described in Law et al.(3)
Atherosclerosis is a lipid driven infl ammatory disease. The pathophysiology of the 
onset and progression of atherosclerosis is complex. Although atherosclerosis mani-
fests itself in various forms, some key infl ammatory processes have been established 
in the development and pr gression of atherosclerotic plaques in IHD. 
Atherosclerotic plaque formation
In general, atherosclerotic plaques tend to form at coronary artery sites with disrupted 
blood fl ow, such as in curvatures and bifurcations of branches, where the vascular 
wall shear-stress is distributed irregularly. Constant wall shear-stress is a requisite for 
well-functioning stable endothelial cells and stimulates atheroprotective pathways.5 In 
case of disturbed wall shear-stress, fl ow-initiated infl ammatory factors are activated in 
the endothelium and may change endothelial cells in dysfunctional cells. These cells 
may induce multiple processes associated with the onset of atherosclerotic plaque. 
13
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First, one of these early processes associated with plaque formation is the reduction 
in nitric oxide production by the dysfunctional endothelium.6 Nitric oxide is involved 
in various atheroprotective processes, and one of its major functions is endothelium-
dependent vasodilatation. Dysregulation of the vascular tone may induce vasospasms 
and early ischemia. 
Secondly, it has been established that the permeability of the endothelial wall changes 
during the onset of plaque formation.7, 8 The increasing permeability of the endothelial 
wall may induce infl ux of extracellular macromolecules. In the presence of high blood 
concentrations of lipoproteins, this may result in the migration and accumulation of 
lipoproteins in the endothelial wall. Sub-endothelial cell accumulation may be accompa-
nied by the recruitment of immune cells such as monocytes and T-lymphocytes.8 Under 
normal conditions, monocytes migrate into the endothelial wall to decrease further entry 
of infl ammatory cells and to diff erentiate in macrophages to absorb lipoproteins and 
eff erocytose apoptotic cells.9 However, under disturbed conditions, monocytes will ac-
cumulate increasingly, and fail to both reduce entry of other cells and remove abundant 
cells. Moreover, T-lymphocyte recruitment continues, promoting further infl ammation.
Lastly, under these disturbed conditions, the dysfunctional endothelium may upregu-
late the expression of adhesion molecules, facilitating the increasing sub-endothelial 
accumulation of lipoproteins and infl ammatory cells.8 Together, these processes pre-
cipitate the formation of an atherosclerotic plaque (Figure 3). 
Atherosclerotic plaque progression
The progression of a formed plaque is associated with sub-endothelial foam cell 
formation. Foam cell formation is initiated by oxidants produced by the dysfunctional 
endothelium. These oxidants modify sub-endothelial low-density lipoproteins (LDL).10, 11 
Subsequently, accumulated macrophages will absorb these modifi ed LDL molecules 
and turn into fat-laden macrophages called foam cells. Foam cells are prone to apop-
tosis and necrosis. Moreover, the foam cell production process is associated with in-
creased dysregulation of the sub-endothelial lipid metabolism and impairs the removal 
of cholesterol molecules by macrophages from the endothelial wall. 10, 11 Altogether, 
this process is responsible for increasing sub-endothelial lipoprotein accumulation and 
the formation of a necrotic core. At the same time, the chronic infl amed endothelium 
increases recruitment of monocytes and T-cells, advancing infl ammatory exacerbation 
(Figure 3).8
In reaction to these plaque destabilising processes, smooth muscle cells of the media 
may migrate to the intima of the artery wall.12 These smooth muscle cells can produce 
extra cellular matrix proteins which, in turn, stabilise the plaque by forming a fi brous cap 
around the atherosclerotic plaque cells. In addition, migrated smooth muscle cells may 
undergo apoptosis and calcify, which adds stability to the plaque.13 Consequently, an 
14
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advanced plaque may be characterised by chronic infl ammation, abundance of foam 
cells, necrotic core, smooth muscle cell infi ltration, calcifi cation, and a fi brous cap.
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Figure 3. Brief overview of the processes underlying atherosclerotic plaque progression  
 
Atherosclerotic plaque rupture  
A stable advanced plaque is characterised by a robust fibrous cap that is able to resist the 
vascular shear-stress on the endothelial wall, separating the atherosclerotic plaque cells from 
the blood stream.(14) However, if the integrity of the cap weakens, an advanced plaque may 
become vulnerable and rupture (Figure 3).(15) In response, atherosclerotic plaque cells will 
excrete large amounts of tissue factor, stimulating thrombus formation.(16) In addition, 
fibrinolytic pathways responsible for the stability of a thrombus will be activated.(14) a 
thrombus can subsequently partly or completely occlude a coronary artery, and cause ischemia 
and subsequent myocardial infarction.  
    In addition to the mechanism of plaque rupture described above, plaque erosion or calcified 
noduli of a stable plaque extending in the lumen of a coronary artery may also result in 
thrombosis causing ischemia and subsequent ACS.(17)  
 
Coronary imaging and biomarkers in ischemic heart disease 
As mentioned previously, to further improve risk stratification in IHD patients, parameters that 
feature the coronary atherosclerotic burden of these patients, and that reflect the dynamics of 
plaque progression are warranted. Potentially, these parameters may effectuate a more 
precision-based approached to prognostication in IHD patients. In this context, invasive imaging 
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infra-red spectroscopy (NIRS) and intra-vascular ultrasound (IVUS) may be of pivotal value. NIRS 
and IVUS can be used to quantify and qualify coronary atherosclerotic burden. NIRS is applied 
to measure the intracoronary lipid content of atherosclerosis by creating a chemogram of the 
coronary wall and expressing the detected amount of lipid tissue in a lipid core burden index 
(LCBI).(18) Grayscale IVUS is used to quantify total intracoronary plaque volume and burden 
and radiofrequency IVUS is used to qualify plaque components as fibrous, fibro-fatty, necrotic 
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Atherosclerotic plaque ruptu e 
A stable advanced plaque is characterised by a robust fi brous cap that is able to resist 
the vascular shear-stress on the endothelial wall, separating the atherosclerotic plaque 
cells from th  blood stream.14 However, if the integrity of the cap weakens, an dvanced 
plaque may become vulnerable a  rupture (Figur  3).15 In response, atherosclerotic 
plaque cells will excrete large amounts of tissue factor, stimulating thrombus forma-
tion.16 In addition, fi brinolytic pathways responsible for the stability of a thrombus will 
be activated.14 a thrombus can subsequently partly or completely occlude a coronary 
artery, and cause ischemia and subsequent myocardial infarction. 
In ddition to the mechanism of plaque rupture described above, plaque erosion or 
calcifi ed noduli of a stable plaque extending in the lumen of a coronary artery may also 
result in thrombosis causing ischemia and subsequent ACS.17 
Coronary imaging and biomarkers in ischemic heart disease
As mentioned previously, to further improve risk stratifi cation in IHD patients, param-
eters that feature the coronary atherosclerotic burden of these patients, and that refl ect 
the dynamics of plaque progression are warranted. Potentially, these parameters may 
eff ectuate a more precision-based approached to prognostication in IHD patients. In 
this context, invasive imaging modalities such as coronary angiography (CAG) or intra-
coronary imaging m dalities such s infra-red pectroscopy (NIRS) and intra-vascular 
ultrasound (IVUS) may be of pivotal value. NIRS and IVUS can be used to quantify and 
qualify coronary atherosclerotic burden. NIRS is applied to measure the intracoronary 
lipid content of atherosclerosis by creating a chemogram of the coronary wall and 
expressing the detected amount of lipid tissue in a lipid core burden index (LCBI).18 
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Grayscale IVUS is used to quantify total intracoronary plaque volume and burden 
and radiofrequency IVUS is used to qualify plaque components as fi brous, fi bro-fatty, 
necrotic core and dense calcium tissue.19, 20 Information on plaque characteristics might 
provide insights on the degree of a patient’s coronary atherosclerotic disease and the 
risk for future cardiac events.
In addition, circulation biomarkers are of interest, since they may serve as a proxy 
for atherosclerotic disease progression. A circulation biomarker is any substance mea-
surable in the blood that infl uences or refl ects changes in disease. Although the key 
mechanisms of plaque progression might be similar among patients, the actual triggers 
responsible for an event may diff er.21 Therefore, we need to identify (novel) biomarkers 
involved in infl ammatory pathways that advance plaque progression.
16
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Thesis outline 
In this thesis we assess the prognostic value of invasive imaging modalities and cir-
culation biomarkers in patients with established IHD. In the first  part, we study plaque 
extent and characteristics of patients admitted to the hospital with SAP or ACS under-
going CAG or percutaneous coronary intervention (PCI) and their follow-up. First, we 
assess in these patients at baseline the relationship between the SYNTAX score, an 
validated anatomical CAG-based prediction tool for long-term mortality, and coronary 
wall pathology as measured by NIRS and IVUS.  Secondly, we assess in these patients 
the long-term prognostic value of NIRS and IVUS. Lastly, we study the performance of 
the SYNTAX score II, the scoring tool incorporating both the anatomical-based SYNTAX 
score as well as clinical characteristics to predict long-term mortality in the patients 
admitted with one- or two-vessel disease.
In the second part of this thesis, we assess in detail the temporal patterns of various 
circulation biomarkers in patients admitted to the hospital with ACS, using repeated 
measurements during one year follow-up. As such, we are able to study the trajectory 
of these biomarkers after an ACS and prior to the development of recurrent CV events 
during follow-up. Moreover, we are able to assess the prognostic value of repeatedly 
measured circulation biomarkers, and may identify novel (inflammatory) modulators of 
recurrent CV events. In addition, we describe the intra-individual LDL variation during 
one year, in statin-treated post-ACS patients. Lastly, we establish in a systematic review 
whether auto-antibodies to oxidized LDL molecules are associated with the degree 
of coronary artery disease of a patient as quantified by CAG, NIRS or IVUS, and if 
these auto-antibodies are associated with coronary events in patients with and without 
prevalent IHD.
17
Introduction
REFERENCES
 1. Atlas Writing G, Timmis A, Townsend N, Gale C, Grobbee R, Maniadakis N, et al. European 
Society of Cardiology: Cardiovascular Disease Statistics 2017. Eur Heart J. 2018;39(7):508-
79.
 2. Pearte CA, Furberg CD, O’Meara ES, Psaty BM, Kuller L, Powe NR, et al. Characteristics 
and baseline clinical predictors of future fatal versus nonfatal coronary heart disease events 
in older adults: the Cardiovascular Health Study. Circulation. 2006;113(18):2177-85.
 3. Law MR, Watt HC, Wald NJ. The underlying risk of death after myocardial infarction in the 
absence of treatment. Arch Intern Med. 2002;162(21):2405-10.
 4. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European 
Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task 
Force of the European Society of Cardiology and Other Societies on Cardiovascular Dis-
ease Prevention in Clinical Practice (constituted by representatives of 10 societies and by 
invited experts)Developed with the special contribution of the European Association for 
Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-81.
 5. Traub O, Berk BC. Laminar shear stress: mechanisms by which endothelial cells transduce 
an atheroprotective force. Arterioscler Thromb Vasc Biol. 1998;18(5):677-85.
 6. Forstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I, et al. Nitric oxide 
synthase isozymes. Characterization, purification, molecular cloning, and functions. Hyper-
tension. 1994;23(6 Pt 2):1121-31.
 7. Komarova Y, Malik AB. Regulation of endothelial permeability via paracellular and transcel-
lular transport pathways. Annu Rev Physiol. 2010;72:463-93.
 8. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines in 
atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31(5):969-79.
 9. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat 
Rev Immunol. 2013;13(10):709-21.
 10. McLaren JE, Michael DR, Ashlin TG, Ramji DP. Cytokines, macrophage lipid metabolism and 
foam cells: implications for cardiovascular disease therapy. Prog Lipid Res. 2011;50(4):331-
47.
 11. Lusis AJ. Atherosclerosis. Nature. 2000;407(6801):233-41.
 12. Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: 
the pathologists’ view. Eur Heart J. 2013;34(10):719-28.
 13. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll 
Cardiol. 2006;47(8 Suppl):C13-8.
 14. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91(11):2844-
50.
 15. Lafont A. Basic aspects of plaque vulnerability. Heart. 2003;89(10):1262-7.
 16. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal 
vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A. 1989;86(8):2839-
43.
 17. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary 
death: a comprehensive morphological classification scheme for atherosclerotic lesions. 
Arterioscler Thromb Vasc Biol. 2000;20(5):1262-75.
 18. Waxman S, Dixon SR, L’Allier P, Moses JW, Petersen JL, Cutlip D, et al. In vivo validation 
of a catheter-based near-infrared spectroscopy system for detection of lipid core coronary 
18
Chapter 1
plaques: initial results of the SPECTACL study. JACC Cardiovasc Imaging. 2009;2(7):858-
68.
 19. Garcia-Garcia HM, Costa MA, Serruys PW. Imaging of coronary atherosclerosis: intravas-
cular ultrasound. Eur Heart J. 2010;31(20):2456-69.
 20. Garcia-Garcia HM, Mintz GS, Lerman A, Vince DG, Margolis MP, van Es GA, et al. Tissue 
characterisation using intravascular radiofrequency data analysis: recommendations for 
acquisition, analysis, interpretation and reporting. EuroIntervention. 2009;5(2):177-89.
 21. Buffon A, Biasucci LM, Liuzzo G, D’Onofrio G, Crea F, Maseri A. Widespread coronary 
inflammation in unstable angina. N Engl J Med. 2002;347(1):5-12.


Chapter 2 
SYNTAX score in relation to intravascular ultrasound 
and near-infrared spectroscopy for the assessment 
of atherosclerotic burden in patients with 
coronary artery disease
Maxime M. Vroegindewey*,  Anne-Sophie Schuurman*,  Isabella Kardys,  Sharda S. Anroedh, 
Rohit M. Oemrawsingh, Jurgen Ligthart, Hector M. Garcia-Garcia, Robert-Jan M. van Geuns, 
Evelyn Regar,  Nicolas M. van Mieghem, Patrick W. Serruys, Eric Boersma, K. Martijn Akkerhuis 
*These authors contributed equally.
EuroIntervention. 2019; 14:1408-1415. 
22
Chapter 2 
ABSTRACT
Aims
To examine the relationship between the anatomical SYNTAX score (SXscore), derived 
from all three coronary arteries, and coronary wall pathology measured by radiofre-
quency-intravascular ultrasound (RF-IVUS) and near-infrared spectroscopy (NIRS) in a 
single non-culprit segment.
Methods and results
In patients referred for coronary angiography (N=88) or PCI (N=592) for stable angina 
or acute coronary syndrome, the SYNTAX score calculator (www.syntaxscore.com) was 
used to determine SXscore before PCI, if applicable. RF-IVUS and/or NIRS were per-
formed in a non-stenotic 40 mm study segment following the clinically indicated angiog-
raphy/PCI. After adjustment for multiple confounders, a higher SXscore was associated 
with higher segmental plaque volume in the study segment (2.21 mm3 per SXscore 
point, 95%CI 0.92-3.50, p-value 0.001), as well as with higher volume of fibrous (0.93 
mm3 per point) and fibro-fatty tissue (0.29 mm3 per point). A higher SXscore was also 
associated with a higher NIRS-derived lipid core burden index in the full study segment 
(1.35 units per SXscore point, 95%CI 0.22-2.47, p-value 0.019). Importantly, SXscore 
correlated with the fatty/fibro-fatty and LCBI signals despite adjusting for plaque burden.
Conclusions
In patients with CAD, higher SXscores are associated with higher atherosclerotic burden 
as assessed by RF-IVUS and NIRS in a single non-stenotic coronary artery segment.
23
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INTRODUCTION
The SYNTAX score (SXscore) is an angiographic tool that grades the complexity of 
coronary artery disease (CAD) and is also used for short- and long-term prediction of 
major adverse cardiac events (MACE) in patients undergoing percutaneous coronary 
intervention (PCI) and/or coronary artery bypass graft surgery (CABG).1-2 The severity 
and composition of coronary atherosclerosis as assessed by (radiofrequency-)intravas-
cular ultrasound (RF-IVUS) and near-infrared spectroscopy (NIRS) in one (non-)ste-
notic coronary artery segment have recently also shown prognostic value for MACE.3-8 
Furthermore, RF-IVUS and NIRS in one (non-)stenotic coronary artery segment have 
previously been used to evaluate the effects over time of anti-atherosclerotic therapy 
under the assumption that these assessments are representative of the total coronary 
atherosclerotic burden.9 However, it has never been investigated in a large cohort how 
well the atherosclerotic burden as graded by NIRS and RF-IVUS measured in one 
(non-) stenotic coronary artery segment correlates with the atherosclerotic burden as 
assessed by the SXscore which is derived from all three coronary arteries. 
It is important to realize that the three methods differ from each other in the assess-
ment and quantification of CAD. The SXscore is an anatomical scoring tool that grades 
luminal coronary obstruction, directly from the coronary angiography (CAG). Therefore, 
it lacks detail with respect to coronary artery wall pathology. Conversely, RF-IVUS and 
NIRS have been shown to provide information on plaque morphology in the imaged 
coronary segment. However, both of these imaging techniques require additional intra-
coronary catheters, whereas the SXscore itself does not require instrumentation of the 
coronary lumen.
The aim of this study is to examine the relationship between the coronary atheroscle-
rotic burden measured as luminal coronary obstruction graded by the SXscore, derived 
from all three coronary arteries, and the atherosclerotic burden by assessing coronary 
artery wall pathology measured by RF-IVUS and NIRS in one non-stenotic segment of 
a single non-culprit coronary artery.
METHODS
Study population
This study constitutes a combined analysis of two cohorts: The European Collabora-
tive Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis-IVUS 
(ATHEROREMO-IVUS) study and the Integrated Biomarker and Imaging Study-3 (IBIS-
3). The design of both studies has been described elsewhere.9-11 In total, 770 patients 
with an indication for diagnostic CAG and/or PCI due to either stable angina pectoris 
24
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(SAP) or an acute coronary syndrome (ACS) were included and had a RF-IVUS and/or 
NIRS performed in a non-stenotic segment of a non-culprit coronary artery.
Both studies were approved by the Medical Ethics Committee of the Erasmus MC 
and performed in accordance with the Declaration of Helsinki. Written informed consent 
was obtained from all included patients. ATHEROREMO-IVUS is registered in Clini-
calTrials.gov, number NCT01789411, and IBIS-3 is registered in The Netherlands trial 
register, number NTR2872.
Coronary intravascular ultrasound and near-infrared spectroscopy 
RF-IVUS and NIRS methods have been described in detail previously.9-11 For a compre-
hensive methods section, refer to the Supplementary Methods.
SYNTAX Score
The SXscore was calculated (pre-PCI) for every CAG taken at study entry using the 
SYNTAX Score calculator (www.syntaxscore.com). Details concerning the calculation 
of the SXscore have been described elsewhere.1 In brief, the three coronary arteries are 
divided in 16 segments, each with a corresponding weighting factor. If there is a lesion 
producing 50% or more luminal obstruction, the weighting factor is added. Moreover, 
other factors that reflect the severity of the atherosclerotic lesion and the possible dif-
ficulty of a percutaneous treatment, for example lesion length and diffuse disease of the 
vessel, are taken into account. Eventually, all points are summed to obtain the SXscore 
reflecting the complexity of the CAD of the patient.
As applied in other all-comers and ST-segment elevation myocardial infarction 
(STEMI) populations, lesions caused by in-stent restenosis were considered as de novo 
lesions.12-14 Occlusions in patients presenting with ACS were scored as occlusions of 
unknown duration, as the analyst was blinded to all other patient information.15 
In case of a codominant coronary artery circulation, the vessel mainly responsible for 
the perfusion of the posterior side of the heart was designated as the dominant coronary 
artery. Last, patients with a pre-existing CABG, whose CAG is unquantifiable using the 
SXscore, were excluded. 
The SXscores were determined by a trained analyst who was blinded with respect to 
other patient characteristics and clinical outcome.
Statistical analysis
Categorical variables are presented as numbers and percentages. The distribution of 
the continuous variables, including RF-IVUS and NIRS parameters, was examined for 
normality with Kolmogorov-Smirnov tests. Normally-distributed continuous variables 
are presented as mean ± standard deviation(SD). Non-normally distributed continu-
ous variables are presented as median and interquartile range(IQR). SXscores were 
25
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categorized into tertiles based on the distribution of the SXscores in the particular group 
that was being examined. Kruskal-Wallis tests were used for multiple group comparison 
of continuous variables. Categorical variables were compared using Pearson Chi-
square tests or Fisher-Freeman-Halton Exact tests when appropriate.
Linear and logistic regression analyses were applied to evaluate the relation be-
tween SXscore (explanatory) and RF-IVUS- and NIRS-derived (dependent) variables. 
Variables concerning plaque volume were first normalized for the imaged segment 
length (i.e. normalized plaque volume=plaque volume / imaged segment length*median 
segment length of study population). In multivariable analyses, age, gender, hyperten-
sion, renal impairment, hypercholesterolemia, diabetes mellitus, smoking, indication for 
CAG, history of PCI, as well as segmental plaque burden were entered as potential 
confounders/explanatory factors. Thus, the models allow to conclude on the relation 
between SXscore and the RF-IVUS/NIRS imaging signals, irrespective of the patient’s 
segmental plaque burden. Assumptions underlying linear regression models were 
evaluated by visual examination of the residuals.
All statistical tests were 2-tailed and p-values <0.05 were considered significant. 
SPSS, Version 21.0 (IBM Corp., Armonk, NY, USA) was used for all the analyses.
RESULTS
Baseline characteristics
The current study included 680 patients from the combined ATHEROREMO-IVUS and 
IBIS-3 cohorts (Figure 1). The overall SXscore ranged from 0 to 37.5 with a median 
of 7 (IQR:3-13) and a mean of 8.6±7.4. Baseline clinical and angiographic variables 
were stratified according to tertiles reflecting the obtained Sxscores (lowest tertile, ≤4; 
middle tertile, >4 to ≤10; highest tertile >10, Table 1). The highest tertile comprised more 
men. As expected, more patients in the higher tertiles exhibited 2-or 3-vessel disease, 
whereas no significant stenosis or 1-vessel disease was more frequently present in 
patients with the lowest SXscores. More patients with lower SXscores had previously 
undergone a PCI.
Coronary intravascular ultrasound in relation to SXscore
After adjustment for multiple confounders/explanatory factors, a higher SXscore was 
associated with a higher plaque volume in the study segment (2.21 mm3 per SXscore 
point, 95%CI 0.92-3.50, p-value 0.001) (Table 2). The relation between SXscore and 
plaque burden was consistent with this observation, although statistically non-significant 
(p-value 0.078). A higher SXscore was also associated with a higher volume of fibrous 
(0.93 mm3 per SXscore point, 95%CI  0.53-1.33, p-value <0.001) and fibro-fatty tissue 
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(0.29 mm3 per SXscore point, 95% CI 0.17-0.42, p-value <0.001) (Tables 2, Figure 2). 
Importantly, the SXscore correlated with the fatty/fibro-fatty signals despite adjusting 
for plaque burden. In contrast, we found no association  between SXscore and necrotic 
core volume (p-value 0.16) or the presence of TCFA (p-value 0.46).
Figure 1. Patient inclusion 
RF-IVUS is available in 670 patients(light grey) and NIRS is available in 259 patients(dark grey).
ATHEROREMO-IVUS: The European Collaborative Project on Inflammation and Vascular Wall Remodeling in 
Atherosclerosis-IVUS study, IBIS-3:Integrated Biomarker and Imaging Study-3, NIRS: near-infrared spectroscopy 
RF-IVUS: radiofrequency intravascular ultrasound, SXscore: SYNTAX score
Figure 2. Distribution of RF-IVUS derived plaque components across the SXscore categorized 
in tertiles 
The mean volumes of the different plaque components: fibrous, fibro-fatty, dense calcium and necrotic tissue are 
divided across the SXscore categorized in tertiles (cut-off points 4 and 10).
RF-IVUS: radiofrequency intravascular ultrasound SXscore: SYNTAX score
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Table 1. Baseline characteristics 
Low SXscore Mid SXscore High SXscore
p-value≤4 
(n=236)
>4 to ≤10 
(n=221)
>10
(n=223)
Patient characteristics     
Age, years 60.4±10.9 61.3±10.7 61.2±11.0 0.70
Men, n(%) 169(71.6) 169(76.5) 184(82.5) 0.022
Risk factors
Diabetes Mellitus, n(%) 48(20.3) 42(19.0) 40(17.9) 0.79
Hypertension, n(%) 130(55.1) 130(58.8) 107(48.0) 0.064
Hypercholesterolemia, n(%) 119(50.4) 138(62.4) 118(52.9) 0.028
Smoking, n(%) 63(26.7) 66(29.9) 70(31.4) 0.55
History 
Positive family history, n(%) 138(58.5) 117(52.9) 101(45.3) 0.018
Previous myocardial infarction, n(%) 79(33.5) 59(26.7) 61(27.4) 0.21
Previous PCI, n(%) 94(39.8) 63(28.5) 52(23.3) <0.001
Previous stroke, n(%) 15(6.4) 12(5.4) 15(6.7) 0.84
History of peripheral artery disease, n(%) 12(5.1) 19(8.6) 14(6.3) 0.31
History of renal insufficiency, n(%) 13(5.5) 10(4.5) 11(4.9) 0.89
History of heart failure, n(%) 8(3.4) 4(1.8) 5(2.2) 0.56
Procedural characteristics     
Indication for coronary angiography 0.001
Stable angina, n(%) 130(55.1) 95(43.0) 88(39.5)
Acute coronary syndromes, n(%) 106(44.9) 126(57.0) 135(60.5)
Extent of coronary artery disease <0.001
No significant stenosis, n(%) 91(38.6) 1(0.5) 0(0.0)
1-vessel disease, n(%) 134(56.8) 138(62.4) 72(32.3)
2-vessel disease, n(%) 11(4.7) 69(31.2) 114(51.1)
3-vessel disease, n(%) 0(0.0) 13(5.9) 37(16.6)
Imaged coronary artery characteristics     
Imaged segment length, mm 44.7±14.1 42.6±13.1 44.4±14.7 0.17
Imaged coronary artery for RF-IVUS 0.004
Left anterior descending, n(%) 107(46.7) 76(34.5) 64(28.8)
Left circumflex, n(%) 58(25.1) 78(35.6) 81(36.5)
Right coronary artery, n(%) 65(28.1) 65(29.9) 76(34.6)
Imaged coronary artery for NIRS 0.003
Left anterior descending, n(%) 40(44.4) 34(39.1) 20(24.4)
Left circumflex, n(%) 22(24.4) 36(41.4) 31(37.8)
Right coronary artery, n(%) 28(31.1) 17(19.5) 31(37.8)  
CABG: coronary artery bypass graft, IQR: interquartile range, LCBI: Lipid Core Burden Index, NIRS: near-infrared 
spectroscopy, PCI: percutaneous intervention, RF-IVUS:(radiofrequency) intravascular ultrasound,  SXscore: SYN-
TAX score
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Near-infrared spectroscopy in relation to SXscore
A higher SXscore was associated with a higher NIRS-derived lipid core burden 
index(LCBI) in the full study segment (1.35 units per SXscore point, 95%CI 0.22-2.47, 
p-value 0.019) (Tables 2, Figure 3). Consistent results were observed for the 10 and 4 
mm segments with highest LCBI values. Again, it is relevant to note that the observed 
correlation between SXscore and LCBI signals was independent of segment plaque 
burden.
Table 2. Associations between the SYNTAX score and RF-IVUS and NIRS derived variables in 
multivariable analyses
Mean/OR (95%CI)  β/OR† (95% CI)
p-value†RF-IVUS derived variables SXscore ≤ 4 4 < SXscore ≤ 10 Sxscore > 10   
No. of patients 230 219 221 670
Plaque volume, mm3 ‡ 230.1 (215.7-244.4) 246.0 (222.3-269.6) 242.4 (228.8-276.1) 2.21 (0.92-3.50) 0.001
Plaque burden, %‡ 38.1 (36.8-39.5) 38.8 (36.7-40.9) 39.0 (37.0-41.1) 0.10 (-0.011-0.22) 0.078
Plaque composition     
Fibrous, mm3  61.4 (55.1-67.7) 68.0 (60.7-75.4) 72.6 (65.3-80.2) 0.93 (0.53-1.33) <0.001
Fibro-fatty, mm3 10.8 (9.3-12.3) 13.6 (11.3-15.9) 14.9 (12.6-17.2) 0.29 (0.17-0.42) <0.001
Dense calcium, mm3 13.3 (11.3-15.3) 14.3 (11.9-16.8) 13.9 (11.4-16.3) 0.023 (-0.11-0.16) 0.73
Necrotic core, mm3 26.1 (22.8-29.3) 29.2 (25.7-32.6) 27.5 (24.0-30.9) 0.14 (-0.52-0.33) 0.16
Lesion morphology      
TCFA 1 0.97 (0.63-1.50) 0.81 (0.53-1.24) 0.99 (0.97-1.01) 0.46
MLA ≤4.0mm2 ‡ 1 0.74 (0.44-1.23) 0.95 (0.59-1.54) 1.00 (0.97-1.02) 0.80
Plaque burden ≥70%‡ 1  1.05 (0.58-1.88) 1.47 (0.85-2.53) 1.02 (1.00-1.05) 0.092
NIRS-derived variables SXscore ≤ 3 3 < SXscore ≤ 8 SXscore > 8    
No. of patients 90 87 82 259  
LCBI region of interest 39.4 (27.9-50.8) 56.0 (36.2-75.9) 62.7 (42.6-82.9) 1.35 (0.22-2.47) 0.019
LCBI worst 10 mm 118.1 (90.9-145.3) 150.3 (106.4-194.3) 176.9 (132.2-221.6) 2.89 (0.39-5.38) 0.024
LCBI worst 4 mm 190.4 (154.6-226.2) 231.3 (175.7-286.5) 266.6 (210.2-323.1)  3.83 (0.69-6.97) 0.017
We present means and odds ratios with 95%CI based on multivariable models with SX score included as cat-
egorical (explanatory) variable. In addition, we present β’s and odds ratios with SXscore included as continuous 
(explanatory) variable. Multivariable models are adjusted for age, gender, hypertension, renal impairment, hyper-
cholesterolemia, diabetes mellitus, smoking, indication for CAG, history of PCI and plaque burden.
† Based on multivariable models with SXscore included as continuous (explanatory) variable
‡ Multivariable model without adjustment for plaque burden
CI: confidence interval, LCBI: lipid core burden index, MLA: minimum luminal area, NIRS: near-infrared spectros-
copy, No: number, OR: odds ratio, RF-IVUS: radiofrequency intravascular ultrasound, SXscore: SYNTAX score, 
TCFA: thin-cap fibroatheromas
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DISCUSSION
This is the first study, to our knowledge, that systematically examined a large patient 
population for the correlation of coronary atherosclerotic burden as determined by the 
SXscore and the extent and characteristics of coronary atherosclerosis as assessed by 
RF-IVUS and NIRS in one non-stenotic segment of a single non-culprit coronary artery. 
This study shows that there is a significant and independent association between these 
entities in patients with CAD. 
The SXscore is a well-established angiographic tool for the assessment of the sever-
ity and complexity of CAD.2 It not only evaluates the number of significant stenoses but 
also lesion length and amount of calcification, amongst others. Still, as the SXscore is 
based on coronary luminography, it is limited in the assessment of the extent of (non-
stenotic) plaque burden and plaque morphology, including the identification of high-risk 
plaque characteristics and vulnerable plaques. We demonstrated that the SXscore is 
associated with RF-IVUS and NIRS derived information on the extent and composition 
of coronary atherosclerosis in patients with CAD. The correlation between SXscore and 
the amount of fatty/fibro-fatty tissue as well as LCBI were most striking. In this respect 
it is relevant to note the absence of relations between SXscore and plaque phenotype 
(necrotic core volume) and lesion morphology (TCFA). 
Previously, a significant relation between atherosclerotic burden in one non-culprit 
coronary segment as assessed by RF-IVUS or NIRS and cardiovascular outcome was 
demonstrated which persisted after exclusion of culprit-related and imaged segment-re-
lated cardiac events.5,7 This indirectly supported the assumption that the atherosclerotic 
Figure 3. Distribution of NIRS-derived LCBI across the SXscore categorized in tertiles 
The mean LCBI of the region of interest is divided across the SXscore categorized in tertiles (cut-off points 3 and 8). 
LCBI: lipid core burden index, SXscore: SYNTAX score
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burden in one non-culprit coronary segment may be representative for the atheroscle-
rotic disease of the entire coronary tree. The current study shows a direct association 
between angiographic atheroma burden of all three vessels and intravascular coronary 
wall evaluation of a non-culprit segment. 
Although pre-specified high-risk plaque phenotypes (TCFA, MLA≤4.0mm2 and le-
sions with a plaque burden of ≥70%) were not significantly associated with an increase 
in SXscore, the volume of fibrous and fibro-fatty tissue in plaques was higher in patients 
with a higher SXscore. Although a previous study has shown that plaque morphol-
ogy, as measured by three-vessel imaging by optical coherence tomography (OCT) or 
IVUS, is associated with and may be used for the identification of vulnerable plaques in 
patients with ACS,19 it appears from our study that it is the amount of tissue type which 
is associated with SXscore and not plaque morphology (the layout of the tissue) per se. 
In light of the relatively overall low angiographic burden of disease in our population, 
however, it needs to be considered that this finding may not be applicable in a patient 
population with more advanced CAD. Moreover, necrotic core and dense calcium did 
not show a significant association with a higher SXscore.
Previously, in one other small cohort, the relationship between NIRS and SXscore 
was explored but no association was found.17 The relationship between NIRS and the 
SXscore has also been studied in a subset of patients from ATHEROREMO-IVUS.18 
The enrichment of the ATHEROREMO-IVUS cohort with the IBIS-3 cohort in the current 
study substantially increases the sample size and creates more robust data. 
In most studies, SXscore is stratified in tertiles or even quartiles reflecting the dis-
tribution of the scores found in the respective cohort.2 The thresholds of the original 
SYNTAX trial (cut-off points:22 and 33) have been incorporated in the guidelines for 
the decision-making regarding CABG and PCI, but these thresholds apply to patients 
with left main and/or three-vessel disease.19 Our population also consisted of patients 
with single or two vessel disease and hence, understandably, our mean SXscore and 
cut-off values for the tertiles were relatively low. It warrants further research to assess 
which absolute SXscore thresholds are applicable in a heterogeneous population for 
risk prediction of adverse outcome in patients with CAD. 
Furthermore, we argue that combined IVUS-NIRS intracoronary imaging holds prom-
ise for more precise detection and quantification of atherosclerotic burden in patients 
with CAD, and in the future may even be of interest for the prediction of adverse events. 
However, further research is warranted to assess the application of combined IVUS-
NIRS intracoronary imaging for the prediction of adverse events. 
Limitations
This cohort, composed of two prospective studies, has broad inclusion criteria which 
enable the results to be applicable in a broad patient population with CAD. Data collec-
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tion, processing and analyses were conducted by researchers independent and blinded 
for patient and outcome data. However, a few limitations deserve consideration.
As indicated, our study includes patients with relatively low SXscores. This might 
induce an underestimation of the studied associations and insufficient power to reveal 
additional associations. However, a subgroup analysis with exclusion of patients with-
out significant CAD, showed results that were essentially similar. Moreover, the lowest 
tertile in this cohort contains significantly more patient with a previous PCI, which may 
indicate an underestimation of the severity of CAD caused by a low SXscore derived 
at study entry. 
Furthermore, while the SXscore analyst was blinded for all patient information, 
occlusions in STEMI patients were scored as occlusions of unknown duration. In the 
MI SYNTAXscore study, it was suggested to calculate occlusions in STEMI patients 
post-wiring.20 However, the MI SYNTAXscore did not show better performance than the 
original SXscore calculated in STEMI patients.
Lastly, although literature demonstrated that experienced operators produce reason-
able SXscores, the modest reproducibility of the SXscore in general has to be acknowl-
edged.21 However, because of the overall relatively low angiographic burden of disease 
in our study population, we expected a fair reproducibility of the SXscore in our study. To 
address the reproducibility of our SXscores, a second experienced operator, blinded for 
patient characteristics and previously scored SXscores, repeated SXscore analysis in 
a representative random sample. Cohen’s kappa showed to be 0.91, indicating a good 
interobserver agreement. 
Conclusions 
In patients with CAD, there is a clear and significant correlation between a higher SX-
score and a higher atherosclerotic burden as assessed by RF-IVUS and NIRS in one 
non-stenotic segment in a single non-culprit coronary artery. 
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SUPPLEMENTARY APPENDIX
Methods coronary intravascular ultrasound 
Following CAG, IVUS was performed in a proximal non-stenotic (<50% stenosis) seg-
ment of at least 40 mm of a non-culprit artery. The order of preference used for selection 
of the non-culprit vessel was predefined in the study protocol: 1) left anterior descend-
ing artery; 2) right coronary artery; 3) left circumflex artery. All IVUS data were obtained 
with the Volcano s5/s5i Imaging System (Volcano Corp., San Diego, CA, USA) using 
a Volcano Eagle Eye Gold IVUS catheter (20 Mhz). An automatic pullback system was 
used with a standard pullback speed of 0.5 mm per second. The baseline IVUS images 
were sent to an independent core laboratory (Cardialysis, Rotterdam, the Netherlands) 
for offline analysis. The core laboratory personnel were blinded for baseline patient 
characteristics and clinical outcome. The RF-IVUS analysis was performed using pcVH 
2.1 and qVH (Volcano Corp., San Diego, CA, USA) software. 
The external elastic membrane and luminal borders were contoured for each frame 
(median interslice distance, 0.40 mm). Plaque burden was defined as the plaque and 
media cross-sectional area divided by the external elastic membrane cross-sectional 
area. A coronary lesion was defined as a segment with a plaque burden of more than 
40% in at least 3 consecutive frames. The composition of atherosclerotic plaque was 
characterised into 4 different tissue types: fibrous, fibro-fatty, dense calcium and necrotic 
core [22]. Three types of high-risk lesions were identified: 1) thin-cap fibroatheroma 
(TCFA) lesion, defined as a lesion with presence of >10% confluent necrotic core in 
direct contact with the lumen; 2) lesion with large plaque burden, defined as a lesion 
with a plaque burden of ≥70%; 3) stenotic lesion, defined as a lesion with a minimal 
luminal area (MLA) of ≤4.0 mm².4,23 
Methods near-infrared spectroscopy 
In a subset of patients, NIRS imaging was performed in the same segment as IVUS. The 
NIRS system used consists of a 3.2 Fr rapid exchange catheter, a pullback and rotation 
device and a console (Infraredx, Burlington, MA, USA), approved by the U.S. Food 
and Drug Administration. Image acquisition was performed by a motorised catheter 
pullback at a speed of 0.5 mm/s and 240 rpm. The system performed 1,000 chemical 
measurements per 12.5 mm. Each measurement interrogated 1 to 2 mm² of vessel wall 
from, approximately, 1 mm in depth from the luminal surface towards the adventitia.4,5 
The NIRS measurements were used to create a chemogram. The fraction of yellow 
pixels from the chemogram was multiplied by 1,000, to calculate the lipid core burden 
index (LCBI). Thus, the LCBI value, with a range between 0 and 1,000, represents the 
amount of lipid core in the assessed segment. 24 In addition, within this region of inter-
est, the 10 mm and 4 mm segment with the highest LCBI was defined. NIRS images 
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were analysed offline by an independent core laboratory (Cardialysis, Rotterdam, the 
Netherlands). Core laboratory personnel were blinded to all other patient and outcome 
data.
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ABSTRACT
Aims
Near-infrared spectroscopy (NIRS) is able to quantify cholesterol within coronary arteries 
by the lipid core burden index (LCBI). We studied the prognostic value of NIRS-derived 
LCBI in patients with coronary artery disease (CAD) for adverse cardiac outcome during 
long-term follow-up. 
Methods and results
During 2009-2013, NIRS was performed in a non-culprit artery of 275 patients undergo-
ing coronary angiography for acute coronary syndrome (ACS) or stable angina. LCBI 
was quantified by an independent corelab for the region of interest (LCBIROI) and the 
4 and 10 mm long segment with the maximum LCBI (MaxLCBI4mm and MaxLCBI10mm). 
The primary endpoint was major adverse cardiac events (MACE), defined as the com-
posite of all-cause death, non-fatal ACS, or unplanned revascularization. Hazard ratios 
(HR) were adjusted for age, gender, clinical risk factors and segment plaque burden 
based on intravascular ultrasound. During a median follow-up of 4.1 years, 79 patients 
(28.7%) had MACE. There was a statistically significant and independent continuous 
relationship between higher MaxLCBI4mm values and a higher risk of MACE. Each 100 
units increase of MaxLCBI4mm was associated with a 19% increase in MACE (HR 1.19, 
95%CI:1.07-1.32, p=0.001). Continuous MaxLCBI4mm remained independently associ-
ated with MACE after exclusion of target lesion-related events (HR 1.21, 95CI%:1.08-
1.35), as well as after exclusion of adverse events related to the NIRS-imaged coronary 
segment (HR 1.19, 95%CI:1.06-1.34). Results for MaxLCBI10mm were comparable.
Conclusion
NIRS-derived LCBI is associated with adverse cardiac outcome in CAD patients during 
long-term follow-up independent of clinical risk factors and plaque burden.
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INTRODUCTION
Coronary artery disease (CAD) is projected to remain the leading cause of mortality and 
morbidity worldwide. Patients with a history of CAD are at higher risk of subsequent 
adverse cardiovascular events, such as an acute coronary syndrome (ACS). In ap-
proximately 75% of all cases, an ACS is caused by rupture or fissure of a vulnerable, 
lipid rich core-containing plaque in the coronary arteries.1, 2 While coronary angiography 
(CAG) is unable to identify such lipid rich core-containing plaques in the coronary artery 
wall,3 they can be identified by near-infrared spectroscopy (NIRS), a catheter-based in-
tracoronary imaging technique based on diffuse reflectance spectroscopy.4-6 Therefore, 
NIRS may be useful in identifying patients at increased risk of adverse cardiovascular 
outcome.5-7
The European Collaborative Project on Inflammation and Vascular Wall Remodel-
ing in Atherosclerosis (ATHEROREMO) and the Integrated Biomarker Imaging Study 
3(IBIS-3) studies were designed to investigate phenotypes and vulnerability of coronary 
atherosclerosis as determined by intravascular ultrasound (IVUS) and NIRS.8, 9 NIRS 
became available in our cardiac catheterization laboratory during the course of both 
the ATHEROREMO and IBIS-3 study.10 In the current study, we performed long-term 
follow-up of both the ATHEROREMO-NIRS and IBIS-3-NIRS substudies, with the aim 
to investigate the long-term prognostic value of lipid rich core-containing plaques as 
assessed by NIRS in patients with CAD undergoing CAG. 
METHODS
Study design and population
The current investigation combines the populations of the ATHEROREMO-NIRS and 
the IBIS-3-NIRS substudies. Both of these studies were conducted at the Erasmus 
Medical Center, Rotterdam, The Netherlands, and had similar enrollment criteria and 
baseline study procedures. The study designs and methods of ATHEROREMO-NIRS 
and IBIS-3-NIRS have been described in detail elsewhere.8-10 Briefly, patients undergo-
ing diagnostic CAG or PCI for ACS or stable angina pectoris (SAP) underwent baseline 
invasive imaging by NIRS and IVUS, and were subsequently followed-up on adverse 
cardiovascular events.11, 12 The obtained images were analyzed off-line, and findings 
were not used for patient care. In ATHEROREMO-NIRS, patient management was left 
to the discretion of the treating physician. In IBIS-3, as per protocol, high-dose rosuv-
astatin was prescribed during the first year after the index event. ATHEROREMO-NIRS 
enrolled 203 patients between April 2009 and January 2011, and IBIS-3-NIRS enrolled 
131 patients between January 2010 and June 2013. Since 48 patients participated in 
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both studies, a total of 286 patients were available. Of these patients, 275 patients had 
baseline data available on both NIRS and IVUS, and were therefore included in the 
current analysis.
The medical ethics committee of the Erasmus MC approved both the ATHERORE-
MO-NIRS and IBIS-3-NIRS substudy. These two studies were performed in accordance 
with the declaration of Helsinki. All patients provided written informed consent for their 
participation and for compliance with the study protocols, including long-term follow-up. 
The ATHEROREMO study is registered in ClinicalTrials.gov, number NCT01789411, 
and the IBIS-3 study is registered in The Netherlands trial register, number NTR2872.
Near-infrared spectroscopy
Subsequent to the standard index CAG, invasive imaging with IVUS and NIRS was 
performed in a non-culprit coronary artery. The NIRS target segment in this non-culprit 
coronary artery was required to be at least 40 mm in length and without significant 
luminal narrowing (<50% stenosis) as assessed by on-line angiography. The study 
protocol predefined the order of preference for the selection of the non-culprit vessel.8, 9 
The NIRS system included a 3.2-F rapid exchange catheter, a console and a rotation 
and pullback device (InfraRedx, Burlington, Massachusetts). Images were acquired by 
the NIRS catheter that was automatically pulled back at a speed of 0.5 mm/s and 240 
rotations per minute in a proximal segment of the non-culprit artery, as described in 
detail previously.5, 10 The fraction of yellow pixels obtained from the chemogram, an 
image map derived from the NIRS measurements, was multiplied by 1000 to com-
pute the Lipid Core Burden Index (LCBI). Therefore, the 4 mm long segment with the 
maximum LCBI (MaxLCBI4mm) ranged from 0 to 1000 representing the percentage of 
lipid core in the investigated segment.6 Moreover, the 10 mm long segment with the 
maximum LCBI (MaxLCBI10mm) was quantified, and the same was done for the region 
of interest (LCBIROI) of the investigated segment. NIRS data were analyzed off-line by 
an independent corelab (Cardialysis, Rotterdam, The Netherlands) blinded to all other 
patient and outcome data. 
Intravascular ultrasound
After the standard index CAG, the non-culprit segment was first examined by IVUS. 
IVUS images were acquired by the Volcano Eagle Eye Gold IVUS catheter (20 MHz).8 
Analyses of the IVUS gray-scale data were performed using the pcVH 2.1 and qVH 
software (Volcano Corp., San Diego, CA, USA). Segmental plaque burden was defined 
as the plaque and media cross-sectional area divided by the external elastic membrane 
cross-sectional area.8 IVUS gray-scale data were also analyzed off-line. 
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Study endpoints
The primary endpoint consisted of major adverse cardiac events (MACE), defined as 
the composite of all-cause death, non-fatal ACS, or unplanned coronary revasculariza-
tion during long-term follow-up. A secondary analysis was performed on the composite 
endpoint of cardiac death, non-fatal ACS, or unplanned revascularization. Furthermore, 
additional analyses were performed on these two endpoints after exclusion of definite 
target lesion-related events, as well as after exclusion of adverse events related to the 
NIRS-imaged coronary segment.
Follow-up was conducted in January 2015. Vital status of the patients was obtained 
from municipal civil registries. Follow-up questionnaires were subsequently sent to 
all living patients as a first screening method for identifying possible adverse events. 
Thereafter, hospital discharge letters were obtained if any hospitalization or possible 
event was reported. In patients who did not return the questionnaire, the local hospital 
records were investigated for possible events. Cause of death was obtained from hos-
pital records, autopsy reports or general practitioners notes.
MACE were adjudicated based on original source data by a clinical events commit-
tee blinded to patient characteristics and NIRS and IVUS data. In accordance with the 
guidelines of the European Society of Cardiology, non-fatal ACS was defined as the 
clinical diagnosis of ST-segment Elevation Myocardial Infarction (STEMI), non-STEMI 
(NSTEMI), or unstable angina pectoris.13, 14 Unplanned coronary revascularization was 
defined as any PCI or coronary artery bypass grafting (CABG) that was not planned after 
the index angiography and enrollment in the study. Cardiac death was defined as any 
death due to proximate cardiac cause, unwitnessed death or death of unknown cause.
Furthermore, the clinical event committee adjudicated whether the cardiac events 
were related to the target lesion that was treated during the index procedure, as well 
as whether the events were related to the coronary artery segment that was imaged at 
baseline.
Statistical analysis
Normality of continuous variables was assessed by the Kolmogorov-Smirnov test. 
Normally-distributed continuous variables were reported as means and standard de-
viations. Non-normally-distributed continuous variables were reported as medians and 
interquartile ranges (IQR), categorical variables as numbers and percentages.
Patients that were lost to follow-up were censored at the date of last contact. The first 
event was considered in case a patient had multiple events. The Kaplan-Meier method 
was used to estimate cumulative event rate. All subsequent analyses were performed 
for each of the three LCBI variables. The log-rank test was used to compare cumulative 
event rates between quartiles of the LCBI variables and pairwise comparisons were 
performed when the overall log-rank test showed statistical significant differences. 
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The association between LCBI and the long-term incidence of study endpoints was 
analyzed by Cox proportional hazard regression analyses. Furthermore, to evaluate 
whether the association between LCBI and log(hazard) was linear enough to fit as a single 
degree of freedom regression term, a spline was inserted in each full Cox proportional 
hazard regression model and visual inspection of the estimated relation was performed. 
No evidence was found for non-linearity with respect to MaxLCBI4mm, whereas findings 
with respect to MaxLCBI10mm and LCBIROI were borderline significant. Visual inspection 
of the estimated relation showed that categorization of LCBI in quartiles resulted in an 
acceptable piece-wise linearity for all endpoints. For Cox regression analyses, consecu-
tively, unadjusted models and multivariable models containing clinical characteristics and 
IVUS derived plaque burden were used. Potential confounders were chosen based on 
existing literature. The multivariable models contained the following potential confound-
ers: age, gender, indication for index CAG (ACS or SAP), diabetes mellitus, history of 
cerebrovascular accident, history of peripheral artery disease and IVUS derived seg-
mental plaque burden. Hazard ratios (HRs) were reported with 95% confidence intervals 
(CIs). Although this study did not aim to develop a prognostic model per se, a C-index 
was reported for each multivariable model to provide some indication of the prognostic 
value of continuous LCBI in addition to clinical risk factors and plaque burden.
All statistical tests were two-tailed and p-values <0.05 were considered statistically 
significant. Statistical analyses were performed using IBM SPSS statistics version 21.0 
(IBM Corp., Armonk, New York).
RESULTS
Baseline characteristics
Mean age of the patients was 62.5 years and 76.7% were men (Table 1). A total of 
42.5% of the patients presented with an ACS. MaxLCBI4mm values in the non-culprit 
artery ranged from 0 to 930, with a median of 227.0 (IQR:83.0-360.0). The LCBIROI 
values ranged from 0 to 571, with a median of 40.0 (IQR:13.0-79.0). PCI was performed 
in 88.4% of the patients during the index procedure. 
Incidence of primary endpoint
Median follow-up time was 4.1(IQR:3.2-4.5) years. The follow-up questionnaire assessing 
the occurrence of MACE was completed by 90% of the patients. The primary composite 
endpoint of all-cause death, non-fatal ACS or unplanned revascularization occurred in 79 
patients (28.7%). All-cause death occurred in 20 patients, non-fatal ACS in 40 patients 
and unplanned revascularization in 62 patients. The composite endpoint of cardiac death, 
non-fatal ACS or unplanned revascularization occurred in 70 patients (25.5%).
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Table 1. Baseline characteristics 
 N=275 patients
Clinical characteristics  
Age, years 62.5 ± 10.7
Men, n(%) 211 (76.7)
Diabetes, n(%) 59 (21.5)
Hypertension, n(%) 165 (60.0)
Dyslipidemia, n(%) 158 (57.5)
Current smoking, n(%) 69 (25.1)
Previous MI, n(%) 94 (34.2)
Previous PCI, n(%) 98 (35.6)
Previous CABG, n(%) 6 (2.2)
Previous CVA, n(%) 16 (5.8)
History of PAD, n(%) 15 (5.5)
History of renal impairment, n(%) 14 (5.1)
Laboratory measurements, (mmol/l)  
Median total cholesterol (IQR) 4.10 [3.60-5.00]
Median low-density lipoprotein (IQR) 2.42 [1.93-3.13]
Median high-density lipoprotein (IQR) 1.14 [0.92-1.35]
Procedural characteristics  
Indication for coronary angiography
ACS, n(%) 117 (42.5)
Acute MI, n(%) 31 (11.3)
Unstable angina, n(%) 86 (31.3)
Stable angina, n(%) 158 (57.5)
PCI performed in non-imaged vessel, n(%) 243 (88.4)
Coronary artery disease
No significant stenosis, n(%) 18 (6.5)
1-vessel disease, n(%) 144 (52.4)
2-vessel disease, n(%) 87 (31.6)
3-vessel disease, n(%) 26 (9.5)
NIRS characteristics  
Imaged coronary artery
Left anterior descending, n(%) 96 (34.9)
Left circumflex, n(%) 97 (35.3)
Right coronary artery, n(%) 82 (29.8)
Median imaged segment length, mm (IQR) 56.4 [45.3-67.2]
Median LCBIROI (IQR) 40.0 [13.0-79.0]
Median MaxLCBI10mm (IQR) 129.0 [48.0-234.0]
Median MaxLCBI4mm (IQR) 227.0 [83.0-360.0]
IVUS derived Segment Plaque Burden (%) 39.3 ± 11.0
ACS: acute coronary syndrome, CABG: coronary bypass grafting, CVA: cerebrovascular accident, IQR: interquar-
tile range, IVUS: intravascular ultrasound, MI: myocardial infarction, NIRS: near-infrared spectroscopy, PAD: pe-
ripheral artery disease, PCI: percutaneous coronary intervention
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Association between LCBI and MACE
The cumulative distribution of the MaxLCBI4mm values in patients with and without 
MACE shows that patients with MACE had higher MaxLCBI4mm values as compared to 
those without MACE (Figure 1).
Quartiles of MaxLCBI4mm, MaxLCBI10mm and LCBIROI, and cumulative MACE incidence 
were pairwise compared. Pairwise comparisons consequently showed that patients in 
the third and fourth quartiles had significantly higher event rates compared to those in 
the first quartile (Figure 2). After adjustment for clinical characteristics and IVUS-derived 
plaque burden in the multivariable model, the third and fourth quartile of MaxLCBI4mm 
remained significantly associated with MACE (HR 3.09 (95%CI: 1.41-6.74) and HR 
3.58 (95CI%: 1.67-7.70), respectively). Results for the LCBIROI and MaxLCBI10mm were 
comparable (Table 2).
There was a statistically significant continuous relationship between higher Max-
LCBI4mm values and a higher risk of MACE (Table 3). After multivariable adjustment, 
MaxLCBI4mm remained significantly associated with MACE (HR 1.19 per 100 units 
increase in LCBI, 95%CI: 1.07-1.32), as well as with MACE after exclusion of target 
lesion-related events (HR 1.21 (95CI%: 1.08-1.35)).  Similarly, MaxLCBI4mm remained 
also independently associated with MACE after exclusion of adverse events related 
to the NIRS-imaged coronary segment (HR 1.19 (95%CI:1.06-1.34)). Cox regression 
analysis with follow-up duration as time-dependent variable demonstrated that continu-
ous MaxLCBI4mm also predicted MACE beyond 1-year of follow-up [HR (95%CI) 1.15 
(1.00-1.33) versus 1.23 (1.07-1.42) for the first year]. 
Figure 1. Cumulative distribution of the MaxLCBI4mm of patients with and without MACE 
(p=0.001, Mann-Whitney U test).
MACE: major adverse cardiac events, MaxLCBI4mm: the 4 mm long segment with the maximum LCBI 
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The C-indices indicate that NIRS-derived LCBI has prognostic value in addition to 
clinical risk factors and IVUS-derived plaque burden, with C-indices of the models with 
only covariates ranging from 0.607 to 0.617 and C-indices of the multivariable models 
including continuous LCBI ranging from 0.674 to 0.704 (Table 3).
Figure 2. Assocation between quartiles of MaxLCBI4mm and the occurrence of MACE 
*p<0.01 as compared to first quartile (reference).
LCBI: lipid core burden index, MACE: major adverse cardiac events
Figure 3. Assocation between quartiles of MaxLCBI4mm and the occurrence of cardiac death, 
non-fatal ACS and unplanned revascularization 
*p<0.05 as compared to first quartile (reference).
LCBI: lipid core burden index, MACE: major adverse cardiac events, NIRS: near-infrared spectroscopy 
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Table 2. Associations between quartiles of LCBI and risk of MACE at 4-years follow-up
 Cut-off 
LCBI value
Cumulative MACE 
incidence (%)
Unadjusted model  Multivariable model  
 HR (95%CI) p-value HR (95%CI) p-value
MaxLCBI4mm
Quartile 1 0-83 14.7 1 1
Quartile 2 ≥83-227 27.9 1.99 (0.93-4.28) 0.078 2.11 (0.96-4.60) 0.062
Quartile 3 ≥227-360 34.3 2.77 (1.32-5.81) 0.007 3.09 (1.41-6.74) 0.005
Quartile 4 ≥360 38.6 3.22 (1.56-6.65) 0.002 3.58 (1.67-7.70) 0.001
MaxLCBI10mm
Quartile 1 0-48 13.2 1 1
Quartile 2 ≥48-129 30.9 2.56 (1.17-5.60) 0.018 2.66 (1.20-5.93) 0.017
Quartile 3 ≥129-234 36.8 3.36 (1.57-7.20) 0.002 3.47 (1.59-7.61) 0.002
Quartile 4 ≥234 34.3 3.06 (1.42-6.59) 0.004 3.27 (1.46-7.29) 0.004
LCBIROI
Quartile 1 0-13 15.4 1 1
Quartile 2 ≥13-40 25.7 1.72 (0.79-3.73) 0.17 1.93 (0.88-4.25) 0.10
Quartile 3 ≥40-79 37.1 2.90 (1.40-6.02) 0.004 3.24 (1.53-6.88) 0.002
Quartile 4 ≥79 35.7 2.67 (1.28-5.56) 0.009 3.14 (1.43-6.87) 0.004
Cumulative MACE incidence by Kaplan-Meier method. P-values obtained with Cox regression analyses on pair-
wise comparisons between each quartile and first quartile (reference). 
HR: hazard ratio, LCBI, lipid core burden index: MACE, major adverse cardiac events, ROI: region of interest 
Table 3. Continuous LCBI values and risk of MACE at 4-years follow-up
Unadjusted model Multivariable model
HR(95%CI) p-value HR(95%CI) p-value C-index
MACE
Covariates only 0.608
MaxLBCI4mm 1.19 (1.08-1.31) 0.001 1.19 (1.07-1.32) 0.001 0.674
MaxLBCI10mm 1.17 (1.04-1.31) 0.011 1.17 (1.03-1.34) 0.017 0.660
LCBIROI 1.18 (0.93-1.51) 0.18 1.24 (0.95-1.63) 0.12 0.652
MACE with exclusion of TLR-events
Covariates only 0.617
MaxLBCI4mm 1.22 (1.10-1.36) <0.001 1.21 (1.08-1.35) 0.001 0.704
MaxLBCI10mm 1.21 (1.07-1.37) 0.003 1.22 (1.06-1.40) 0.005 0.691
LCBIROI 1.24 (0.97-1.60) 0.087 1.31 (0.99-1.74) 0.059 0.683
MACE with exclusion of NIRS imaged segment-related events
Covariates only 0.607
MaxLBCI4mm 1.17 (1.06-1.30) 0.003 1.19 (1.06-1.34) 0.003 0.683
MaxLBCI10mm 1.13 (0.99-1.28) 0.072 1.15 (1.00-1.33) 0.050 0.665
LCBIROI 1.09 (0.81-1.46) 0.58 1.18 (0.86-1.62) 0.31 0.659
Hazard ratios per 100 units increase in MaxLCBI4mm, MaxLCBI10mm and LCBIROI. 
HR: hazard ratio, LCBI: lipid core burden index, MACE: major adverse cardiac events, NIRS: near-infrared spec-
troscopy, ROI: region of interest, TLR: target lesion-related revascularization 
49
Long-term prognostic value of NIRS in IHD patients
Association between LCBI and the composite endpoint of cardiac 
death, non-fatal ACS or unplanned revascularization 
The cumulative incidence of the composite of cardiac death, non-fatal ACS or unplanned 
revascularization was higher in patients in the second (25.0%), third (31.3%) and fourth 
(35.7%) quartile of MaxLCBI4mm as compared to those in the first (10.3%) quartile of 
MaxLCBI4mm (log-rank pairwise comparisons p=0.031, p=0.002 and p=<0.001, respec-
tively, Figure 3). The second, third and fourth quartiles of MaxLCBI4mm were significantly 
associated with the composite of cardiac death, non-fatal ACS or unplanned revascu-
larization after adjustment for clinical characteristics and IVUS-derived plaque burden 
in the multivariable model (Table 4). A similar significant association was observed 
for MaxLCBI4mm as a continuous variable (Table 5). This association persisted after 
exclusion of target lesion-related events and after exclusion of events related to the 
imaged segment (Table 5). In general, the associations observed between MaxLCBI4mm, 
MaxLCBI10mm and LCBIROI and the occurrence of adverse events were stronger and 
more significant when the composite endpoint included cardiac death instead of all-
cause mortality (Tables 2-5).
Table 4. Associations between quartiles of LCBI and risk of composite of cardiac death, non-
fatal ACS, or unplanned revascularization at 4-years follow-up
Cut-off LCBI 
value Cumulative incidence (%)
Unadjusted 
model
Multivariable 
model
   HR(95%CI) p-value HR(95%CI) p-value
MaxLCBI4mm       
Quartile 1 0-83 10.3 1 1
Quartile 2 ≥83-227 25.0 2.53 (1.05-6.11) 0.039 2.66 (1.09-6.50) 0.032
Quartile 3 ≥227-360 31.3 3.60 (1.53-8.46) 0.003 4.07 (1.67-9.92) 0.002
Quartile 4 ≥360 35.7 4.16 (1.80-9.62) 0.001 4.57 (1.90-10.98) 0.001
MaxLCBI10mm       
Quartile 1 0-48 10.3 1 1
Quartile 2 ≥48-129 26.5 2.80 (1.17-6.70) 0.021 2.96 (1.21-7.21) 0.017
Quartile 3 ≥129-234 30.9 3.60 (1.53-8.47) 0.003 3.73 (1.55-8.94) 0.003
Quartile 4 ≥234 34.3 3.85 (1.66-8.93) 0.002 4.01 (1.66-9.67) 0.002
LCBIROI       
Quartile 1 0-13 10.8 1 1
Quartile 2 ≥13-40 21.4 2.05 (0.84-5.02) 0.12 2.30 (0.93-5.73) 0.073
Quartile 3 ≥40-79 32.9  3.64 (1.56-8.49) 0.003 4.09 (1.72-9.73) 0.001
Quartile 4 ≥79 35.7 3.73 (1.61-8.62) 0.002 4.18 (1.72-10.17) 0.002
Cumulative endpoint incidence by Kaplan-Meier method. P-values obtained with Cox regression analyses on pairwise 
comparisons between each quartile and first quartile (reference). 
ACS: acute coronary syndrome, CI: confidence interval, HR: hazard ratio, LCBI: lipid core burden index, ROI: region of 
interest
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DISCUSSION
This study investigated the association between lipid rich core-containing plaques as 
identified by NIRS in a non-culprit coronary artery and the occurrence of adverse car-
diac events during long-term follow-up in patients undergoing CAG. This study showed 
that LCBI values were significantly and independently associated with the incidence of 
adverse cardiac outcome in patients with CAD over 4 years of follow-up. To the best 
of our knowledge, this is the first study to investigate the association between LCBI in 
a non-culprit coronary artery and adverse cardiac outcome over 4 years of follow-up, 
which represents the longest follow-up period so far reported. 
Studies on the relationship between LCBI and (long-term) follow-up are scarce. Re-
cently, the COLOR study demonstrated that the MaxLCBI4mm obtained prior to stenting 
in a culprit coronary segment was not associated with culprit-related MACE during 2 
years of follow-up.15 Our study provides new evidence on the prognostic value of NIRS, 
since we demonstrated that NIRS is predictive of MACE on the long-term by identifying 
high-risk lipid rich core-containing plaques in a non-culprit artery. The upcoming Lipid 
Rich Plaque (LRP) and PROSPECT-2 studies are also investigating the ability of NIRS-
derived LCBI in non-culprit coronary arteries to predict adverse cardiovascular outcome 
during 2-year follow-up. 
This study extends our previous 1-year follow-up data of the ATHEROREMO-NIRS 
study, which investigated the 1-year prognostic value of NIRS in that cohort and showed 
that high LCBI values were associated with an increased incidence of MACE.10 The cur-
Table 5. Continuous LCBI values and risk of composite of cardiac death, non-fatal ACS or 
unplanned revascularization at 4-years follow-up
Unadjusted model Multivariable model
 HR(95%CI) p-value HR(95%CI) p-value
MaxLBCI4mm 1.21 (1.10-1.34) <0.001 1.21 (1.08-1.35) 0.001
MaxLBCI10mm 1.20 (1.06-1.35) 0.003 1.20 (1.05-1.37) 0.007
LCBIROI 1.24 (0.98-1.58) 0.078 1.29 (0.98-1.70) 0.065
Composite endpoint with exclusion of TLR-events
MaxLBCI4mm 1.25 (1.12-1.40) <0.001 1.24 (1.10-1.39) <0.001
MaxLBCI10mm 1.25 (1.10-1.42) 0.001 1.25 (1.09-1.44) 0.002
LCBIROI 1.32 (1.03-1.68) 0.027 1.38 (1.04-1.83) 0.027
Composite endpoint with exclusion of NIRS imaged segment-related events
MaxLBCI4mm 1.20 (1.08-1.34) 0.001 1.22 (1.08-1.38) 0.001
MaxLBCI10mm 1.16 (1.02-1.33) 0.026 1.19 (1.03-1.38) 0.022
LCBIROI 1.16 (0.87-1.55) 0.31 1.24 (0.90-1.70) 0.18
Hazard ratios per 100 units increase in MaxLCBI4mm, MaxLCBI10mm and LCBIROI. 
ACS: acute coronary syndrome, LCBI: lipid core burden index, NIRS: near-infrared spectroscopy, ROI: region of 
interest, TLR: target lesion-related revascularization
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rent study demonstrated that these results persist over a period of 4 years, suggesting 
that the increased risk at 1-year was not due to chance and LCBI of a non-culprit artery 
also has prognostic value beyond 1-year after the index CAG. As compared to the 
1-year follow-up, the current study was conducted over a longer follow-up period, had a 
larger sample size and, consequently, a larger number of endpoints. The latter allowed 
us to investigate the associations between continuous LCBI values, as well as quartiles 
of LCBI, and adverse cardiac outcome instead of using a median split for LCBI. These 
analyses showed a significant and independent continuous relationship between higher 
LCBI values in a non-culprit coronary artery and adverse cardiac outcome. Importantly, 
this relationship persisted, and remained essentially unchanged, when target-lesion 
related adverse cardiac events (TLR) were excluded from the study endpoint, as well as 
when adverse events related to the imaged coronary segment were excluded. This indi-
cates that LCBI values obtained in a non-culprit coronary artery segment are associated 
with adverse cardiac events throughout the entire coronary tree. As such, this finding 
supports the hypothesis that NIRS imaging in a non-culprit coronary artery segment 
may reflect vulnerability of the entire coronary tree.8, 16
Previously, the ATHEROREMO-IVUS study demonstrated that IVUS-derived imag-
ing parameters were predictive of MACE. For this reason, we included IVUS-derived 
plaque burden in the multivariable model to evaluate the independent prognostic value 
of NIRS. Given that progression of coronary atherosclerosis depends on multiple fac-
tors that are cumulative, interactive and nonlinear, a combination of these two imaging 
techniques is likely to result in a higher predictive value.
Other studies used NIRS to investigate the effect of anti-atherosclerotic therapy on 
the amount of lipid core-containing plaques. The YELLOW study demonstrated that 
patients with multivessel CAD treated for 6 to 8 weeks with rosuvastatin showed a 
reduction of lipid core in obstructive arteries.17 The IBIS-3 study showed that high-
dose rosuvastatin resulted in a neutral effect on lipid rich core-containing plaques as 
determined by NIRS.18 Recently, it was shown that addition of a PCSK9-inhibitor to 
stable statin therapy resulted in a greater decrease of plaque burden as assessed by 
IVUS.19 NIRS has improved ability to identify lipid core-containing coronary plaques as 
compared to other invasive imaging modalities including IVUS, since NIRS is able to 
distinguish cholesterol from other tissue characteristics.6 In this context, NIRS may be 
used to select patients with high LCBI values in future research to measure the effect of 
anti-atherosclerotic therapy on lipid rich core-containing plaques in the coronary artery 
wall and assess its association with adverse cardiac outcome. Ultimately, this may 
result in improved risk stratification and management of patients with CAD. 
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Limitations
Several study limitations warrant consideration. First, our study population also com-
prised patients from IBIS-3, who received high doses of rosuvastatin after the index 
procedure. This may also in part have affected the effect estimates. However, a post-
hoc analysis did not display significant effect modification according to study. 
Second, the follow-up questionnaire was completed by 90% of the patients. Although 
for the majority of the remaining patients, follow-up information was retrieved from our 
local hospital records, we cannot fully exclude the possibility that loss to follow-up was 
in part selective. However, a post-hoc analysis of clinical and NIRS characteristics of 
the non-responders as compared to those of the responders did not show any differ-
ences that indicated selective loss to follow-up.
Third, the sample size of this single-center study was relatively small. Nevertheless, 
our  study had a large number of endpoints. This allowed us to analyse LCBI as quar-
tiles and as a continuous variable, as well as to investigate the association with adverse 
cardiac outcome after exclusion of target lesion-related and imaged segment-related 
events. When the results of the LRP and PROSPECT-2 studies become available, a 
meta-analysis may provide more precise effect estimates. Furthermore, as the current 
study population comprises a broad spectrum of CAD patients, the results are expected 
to apply to a broad population of CAD patients.
Conclusions
In conclusion, this study demonstrates for the first time that LCBI, as assessed by 
NIRS in one non-culprit coronary artery segment, predicts adverse cardiac outcome, 
independent of clinical characteristics and IVUS, during long-term follow-up over 4 
years in patients referred for CAG because of ACS or SAP. 
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ABSTRACT
Background
It has been shown that intravascular ultrasound (IVUS) and radiofrequency (RF-)IVUS 
can detect high-risk coronary plaque characteristics.
Objectives
The authors studied the long-term prognostic value of (RF-)IVUS-derived plaque 
characteristics in patients with coronary artery disease (CAD) undergoing coronary 
angiography.
Methods
From 2008 to 2011, (RF-)IVUS was performed in 1 non-stenotic segment of a non-culprit 
coronary artery in 581 patients undergoing coronary angiography for acute coronary 
syndrome (ACS) or stable angina. The pre-defined primary endpoint was major adverse 
cardiovascular events (MACE), defined as the composite of all-cause death, nonfatal 
ACS, or unplanned revascularization. Hazard ratios (HRs) were adjusted for age, sex, 
and clinical risk factors.
Results
During a median follow-up of 4.7 years, 152 patients (26.2%) had MACE. The presence 
of a lesion with a minimal luminal area ≤4.0 mm2 was independently associated with 
MACE (HR: 1.49; 95% CI: 1.07 to 2.08; p = 0.020), whereas the presence of a thin-cap 
fibroatheroma lesion or a lesion with a plaque burden ≥70% on its own were not. Results 
were comparable when the composite endpoint included cardiac death instead of all-
cause death. The presence of a lesion with a plaque burden of ≥70% was independently 
associated with the composite endpoint of cardiac death, nonfatal ACS, or unplanned 
revascularization after exclusion of culprit lesion-related events (HR: 1.66; 95% CI: 1.06 
to 2.58; p = 0.026). Likewise, each 10-U increase in segmental plaque burden was 
independently associated with a 26% increase in risk of this composite endpoint (HR: 
1.26 per 10-U increase; 95% CI: 1.03 to 1.52; p = 0.022).
Conclusions
IVUS-derived small luminal area and large plaque burden, and not RF-IVUS-derived 
compositional plaque features on their own, predict adverse cardiovascular outcome 
during long-term follow-up in patients with CAD.
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INTRODUCTION
Patients with coronary artery disease (CAD) are at increased risk of recurrent adverse 
cardiovascular events, such as acute coronary syndromes (ACS).1,2 Whereas coronary 
angiography (CAG) only yields a two-dimensional silhouette of the lumen,3 grayscale 
intravascular ultrasound (IVUS) and radiofrequency (RF-)IVUS have shown to be able 
to identify high-risk coronary plaque characteristics within the coronary artery wall.4-7 
Therefore, (RF-)IVUS may be useful to identify patients who are at increased risk of 
future adverse cardiovascular events.6-8 Autopsy studies suggest that an  ACS is often 
caused by rupture or fissure of a thin-cap fibroatheroma (TCFA), a vulnerable coronary 
plaque containing a large lipid-rich necrotic core overlaid by a thin inflamed fibrous 
cap.9-12 Identification of this vulnerable coronary plaque phenotype by invasive imaging 
may therefore improve risk stratification and management of CAD patients.
To date, a few studies have investigated the prognostic value of (RF-)IVUS for ad-
verse cardiovascular outcome.13,14 The PROSPECT (Providing Regional Observations 
to Study Predictors of Events in the Coronary Tree) study demonstrated that (RF-)
IVUS-derived high-risk plaque characteristics in the three major coronary arteries pre-
dict adverse cardiac events in patients admitted with ACS during long-term follow-up.13 
However, patients with stable angina pectoris (SAP) were not included in PROSPECT, 
and the number of endpoint events in that study was primarily driven by rehospital-
izations. Our ATHEROREMO-IVUS (European Collaborative Project on Inflammation 
and Vascular Wall Remodeling in Atherosclerosis – Intravascular Ultrasound) study 
demonstrated that high-risk plaque characteristics, as derived by (RF-)IVUS in one 
non-stenotic segment of a non-culprit coronary artery were predictive of adverse car-
diovascular events in a broad spectrum of patients with CAD, including SAP, at 1-year 
follow-up.15 We now report the long-term (median 4.7 years) follow-up data.
METHODS
Study design and population
The design of the ATHEROREMO-IVUS study has been described in detail else-
where.15,16 Briefly, between 2008 and 2011, 581 patients undergoing diagnostic CAG or 
percutaneous coronary intervention (PCI) for ACS or SAP underwent (RF-)IVUS imag-
ing of a non-culprit coronary artery in the Erasmus MC, Rotterdam, The Netherlands.15,16 
Baseline (RF-)IVUS images were analyzed off-line and were not used for patient care. 
Thereafter, patients were followed-up on adverse cardiovascular outcome.
The ATHEROREMO-IVUS study was approved by the medical ethics committee of 
the Erasmus MC and was performed in accordance with the declaration of Helsinki. 
60
Chapter 4
All patients provided written informed consent which included approval for long-term 
follow-up. The ATHEROREMO-IVUS study was registered at ClinicalTrialsgov.org 
(NCT01789411). 
Intravascular ultrasound
Subsequent to the standard index CAG, (RF-)IVUS imaging was performed in a non-
stenotic segment of a non-culprit coronary artery. The target segment in this non-culprit 
coronary artery was required to be at least 40 mm in length and without significant 
luminal narrowing (<50% stenosis) as assessed by on-line angiography. The order of 
preference for selection of the non-culprit vessel was; (i) left anterior descending artery, 
(ii) right coronary artery, (iii) left circumflex artery.15,16 IVUS images were acquired by 
the Volcano s5/s5i Imaging system, including a Volcano Eagle Eye Gold IVUS catheter 
(20 MHz) that was automatically pulled back at a standard speed of 0.5 mm/s (Volcano 
Corp., San Diego, CA, USA). Grayscale- and RF-IVUS data were analyzed off-line by 
an independent core laboratory (Cardialysis, Rotterdam, The Netherlands) using the 
pcVH 2.1 and qVH software (Volcano Corp., San Diego, CA, USA). The core laboratory 
was blinded to all other patient characteristics and outcome data. 
Grayscale IVUS measurements included segmental plaque volume and plaque 
burden. The external elastic membrane and luminal borders were contoured for each 
frame (median interslice distance, 0.40 mm). Segmental plaque burden was defined as 
the plaque and media cross-sectional area divided by the external elastic membrane 
cross-sectional area. A coronary lesion was defined as a segment with a plaque burden 
of > 40% in at least 3 consecutive frames. Using RF-IVUS analyses, compositional 
features of coronary lesions were classified as fibrous, fibro-fatty, necrotic core or dense 
calcium.5,15,16 Confluent necrotic core or dense calcium, or the contact of necrotic core 
with the lumen, were assessed by visual examination performed independently by three 
investigators blinded to outcome data. Coronary lesions were further classified into 8 
different lesion types.7,15,16 The mentioned criteria should be present in three consecutive 
frames for a lesion to be considered of a particular category. Three lesions, as identified 
by (RF-)IVUS, were considered as lesions associated with a high risk for subsequent 
adverse cardiac events; 1) TCFA lesion, defined as a lesion with the presence of >10% 
confluent necrotic core in direct contact with the lumen; 2) lesion with a plaque burden 
≥70%; 3) lesion with a minimal luminal area ≤4.0mm2.15
Follow-up
Follow-up was reported by January 2015. The vital status of the patients was obtained 
from municipal civil registries. Subsequently, as a first screening method, follow-up 
questionnaires were sent to all living patients for identifying possible adverse events. 
Thereafter, hospital discharge letters were obtained if any hospitalization or possible 
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event was reported. In patients who did not return the questionnaire, the local hospital 
records were investigated for possible events. Cause of death was obtained from hos-
pital records, autopsy reports, or general practitioner notes.
Study endpoints
The pre-defined primary endpoint consisted of major adverse cardiovascular events 
(MACE), defined as the composite of all-cause death, nonfatal ACS, or unplanned re-
vascularization during long-term follow-up. In accordance with our previous studies on 
the prognostic value of (RF-)IVUS and near-infrared spectroscopy (NIRS) in this study 
population, we also performed a pre-defined analysis on the composite endpoint of car-
diac death, nonfatal ACS, or unplanned revascularization. This analysis was performed 
based on the pathophysiological concept that (RF-)IVUS-derived plaque characteristics 
would hypothetically be more likely associated with (atherosclerotic-driven) cardiovas-
cular events and not with definite noncardiac events (such as death because of malig-
nancy). Similarly, an additional analysis was performed on this endpoint after exclusion 
of definite culprit lesion–related events. This exploratory analysis aimed to determine 
whether the atherosclerotic burden, as assessed in a single, nonculprit coronary artery 
segment, would reflect vulnerability of the entire coronary tree. 
In accordance with the guidelines of the European Society of Cardiology, non-fatal 
ACS was defined as the clinical diagnosis of ST-segment Elevation Myocardial Infarc-
tion (STEMI), non-STEMI, or unstable angina.17,18 Unplanned coronary revasculariza-
tion was defined as urgent revascularization for ACS or unplanned (i.e. not part of 
pre-planned multi-stage PCI) elective revascularization for progressive angina pectoris. 
Cardiac death was defined as any death due to proximate cardiac cause, unwitnessed 
death or death of unknown cause. 
Based on original source data of available coronary angiography and hospital records 
at the time of the event, the clinical event committee adjudicated (blinded to IVUS data) 
whether the event was related to the coronary site that had been treated during the 
index procedure (culprit lesion–related event) or as related to a coronary site that had 
not been treated during the index procedure (non-culprit lesion–related event). Events 
that were related to both the culprit lesion and a non-culprit site (e.g., revasculariza-
tion of multiple vessels with coronary artery bypass grafting) were classified into both 
categories. When information was not sufficient to classify an event as either culprit 
lesion related or non-culprit lesion related, the event was classified as indeterminate.15
Statistical analysis
Normally distributed continuous variables were reported as mean ± SD. Nonnormally-
distributed variables were reported as median (interquartile range [IQR]). Categorical 
variables were reported as numbers and percentages.
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Cumulative event rates were estimated by the Kaplan-Meier method, and differences 
between groups were evaluated by the log-rank test. Patients that were lost to follow-up 
were censored at the date of last contact. In case a patient had multiple events, the first 
event was counted for the composite endpoint.
The associations between (RF-)IVUS characteristics and study endpoints were fur-
ther analyzed by Cox proportional hazard regression analysis. We applied multivariable 
Cox regression, with adjustment for age, sex, diabetes mellitus, hypertension, dyslipid-
emia, indication for CAG (ACS or SAP), history of myocardial infarction, history of PCI, 
history of coronary artery bypass grafting, history of peripheral artery disease, and PCI 
performed at index procedure. These potential confounders were chosen based on 
clinical relevance or their significant association with MACE in univariable Cox regres-
sion analysis. Hazard ratios (HRs) were reported with 95% confidence intervals (CIs).
In case the composite endpoint was defined with exclusion of culprit lesion–related 
events, the occurrence of a culprit lesion–related event as a first event during follow-up 
was not counted and the patient was not censored, as this patient is considered to be 
still at risk of a nonculprit lesion–related or indeterminate event during further follow-up. 
When the composite endpoint was based on nonculprit lesion–related or indeterminate 
events, patients were only censored in case a nonculprit lesion–related or indeterminate 
event occurred, if they were lost-to-follow-up, or if they died.
All statistical tests were 2-tailed, and p values <0.05 were considered statistically 
significant. Statistical analyses were performed using IBM SPSS statistics version 21.0 
(IBM Corp., Armonk, New York). 
RESULTS
Baseline characteristics
Mean age of the patients was 61.6 ± 11.3 years, 75.6% were men and 54.7% presented 
with an ACS (Table 1). Median segmental plaque burden was 39.1 (IQR: 30.0 to 46.4)%, 
and plaque volume was 222.7 (IQR: 136.1 to 326.6)mm3. On the basis of (RF-)IVUS, 
724 lesions were identified in 508 (87.4%) patients that had at least one lesion in the 
imaged segment, including 127 (17.5%) lesions with a plaque burden ≥70% in 124 
(21.3%) patients, 206 (28.5%) lesions with a minimal luminal area ≤4.0 mm2 in 182 
(31.3%) patients and 74 (10.2%) lesions with both plaque characteristics in 74 (12.7%) 
patients. On the basis of RF-IVUS, 271 (37.4%) TCFA lesions were identified in 242 
(41.7%) patients, including 71 (9.8%) TCFA lesions with a plaque burden ≥70% in 69 
patients (11.9%), 61 (8.4%) TCFA lesions with a minimal luminal area ≤4.0 mm2 in 61 
(10.5%) patients and 35 (4.8%) TCFA lesions with both plaque characteristics in 35 
(6.0%) patients.
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Table 1. Baseline characteristics 
 N=581 patients
Clinical characteristics  
Age, years 61.6 ± 11.3
Men, n(%) 439 (75.6)
Diabetes Mellitus, n(%) 99 (17.0)
Hypertension, n(%) 300 (51.6)
Dyslipidemia, n(%) 321 (55.2)
Current smoking, n(%) 169 (29.1)
Positive family history, n(%) 301 (51.8)
Previous MI, n(%) 184 (31.7)
Previous PCI, n(%) 186 (32.0)
Previous CABG, n(%) 18 (3.1)
Previous CVA, n(%) 26 (4.5)
History of peripheral artery disease, n(%) 36 (6.2)
History of renal impairment, n(%) 32 (5.5)
History of heart failure, n(%) 19 (3.3)
Median C-reactive protein, mg/L 2.1 [0.9-5.4]
Procedural characteristics  
Indication for coronary angiography 
Acute MI, n(%) 167 (28.7)
Unstable angina, n(%) 151 (26.0)
Stable angina, n(%) 254 (43.7)
Other, n(%) 9 (1.5)
PCI performed, n(%) 511 (88.0)
Coronary artery disease
No significant stenosis, n(%) 43 (7.4)
1-vessel disease, n(%) 308 (53.0)
2-vessel disease, n(%) 168 (28.9)
3-vessel disease, n(%) 62 (10.7)
IVUS characteristics  
Imaged coronary artery 
Left anterior descending, n(%) 210 (36.1)
Left circumflex, n(%) 195 (33.6)
Right coronary artery, n(%) 176 (30.3)
Median imaged segment length, mm 44.3 [33.8-55.4]
Median segmental plaque burden, % 39.1 [30.0-46.4]
Median segmental plaque volume, mm3 222.7 [136.1-326.6]
CABG: coronary artery bypass graft, CVA: cerebrovascular accident, IVUS: intravascular ultrasound, MI: myocar-
dial infarction, PCI: percutaneous coronary intervention
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Incidence of study endpoints
Median follow-up time was 4.7 (IQR: 4.2 to 5.6) years. Follow-up questionnaires were 
sent to all 528 (90.9%) living patients and were completed by 86%. The predefined 
composite endpoint of all-cause death, non-fatal ACS or unplanned revascularization 
occurred in 152 patients (26.2%) (Table 2). A total of 27 events were classified as 
definite culprit lesion-related, 72 as non-culprit lesion-related and 53 as indeterminate 
event (Table 2). The composite endpoint of cardiac death, non-fatal ACS or unplanned 
revascularization occurred in 125 patients (21.5%) (Table 2). The composite endpoint of 
cardiac death, non-fatal ACS or unplanned revascularization after exclusion of definite 
culprit lesion-related events occurred in 98 patients (16.9%) (Table 2).
Association between (RF-)IVUS and MACE
The presence of a lesion with a minimal luminal area ≤4.0 mm2 was significantly and in-
dependently associated with MACE (cumulative MACE incidence when present: 33.9% 
vs. 22.2% when absent; adjusted HR: 1.49; 95% CI: 1.07 to 2.08; p = 0.020) (Table 3). 
Furthermore, the presence of a TCFA lesion with a plaque burden ≥70% was significantly 
associated with MACE (cumulative MACE incidence when present: 37.7% vs. 24.6% 
when absent; adjusted HR: 1.73; 95% CI: 1.12 to 2.66; p = 0.013), while the presence 
of a TCFA lesion or a lesion with a plaque burden ≥70% itself was not independently as-
sociated with MACE (Table 3). After multivariable adjustment, segmental plaque burden 
and plaque volume remained no longer independently associated with MACE (Table 
3). The results were essentially similar when definite culprit lesion–related events were 
excluded. Cox regression analysis with follow-up duration as a time-dependent variable 
showed that both the presence of a TCFA lesion and a lesion with a plaque burden 
≥70% were strong predictors of MACE for the first year of follow-up, but not beyond 
Table 2. Incidence of composite endpoints
 Definite CLR events
Definite non-
CLR events
Indeterminate 
events
Non-CLR and 
indeterminate 
events 
combined
All events
Composite of MACE, n 27 72 53 125 152*
Death from any cause, n 1 11 38 49 50
Cardiac death, n 1 4 20 24 25
Nonfatal ACS, n 13 24 10 34 47
Unplanned revascularization, n 13 37 5 42 55
Composite of cardiac death, nonfatal 
ACS or unplanned revascularization, n 27 63 35 98
† 125‡
Numbers refer to the first event counted for the composite endpoint.
*Composite of MACE; all-cause death, nonfatal ACS or unplanned revascularization.
†Non-culprit lesion-related and indeterminate cardiac death, nonfatal ACS or unplanned revascularization.
‡Composite of cardiac death, nonfatal ACS or unplanned revascularization.
ACS: acute coronary syndrome, CLR: culprit lesion-related, MACE: major adverse cardiovasulcar events
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Table 3. Associations of (RF-)IVUS and risk of adverse cardiac events at 4.7-years follow-up
Unadjusted model Full model
HR (95% CI) p-value HR (95% CI) p-value
MACE
 TCFA 1.20 (0.87-1.65) 0.27 1.27 (0.91-1.77) 0.16
 PB ≥70% 1.50 (1.05-2.16) 0.028 1.33 (0.92-1.93) 0.13
 MLA ≤4.0 mm2 1.57 (1.13-2.17) 0.007 1.49 (1.07-2.08) 0.020
 TCFA + PB ≥70% 1.90 (1.25-2.90) 0.003 1.73 (1.12-2.66) 0.013
 TCFA + MLA ≤4.0 mm2 1.47 (0.93-2.33) 0.10 1.50 (0.93-2.44) 0.10
 TCFA + PB ≥70% + MLA ≤4.0 mm2 1.64 (0.93-2.89) 0.089 1.74 (0.97-3.13) 0.066
 PB≥70% + MLA ≤4.0 mm2 1.29 (0.83-2.01) 0.26 1.30 (0.82-2.04) 0.26
 Segmental plaque burden, % 1.24 (1.07-1.44) 0.004 1.15 (0.98-1.34) 0.079
 Segmental plaque volume, mm3 1.07 (0.96-1.20) 0.23 1.02 (0.90-1.14) 0.79
Composite endpoint of cardiac death, non-fatal ACS or unplanned revascularization
 TCFA 1.04 (0.73-1.49) 0.83 1.12 (0.77-1.61) 0.56
 PB ≥70% 1.63 (1.10-2.42) 0.014 1.43 (0.96-2.15) 0.083
 MLA ≤4.0 mm2 1.85 (1.30-2.64) 0.001 1.82 (1.26-2.64) 0.001
 TCFA + PB ≥70% 1.95 (1.23-3.09) 0.005 1.78 (1.11-2.85) 0.017
 TCFA + MLA ≤4.0 mm2 1.74 (1.08-2.81) 0.023 1.86 (1.11-3.10) 0.018
 TCFA + PB ≥70% + MLA ≤4.0 mm2 1.84 (1.02-3.34) 0.044 2.09 (1.12-3.89) 0.020
 PB≥70% + MLA ≤4.0 mm2 1.45 (0.91-2.32) 0.12 1.51 (0.93-2.45) 0.093
 
 Segmental plaque burden, % 1.28 (1.09-1.50) 0.003 1.17 (0.99-1.39) 0.070
 Segmental plaque volume, mm3 1.06 (0.93-1.20) 0.40 0.98 (0.86-1.12) 0.80
Composite endpoint  of cardiac death, non-fatal ACS or unplanned revascularization exclusive of culprit lesion-related 
events
 TCFA 0.99 (0.66-1.48) 0.95 1.07 (0.70-1.62) 0.76
 PB ≥70% 2.08 (1.36-3.18) 0.001 1.66 (1.06-2.58) 0.026
 MLA ≤4.0 mm2 2.03 (1.37-3.03) <0.001 1.88 (1.24-2.83) 0.003
 TCFA + PB ≥70% 2.17 (1.32-3.59) 0.002 1.84 (1.10-3.07) 0.021
 TCFA + MLA ≤4.0 mm2 1.64 (0.95-2.84) 0.078 1.75 (0.98-3.13) 0.059
 TCFA + PB ≥70% + MLA ≤4.0 mm2 1.97 (1.02-3.79) 0.042 2.03 (1.03-4.02) 0.041
 PB≥70% + MLA ≤4.0 mm2 1.77 (1.07-2.92) 0.026 1.73 (1.04-2.90) 0.035
 
 Segmental plaque burden, % 1.41 (1.18-1.69) <0.001 1.26 (1.03-1.52) 0.022
 Segmental plaque volume, mm3 1.13 (0.99-1.30) 0.080 1.03 (0.89-1.20) 0.68
Hazard ratios per 10 and 100 units increase in segmental plaque burden and plaque volume, respectively.
CI: confidence interval, HR: hazard ratio, IVUS: intravascular ultrasound, MACE: major adverse cardiovascular events, 
MLA: minimal luminal area, PB: plaque burden, RF: radiofrequency, TCFA: thin-cap fibroatheroma
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1-year follow-up. On the contrary, a lesion with a minimal luminal area ≤4.0 mm2 itself 
was not an independent predictor in the first year of follow-up (adjusted HR: 1.40; 95% 
CI: 0.83 to 2.34; p = 0.21), but did predict MACE beyond 1-year of follow-up (1-year to 
5-year follow-up adjusted HR: 1.58; 95% CI: 1.04 to 2.40; p = 0.032). Results remained 
essentially similar when we performed an exploratory multivariable analysis applying 
the model used for the 1-year follow-up data (which comprised 6 variables instead of 
the 11 variables used in the model for the current analyses) (Table 4).
Association between (RF-)IVUS and the composite endpoint of car-
diac death, non-fatal ACS or unplanned revascularization
The presence of a lesion with a minimal luminal area ≤4.0 mm2 was also significantly 
and independently associated with a higher rate of the composite endpoint of cardiac 
death, nonfatal ACS, or unplanned revascularization (cumulative incidence of compos-
ite endpoint when present: 30.6% vs. 16.9% when absent; adjusted HR: 1.82; 95% CI: 
1.26 to 2.64; p = 0.001) (Figure 1, Table 3). The same was true for TCFA lesions with a 
plaque burden ≥70% or a minimal luminal area ≤4.0 mm2 (Table 3). The highest risk, in 
Table 4. Associations of (RF-)IVUS characteristics and risk of MACE at 4.7-years of follow-up 
using two different models for multivariable adjustment
 
1-year follow-up 
data adjusted model
with 6 covariates  
5-year follow-up 
data adjusted model
with 6 covariates  
5-year follow-up 
data adjusted model
with 11 covariates  
HR (95% CI) p-value HR (95% CI)* p-value HR (95% CI)† p-value
MACE       
TCFA 1.98 (1.09-3.60) 0.026 1.25 (0.90-1.73) 0.18 1.27 (0.91-1.77) 0.16
PB≥70% 2.90 (1.60-5.25) <0.001 1.42 (0.99-2.05) 0.059 1.33 (0.92-1.93) 0.13
MLA≤4.0mm2 1.23 (0.67-2.26) 0.50 1.51 (1.09-2.09) 0.014 1.49 (1.07-2.08) 0.020
TCFA+PB≥70% - - 1.80 (1.18-2.75) 0.007 1.73 (1.12-2.66) 0.013
TCFA+ MLA≤4.0mm2 - - 1.61 (1.01-2.57) 0.046 1.50 (0.93-2.44) 0.10
TCFA+PB≥70%+ 
MLA≤4.0mm2
- - 1.82 (1.02-3.26) 0.043 1.74 (0.97-3.13) 0.066
Segmental plaque burden 
(per 10 units increase)
- - 1.17 (1.01-1.36) 0.040 1.15 (0.98-1.34) 0.079
Segmental plaque volume 
(per 100 units increase)
- - 1.03 (0.92-1.16) 0.63 1.02 (0.90-1.14) 0.79
* Variables entered in the 6-covariate model were age, sex, diabetes mellitus, hypertension, history of percutane-
ous coronary intervention, and indication for coronary angiography.
† Variables entered in the 11-covariate model were age, sex, diabetes mellitus, hypertension, history of percutane-
ous coronary intervention, indication for coronary angiography, dyslipidemia, history of myocardial infarction, his-
tory of coronary artery bypass grafting, history of peripheral artery disease, and percutaneous coronary intervention 
performed at index.
CI: confidence interval, HR: hazard ratio, IVUS: intravascular ultrasound, MACE: major adverse cardiovascular 
events, MLA: minimal luminal area, PB: plaque burden, RF: radiofrequency, TCFA: thin-cap fibroatheroma
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terms of adjusted HRs, was among patients who had a TCFA lesion with both a plaque 
burden ≥70% and a minimal luminal area ≤4.0 mm2 (cumulative incidence of composite 
endpoint when present: 34.3% vs. 20.7% when absent; adjusted HR: 2.09; 95% CI: 
1.12 to 3.89; p = 0.020) (Table 3).
These associations remained essentially unchanged after exclusion of culprit lesion–
related events (Figure 2, Table 3). In addition, a signifi cant association was observed for 
the presence of a lesion with a plaque burden ≥70%, or its combination with a minimal 
luminal area ≤4.0 mm2, as well as for segmental plaque burden with each 10-U in-
crease in segmental plaque burden resulting in a 26% increase in risk for occurrence of 
the composite endpoint of cardiac death, nonfatal ACS, or unplanned revascularization 
after exclusion of culprit lesion-related events (adjusted HR: 1.26 per 10-U increase; 
95% CI: 1.03 to 1.52; p =0.022) (Figure 2, Table 3).
Figure 1. Association between the absence or presence of a lesion with a minimal luminal 
area ≤4.0 mm2  and the composite endpoint of cardiac death, non-fatal ACS or unplanned 
revascularization. 
P-value obtained by the Log-rank test.
ACS: acute coronary syndrome, IVUS: intravascular ultrasound
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DISCUSSION
This 4.7-year follow-up of the ATHEROREMO-IVUS study demonstrated that a small 
luminal area and a large plaque burden, but not RF-IVUS–derived compositional plaque 
features on their own, are independent determinants of (nonculprit lesion–related) ad-
verse cardiac events in patients with CAD. The increased risk associated with a minimal 
luminal area ≤4.0 mm2 was not observed at 1-year follow-up,15 whereas the prognostic 
value of plaque burden ≥70% was confi rmed, although statistical signifi cance was not 
consistently present for all diff erent composite endpoints. In contrast, the independent 
association between a TCFA lesion as an isolated characteristic and adverse outcome 
at 1 year did not persist during long-term follow-up. Still, patients with a TCFA lesion 
with a large plaque burden and/or a small luminal area were at increased risk.
Figure 2. Association between (RF-)IVUS derived lesion characteristics and the composite 
endpoint of cardiac death, non-fatal ACS or unplanned revascularization, after exclusion of 
culprit lesion-related events. 
Percentages are cumulative events rates estimated by the Kaplan-Meier method. Prevalence (%) in the footer re-
fers to the prevalence of the specifi c (RF-)IVUS characteristic. P-values are obtained by the Log-rank test. Hazard 
ratios are estimated by univariate Cox regression analyses. 
ACS: acute coronary syndrome, HR: hazard ratio, MLA: minimal luminal area, PB: plaque burden, TCFA: thin-cap 
fi broatheroma
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In line with the PROSPECT study, we found that a lesion with a large plaque bur-
den, small luminal area, or their combination with a TCFA lesion predicted adverse 
cardiovascular events in patients with CAD during long-term follow-up. In contrast 
to the PROSPECT and VIVA (Virtual histologyIntravascular ultrasound in Vulnerable 
Atherosclerosis) studies, we did not find such an independent association for a TCFA 
lesion on its own.13,14 However, the results of our study and the PROSPECT study 
cannot be directly compared since different definitions of study endpoints were used. 
In addition, PROSPECT only included patients admitted with ACS and the study end-
point was primarily driven by rehospitalizations.13 Furthermore, in the VIVA study only 
univariable regression analysis was performed due to the small number of endpoints.14 
Importantly, in both the PROSPECT and VIVA study, (RF-)IVUS was applied in all three 
major coronary arteries, whereas in our study only one single non-stenotic non-culprit 
coronary artery segment was investigated.13,14
We consider several possible explanations for the inconsistent association between 
the presence of a TCFA lesion as an isolated characteristic and the risk of adverse 
cardiac events during short-term versus long-term follow-up. First, controversy exists 
about the ability of RF-IVUS to correctly discern and identify the thin-cap and necrotic 
core as individual components of a TCFA lesion, due to the limitations with respect to 
spatial resolution.4,19 Secondly, the dynamic nature of TCFA lesions over time should 
be appreciated, because it has been described that particularly (proximal) TCFA le-
sions with a large plaque burden heal less often and might have a greater tendency to 
rupture.20 This may explain our finding that the presence of a TCFA lesion with a large 
plaque burden was associated with an increased risk for adverse cardiac events over 
4.7-years of follow-up, whereas a TCFA lesion in itself was not. Thirdly, previous studies 
have demonstrated that a lesion with a large plaque burden is a consistent and prevalent 
predictor for adverse cardiac outcome. However, whereas the atherosclerotic disease 
burden has been shown as a consistent and strong predictor of adverse cardiovascu-
lar events, no study has yet demonstrated that a TCFA lesion by itself independently 
predicts adverse cardiovascular outcome after adjustment for plaque burden and other 
potential confounders.13,14,21,22
Our current study suggests that a RF-IVUS-derived TCFA lesion only has long-term 
prognostic value if accompanied with other high-risk plaque features. Therefore, this 
study further adds to the discussion as to whether RF-IVUS offers incremental prog-
nostic value to grayscale IVUS in terms of identification of high-risk coronary plaque 
phenotypes based on compositional features. In addition, our current study demon-
strates for the first time that (RF-)IVUS plaque characteristics, as assessed in one 
non-stenotic segment of a non-culprit coronary artery, predicts adverse cardiovascular 
events in patients with CAD during long-term follow-up. A post hoc analysis did not 
show heterogeneity in the HR estimates in patients with ACS versus SAP.  Moreover, 
70
Chapter 4
the large number of endpoints allowed for a separate analysis with exclusion of culprit-
lesion related endpoint events, with results that remained essentially unchanged. This 
indicates that (RF-)IVUS-derived plaque characteristics, as identified in one non-culprit 
coronary artery segment, may reflect atherosclerotic vulnerability of the entire coronary 
tree.
Recently, we have demonstrated that the lipid core burden index, as assessed by 
NIRS in a single non-culprit coronary artery segment, predicts adverse cardiovascular 
outcome, independent of clinical characteristics and IVUS-derived segmental plaque 
burden, over 4 years in CAD patients referred for CAG.23 In this context, a combined 
NIRS-IVUS catheter may improve the (long-term) prognostic value of intravascular 
imaging in patients with CAD.24
Study limitations
First, the number of TCFA lesions might be overestimated by RF-IVUS because of 
the limited spatial resolution with respect to the identification of the thin cap of a TCFA 
lesion. Second, IVUS imaging was not repeated during follow-up. Therefore, we could 
not account for the potential dynamic nature of coronary lesions. It should also be 
noted that this study does not provide insight into how the individual lesion correlates 
to the adverse event. Third, the follow-up questionnaire was completed by 86% of the 
patients. Although, for the majority of the remaining patients, follow-up information was 
retrieved from our local hospital records, we cannot fully exclude the possibility that 
loss to follow-up was in part selective. However, our study reflects daily clinical practice, 
because patients admitted with both ACS and SAP were included. Besides, the current 
study represents a long-term study investigating the association between (RF-)IVUS-
derived plaque characteristics and adverse cardiovascular outcome during 4.7-years of 
follow-up in patients with ACS or SAP, which represents the longest follow-up reported 
so far.
Conclusions
This study demonstrates that a small luminal area and a large plaque burden, and not 
RF-IVUS–derived compositional plaque features on their own, as assessed by (RF-)
IVUS in one single non-stenotic segment of a non-culprit coronary artery, predict (non-
culprit lesion–related) adverse cardiovascular outcomes during long-term follow-up 
over 4.7 years in patients with CAD. In contrast, this study did not show a single isolated 
imaging parameter as derived by RF-IVUS to be of long-term independent prognostic 
value.
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ABSTRACT
Objective
SYNTAX score II (SSII) is a long-term mortality prediction model to guide the decision 
making of the heart-team between coronary artery bypass grafting or percutaneous 
coronary intervention (PCI) in patients with left main or three-vessel coronary artery 
disease. This study aims to investigate the long-term predictive value of SSII for all-
cause mortality in patients with one- or two-vessel disease undergoing PCI.
Methods 
A total of 628 patients (76% men, mean age: 61±10 years) undergoing PCI due to stable 
angina pectoris (43%) or acute coronary syndrome (57%), included between January 
2008 and June 2013, were eligible for the current study. SSII was calculated using 
the original SYNTAX score website (www.syntaxscore.com). Cox regression analysis 
was used to assess the association between continuous SSII and long-term all-cause 
mortality. The area under the receiver-operating characteristic curve was used to as-
sess the performance of SSII.
Results
SSII ranged from 6.6 to 58.2 (median: 20.4, interquartile range: 16.1-26.8). In multi-
variable analysis, SSII proved to be an independent significant predictor for 4.5-year 
mortality (hazard ratio per point increase: 1.10; 95% confidence interval: 1.07-1.13; 
p<0.001). In terms of discrimination, SSII had a concordance index of 0.77.
Conclusion
In addition to its established value in patients with left main and three-vessel disease, 
SSII may also predict long-term mortality in PCI-treated patients with one- or two-vessel 
disease. 
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INTRODUCTION
The SYNTAX score II (SSII) has been established as a long-term mortality prediction 
model to guide the decision making of the heart-team between coronary artery bypass 
grafting (CABG) or percutaneous coronary intervention (PCI) in patients with complex 
coronary artery disease (CAD).1 It combines the original anatomical-based SYNTAX 
score, which grades the complexity of CAD in all coronary arteries, with the clinical 
baseline variables that have shown to be important predictors of 4-year all-cause mor-
tality in the SYNTAX trial.1 
SSII has been validated in large patient cohorts with left main or three-vessel dis-
ease.1-3 However, the predictive performance of SSII on long-term mortality in patients 
with less complex CAD is currently unknown.
This study aims to investigate the long-term predictive value of SSII for all-cause 
mortality in patients with one- or two-vessel disease undergoing PCI. 
METHODS
Study design and population
This study combines the populations of The European Collaborative Project on Inflam-
mation and Vascular Wall Remodeling in Atherosclerosis-intravascular ultrasound 
(ATHEROREMO-IVUS) study and the Integrated Biomarker and Imaging Study-3 
(IBIS-3).4, 5 Study designs and methods of ATHEROREMO-IVUS and IBIS-3 have been 
described in detail elsewhere.4, 5 Baseline study procedures and inclusion criteria were 
similar and both studies were conducted at the Erasmus Medical Center, Rotterdam, 
The Netherlands. In brief, patients undergoing diagnostic coronary angiography (CAG) 
or PCI for an acute coronary syndrome (ACS) or stable angina pectoris (SAP) were 
included. During CAG, invasive imaging was performed in one non-culprit coronary 
artery segment. Subsequently, patients were followed-up on adverse cardiovascular 
events. Patient care was left at the discretion of the physician. During the first year after 
the index procedure, as per protocol, patients included in IBIS-3 received high dose 
rosuvastatin. 
The medical ethics committee of the Erasmus MC approved both the ATHEROREMO-
IVUS and IBIS-3 study. Both studies were performed in accordance with the declaration 
of Helsinki. All patients provided written informed consent for their participation in these 
studies, and compliance with the study protocols, including long-term follow-up. The 
ATHEROREMO-IVUS study is registered in ClinicalTrials.gov, number NCT01789411, 
and the IBIS-3 study is registered in The Netherlands trial register, number NTR2872.
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SYNTAX score II
The anatomical-based SYNTAX score was determined (pre-PCI) for every coronary 
angiogram taken at study entry, by a trained analyst blinded for patient characteristics 
and outcome using the SYNTAX Score Calculator (www.syntaxscore.com). The calcu-
lation of the anatomical-based SYNTAX score has been described in detail previously.6 
In brief, the complete coronary tree is divided in 16 segments and assessed for lesions 
producing 50% or more luminal obstruction. Every segment has a pre-specified corre-
sponding weighing factor which, in case of a significant lesion, is added to the SYNTAX 
score by the SYNTAX Score Calculator. Moreover, other variables (i.e. calcification or 
lesion length) that reflect the complexity of a patient’s CAD and, thus, the complexity of 
treatment are assessed and taken into account in the SYNTAX score. Eventually, the 
SYNTAX score is composed of these total points summed, and reflects the complexity 
of a patient’s CAD. As previously applied in other all-comers and ST-segment elevation 
myocardial infarction (STEMI) populations, lesions caused by in-stent restenosis were 
treated as de novo lesions.7-9 Total occlusions were scored as occlusions of unknown 
duration, as the analyst was blinded for all patient information.10 
Subsequently, data on the baseline variables age, gender, creatinine clearance 
(CRCL), left ventricular ejection fraction (LVEF), peripheral vascular disease and 
chronic obstructive pulmonary disease was collected for the calculation of SSII. We 
used the original SYNTAX Score II Calculator (www.syntaxscore.com) to obtain all SSII 
values. The algorithm of the SSII calculation has been described in detail elsewhere.1
Study endpoint 
The primary endpoint was all-cause mortality. Vital status of the patients was obtained 
from municipal civil registries.
Statistical analysis
The distribution of continuous variables was examined for normality with the Kolmogo-
rov-Smirnov test. ANOVA or Kruskal-Wallis test were used for multiple group compari-
son of continuous variables. Categorical variables were compared using the Pearson 
Chi-square test. 
Data for most of the variables used for the calculation of SSII were complete. 
However, creatinine, required for the calculation of CRCL, was available in 92.8% of 
the patients. LVEF was available in 72.0% of the patients and categorized as good 
(LVEF≥50%), moderate (LVEF 40-49%) and poor (LVEF<40%).11 Because LVEF was 
reported qualitatively, a value of 50% was used for category good, 44.5% for category 
moderate and 35% for category poor for the calculation of SSII. Multiple imputation 
technique was used to impute the missing data of creatinine and LVEF. Ten imputed 
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data sets were generated. Analyses were conducted for both the complete dataset as 
the imputed datasets, which showed similar results.   
Long-term cumulative incidences of all-cause mortality, categorized by SSII in ter-
tiles, were compared with the log-rank test. Cox regression analysis was used to assess 
the association between continuous SSII and long-term all-cause mortality. Patients 
that were lost to follow-up were censored at the date of last contact. Based on exist-
ing literature, variables known to be associated with mortality and not part of the SSII 
(diabetes mellitus, hypertension, smoking, previous PCI and indication for coronary 
angiography) were entered in a multivariable Cox model. Since our study population 
also includes STEMI-patients and the use of SSII has been validated in stable patients, 
a subgroup analysis was performed in patients with SAP only, to compare the results 
of the total study population with the results found in patients with SAP only. In terms 
of discrimination, the area under the receiver-operating characteristic (ROC) curve was 
assessed. All statistical test were two-sided with a type I error level of 0.05. Analyses 
were performed with IBM SPSS Statistics version 21.0.
RESULTS
A total of 628 patients (76% men, mean age: 61 ±10 years) undergoing PCI due to SAP 
(43%) or ACS (57%), included between January 2008 and June 2013, were eligible for 
the current study (Table 1). SSII ranged from 6.6 to 58.2 (median: 20.4, IQR: 16.1-26.8). 
All-cause mortality occurred in 44 patients (7.0%) during a median follow-up of 4.5 
(IQR: 3.4-4.9) years. Patients with a high SSII were older, had a higher prevalence of 
diabetes mellitus, hypertension, hypercholesterolemia and COPD, and more frequently 
had a history of renal insufficiency or heart failure than patients with a mid or low SSII.
Cumulative incidence of all-cause mortality categorized by SSII in tertiles is shown 
in Figure 1. The long-term cumulative incidence of all-cause mortality of patients with 
a high SSII showed to be significantly higher than for patients with a mid or low SSII. 
No statistically significant difference was found between the cumulative incidence of 
all-cause mortality of patients with a mid versus low SSII value. 
In the multivariable Cox model (Table 2), SSII proved to be an independent signifi-
cant predictor for 4.5-year mortality (hazard ratio [HR] per point increase: 1.10; 95% 
confidence interval [CI]: 1.07-1.13). For SAP patients only, results were similar to the 
total study population (HR: 1.06; 95%CI: 1.07-1.11). In terms of discrimination, SSII had 
a concordance index (c-index) of 0.77 (95%CI: 0.69-0.84) (Figure 2).
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Table 1. Baseline characteristics
 
SSII ≤17 17< SSII ≤24 SSII >24  
(n = 209) (n = 210) (n = 209) p-value 
Clinical characteristics     
Age - yrs, ± sd 52.9 ± 7.8 61.5 ± 8.1 69.0 ± 9.2 <0.001
Men, n(%) 204 (97.6) 163 (77.6) 109 (52.2) <0.001
Diabetes mellitus, n(%) 28 (13.4) 40 (19.0) 49 (23.4) 0.051
Hypertension, n(%) 91 (34.5) 112 (53.3) 134 (64.1) <0.001
Hypercholesterolemia, n(%) 96 (45.9) 120 (57.1) 127 (60.8) 0.025
Current smoking, n(%) 88 (42.3) 60 (28.6) 47 (22.5) <0.001
Previous MI, n(%) 55 (26.3) 57 (27.1) 64 (30.6) 0.48
Previous PCI, n(%) 58 (27.8) 65 (31.0) 60 (28.7) 0.74
Previous CVA, n(%) 10 (4.8) 10 (4.8) 18 (8.6) 0.16
History of PAD, n(%) 0 (0.0) 0 (0.0) 46 (22.0) <0.001
History of renal insufficiency, n(%) 6 (2.9) 4 (1.9) 20 (9.6) <0.001
History of heart failure, n(%) 1 (0.5) 2 (1.0) 10 (4.8) 0.003
COPD, n(%) 1 (0.5) 9 (4.3) 23 (11.0) <0.001
Serum creatinine - µmol/L, ± sd 77.3 ± 13.2 74.8 ± 17.3 84.6 ± 28.3 <0.001
Creatinine clearance - ml/min, ± sd 127.8 ± 31.8 111.9 ± 34.3 80.1 ± 27.8 <0.001
LVEF, n (%) <0.001
Good LVEF ≥50% 189 (90.4) 156 (74.2) 136 (65.1)
Moderate LVEF 40-49% 20 (9.6) 54 (25.8) 65 (31.1)
Poor LVEF <40% 0 (0.0) 0 (0.0) 8 (3.8)  
Angiographic characteristics     
Indication for angiography, n(%) 0.16
Acute MI 77 (36.8) 64 (30.6) 51 (24.4)
Unstable angina 58 (27.8) 57 (27.3) 61 (29.2)
Stable angina 74 (35.4) 99 (47.4) 97 (46.4)
Coronary artery disease, n(%) 0.007
1-vessel disease 146 (69.9) 118 (56.5) 115 (55.0)
2-vessel disease 63 (30.1) 92 (43.5) 94 (45.0)
Median SS [IQR] 5.0 [3.0-9.0] 9.0 [5.0-13.5] 9.0 [5.0-15.0] <0.001
CI: confidence interval, COPD: Chronic obstructive pulmonary disease, CVA: Cerebrovascular accident, IQR: inter 
quartile range, LVEF: left ventricular ejection fraction, MI: Myocardial infarction, PAD: Peripheral artery disease, 
PCI: Percutaneous coronary intervention, sd: standard deviation, SS: SYNTAX score, SSII: SYNTAX score II, yrs: 
years
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Figure 1. Cumulative incidence of all-cause mortality at 4.5 years
SSII is divided in tertiles with cut-off points 17 and 24 to compare the cumulative all-cause mortality proportions 
between patients with a low, mid or high SSII value. 
SSII: Syntax score II 
Table 2. Prediction of long-term mortality 
Total population (n=628)   SAP patients only (n=270)   
 Unadjusted HR 
(95%CI) 
p-value  Unadjusted HR 
(95%CI) 
p-value
SSII 1.09 (1.07-1.12) <0.001 SSII 1.05 (1.00-1.10) 0.050
 Adjusted HR 
(95%CI) 
  Adjusted HR 
(95%CI) 
 
SSII 1.10 (1.07-1.13) <0.001 SSII 1.06 (1.07-1.11) 0.037
Smoking 1.01 (0.52-1.98) 0.97 Smoking 1.52 (0.48-4.82) 0.48
Diabetes mellitus 1.60 (0.79-3.24) 0.19 Diabetes mellitus 1.56 (0.52-4.62) 0.43
Hypertension 0.88 (0.46-1.68) 0.70 Hypertension 0.59 (0.21-1.71) 0.33
Previous PCI 1.09 (0.54-2.18) 0.82 Previous PCI 0.59 (0.20-1.75) 0.35
Indication for CAG, SAP 0.59 (0.30-1.15) 0.12     
SSII incorporates the anatomical Syntax score, age, gender, creatinine clearance, left ventricular ejection fraction, 
peripheral vascular disease and chronic obstructive pulmonary disease.  
CAG: coronary angiography, CI: confidence interval, HR: hazard ratio, PCI: percutaneous coronary intervention, 
SAP: stable angina pectoris, SSII: Syntax score II
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DISCUSSION
In this study, we validated for the first time the use of SSII for prediction of long-term 
mortality in a large PCI-treated patient population with one- or two-vessel disease. 
SSII demonstrated to be an independent predictor for 4.5-year all-cause mortality in 
multivariable analysis. Moreover, in terms of discrimination, SSII had a c-index of 0.77 
which is in line with the internally and externally validated c-indices of 0.73 and 0.72, 
respectively, of SSII in the SYNTAX trial for CABG or PCI-treated patients with left main 
or three-vessel disease.1 It is also in line with the c-index (0.75) of SSII found in a study 
of patients with left main or three-vessel disease treated with only PCI.3
Although other known predictors of all-cause mortality in patients with CAD which 
are not part of SSII, such as diabetes mellitus, hypertension and prior PCI, were 
entered in the multivariable Cox model, SSII demonstrated to be the only significant 
predictor for 4.5-year all-cause mortality. Diabetes mellitus is a well-known predictor for 
adverse outcome in patients treated with PCI.12 However, our findings imply that SSII 
incorporates enough relevant clinical prognostic variables to predict long-term all-cause 
mortality in patients with one- or two-vessel disease. Recently, the performance of SSII 
has been compared in diabetic patients versus non-diabetic patients with multi-vessel 
or left main disease undergoing PCI.13 The SSII showed to have a good discriminative 
ability in both patient groups, independent of diabetic status. It may be hypothesized 
Figure 2. Sensitivity and specificity of SSII for the long-term prediction of all-cause mortality 
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that other clinical variables incorporated in the SSII, such as CRCL, sufficiently reflect 
the influence of diabetes mellitus. In this respect, a previous study has demonstrated 
that kidney disease is of greater importance than diabetes mellitus for risk prediction of 
adverse outcome in patients with CAD.14
SSII has been developed for individual risk assessment using a continuous scale to 
overcome the limitations of categorized risk scores. Our study validates the use of SSII 
in patients with one- or two-vessel disease, demonstrating a similar discrimination as 
previously reported in left main or three-vessel disease. 
Limitations
In our study, the calculation of anatomical-based SYNTAX score for SSII  included small 
vessels of at least 1.5mm and intermediate stenosis causing luminal obstruction of 
<70%, as instructed by the SYNTAX trial.6 However, as recently observed in prospec-
tive registries, intermediate stenosis and small vessels <2.0 mm may not have additive 
predictive value for the prognosis of late mortality.15-17 Hence, SSII calculated when 
only including severe stenosis of >70% in vessels of at least 2 mm, may even more 
accurately predict late mortality than currently observed in our study.
Further, the modest reproducibility of the anatomical-based SYNTAX score has to be 
acknowledged.18 However, since our study population with one- or two-vessel disease 
had a relatively low angiographic burden, we expected a fair reproducibility of the 
anatomical-based SYNTAX score. To assess the reproducibility, a second experienced 
analyst repeated the anatomical-based SYNTAX score analysis in a representative ran-
dom sample, blinded for patient information and previously scored SXscores. Cohen’s 
kappa was 0.91, which indicated a good interobserver agreement. Furthermore, since 
SSII is used in a continuous manner and incorporates both anatomical as well as clini-
cal variables, SSII offers higher accuracy than the original anatomical-based SYNTAX 
score.3 
In addition, our single-center study needs external validation. As expected, the 
median SSII score in our population was lower than in the original SSII report and 
further research is required to investigate the relation between the actual SSII and 
corresponding event rate in one- or two-vessel disease. 
Conclusion
This study validates the predictive performance of SSII in patients with one- or two- ves-
sel disease indicating that, in addition to its known value in patients with left main or 
three-vessel disease, SSII may also offer accurate risk prediction in patients with less 
complex CAD.
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ABSTRACT 
Prior studies reported that Myeloperoxidase and Galectin-3, which are biomarkers of 
coronary plaque vulnerability, are elevated in acute coronary syndrome (ACS) patients. 
We studied the temporal evolution of these biomarkers early after ACS admission and 
prior to a recurrent ACS event during 1 year follow-up.
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INTRODUCTION
Myeloperoxidase (MPO) and Galetin-3 (GAL-3) are pro-inflammatory proteins that pro-
mote plaque vulnerability through various mechanisms such as nitric oxide catalysation, 
foam cell formation and vascular smooth muscle cell dedifferentiation.1, 2 Both biomark-
ers, measured at admission, have been associated with cardiac death and non-fatal 
myocardial infarction (MI) during follow-up in patients with acute coronary syndrome 
(ACS).1, 3, 4 Since plaque vulnerability and thus coronary artery disease (CAD) is a highly 
dynamic process, repeated measurements of MPO and GAL-3 during follow-up may 
contain additional predictive value in post-ACS patients. To evaluate this hypothesis, 
we studied the evolution of these biomarkers in detail by means of highly frequent serial 
measurements during one year after ACS admission.
METHODS
Study Design
The BIOMarker study to identify the Acute risk of a Coronary Syndrome (BIOMArCS) 
was designed to reveal temporal evolutions of cardiovascular (CV) biomarkers during 
1 year follow-up in ACS patients.5, 6 Differences in temporal changes between patients 
with and without a recurrent ACS (reACS) were of particular interest. A total of 844 
patients were enrolled in 18 Dutch hospitals, who were aged ≥40 years and had ≥1 CV 
risk factor. Blood sampling was scheduled every two weeks during the first half-year 
and monthly during the second half-year, with the first sample taken at admission or 
at the first outpatient visit (4-6 weeks) after discharge. The study endpoint was defined 
as the composite of cardiac death, MI, or unstable angina requiring urgent coronary 
revascularization, and was reached by 45 patients. BIOMArCS was approved by the 
Institutional Review Boards of all participating hospitals, and all patients gave informed 
consent. BIOMArCS is registered in The Netherlands Trial Register as NTR1698.
Case-cohort approach
A case-cohort approach was used for biomarker determination and analysis of the 
temporal evolution during 1-year follow-up.7 A case-cohort comprises a random sub 
cohort from the full cohort, together with all patients who reach the study endpoint 
(‘cases’). It is an efficient analysis method, while study validity and statistical power 
are maintained.8 We selected a random sub cohort of 150 patients, which appeared 
to include 8 cases. Hence, our case-cohort consisted of (all) 45 study endpoint cases 
and 142 event-free patients. A median of 8 (interquartile range [IQR] 5-11) repeated 
samples were analyzed per patient, totaling 1478 measurements. 
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In order to obtain detailed information on biomarker changes early after ACS 
admission, by design, a series of 68 BIOMArCS patients underwent additional blood 
sampling at day 1 to 4. We included these patients in an analysis of post-ACS biomarker 
stabilization, excluding all 45 study endpoint cases to avoid distortion of the biomarkers 
patterns. As 19 (out of the 68) patients were also part of the case-cohort, a total of 191 
patients contributed to a median of 8 (IQR 5-10) repeated samples per patient totaling 
1507 measurements for this analysis.7 
MPO and Gal-3 measurements
Blood samples were collected on-site and frozen at -80℃ within 82 (25th-75th percen-
tile 58-117) minutes after withdrawal. Subsequently, samples were securely transported 
to the Erasmus MC for long-term storage. Serum samples were used to measure MPO 
and GAL-3 and quantified batch-wise, blinded for patient characteristics. MPO was 
measured with a 384-ELISA plate (Nunc, Thermo #460372), with a lower limit of detec-
tion of 609 pg/ml. The corresponding 10% coefficient of variation was 5.7%. GAL-3 was 
measured with a custom built Luminex immune-assay validated in the University Medi-
cal Centre Utrecht, the Netherlands. The corresponding lower limit of quantification was 
0.06 pg/ml, the upper limit of quantification was 1000 pg/ml and the reference sample 
value was 158.43 pg/ml. The inter-assay coefficient of variation of the used GAL-3 
custom build assay was 13.9% and the intra-assay coefficient of variation was 14.45%. 
Statistical analysis
MPO and GAL-3 had skewed distributions, and were log-transformed for analysis 
purposes. Results are presented on the linear scale.
Linear mixed-effect models (LME) were applied to describe the patterns of MPO and 
GAL-3 early after the index-ACS. We placed two splines to account for possible non-
linearity. Using LME, we calculated the average biomarker values for each post-ACS 
day. We concluded biomarker stabilization when the (relative) difference in biomarker 
level between two consecutive days appeared less than one percent.
Joint models, combining LME and Cox proportional hazard regression models, were 
applied to study the temporal biomarker trajectories in relation to reACS.7 We included 
time from index-ACS as main determinant, while adjusting for GRACE risk score, 
gender, history of diabetes, coronary artery bypass graft, valvular heart disease and 
peripheral vessel disease. In the Cox model, GRACE risk score was added as potential 
confounder of the relation between biomarker level and the time-to-event. Addition-
ally, we performed a post-hoc sensitivity analysis using only the data available after 
biomarker level stabilization to investigate if findings are influenced by early post-ACS 
elevations and variations in biomarker level. 
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Results of the joint models are presented as hazard ratios (HR) with corresponding 
95% confidence interval (CI) per standard deviation (SD) increase of the biomarker (on 
the log-scale). All relevant model assumptions were evaluated, including residual plots, 
and no meaningful deviations were observed.
Analyses were performed with R Statistical Software using packages nlme and 
JMbayes. All statistical tests were two-tailed and the α-level of 0.05 was applied to 
conclude statistical significance. 
RESULTS
Median age was 63.6 (25th-75th percentile 55.3-71.6) years, 79.0% were men and 
index-ACS was classified as STEMI in 43.3% (Table 1). Cases had higher prevalence 
of diabetes and a higher GRACE risk score than event-free patients. 
Myeloperoxidase
MPO level was elevated early after the index-ACS, with a peak value of 78.0 ng/ml at 
the day of admission. Within the first seven days, MPO showed a steep decline, and 
then stabilized after day 6 at 25.7 ng/ml (Figure 1A).  During follow-up, MPO levels in 
cases and event-free patients were similar: after seven days, the average serum level 
Table 1. Baseline characteristics
Endpoint cases Endpoint-free patients p-value
Number of patients 45 142  
Age, yr (IQR) 67.4 (57.1-76.5) 62.6 (55.0-70.9)  0.075
Man (%) 36 (80.0) 111 (78.2)  0.79
Cardiovascular risk factors (%)    
Diabetes Mellitus 17 (37.8) 24 (16.9)  0.003
Hypertension 22 (48.9) 77 (54.2)  0.53
Hypercholesterolemia 20 (44.4) 72 (50.7)  0.46
Current smoker 17 (37.8) 60 (42.2)  0.52
Presentation on admission    
Diagnosis
STEMI 16 (35.6) 65 (45.8)  0.46
NSTEMI 22 (48.9) 56 (39.4)
Unstable angina pectoris 7 (15.6) 21 (14.8)
PCI performed 34 (87.2) 109 (82.6)  0.50
GRACE risk score (IQR) 121 (98-141) 109 (88-130)  0.022
Continuous variables are presented as median with IQR. Categorical variables are presented as numbers and 
percentages. 
GRACE risk score: Global Registry of Acute Coronary Events risk score, NSTEMI: non-STEMI, PCI: Percutaneous 
coronary intervention, STEMI: ST-elevation myocardial infarction, yr: year
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of MPO was 26.4 (IQR: 22.1-32.4) ng/ml in cases and 25.3 (IQR: 19.9-31.9) ng/ml in 
endpoint-free patients. We did not observe a steady or sudden increase in MPO level 
prior to the reACS event (Figure 1B). The unadjusted HR for reACS per SD increase 
in MPO was 0.84 (95% CI 0.61-1.26) Adjustment for multiple factors did not result in a 
meaningful change of the estimate (Table 2).
Galectin-3
Gal-3 was only slightly elevated at the index-ACS, and stabilized after day 3 at 0.21 ng/
ml (Figure 1C). Gal-3 remained constant during follow-up, and mean levels did not differ 
between cases and event-free patients (Figure 2D). After 7 days, the average serum 
level of GAL-3 was 0.24 (IQR: 0.16 – 0.30) ng/ml in cases and 0.23 (IQR: 0.17 – 0.30) 
ng/ml in endpoint-free patients. Prior to reACS, we observed no steady or sudden el-
evation in GAL-3 in cases. The unadjusted HR for reACS per SD increase in GAL-3 was 
1.41 (95% CI 0.77-2.42), which remained unaltered after multiple adjustment (Table 2). 
Figure 1. Temporal evolution of Myeloperoxidase and Galectin 3
Panel 1A and 1C depict the early time-course of MPO and GAL-3 after the index-ACS. Panel 1B and 1D depict the 
median value of the patient-level mean of MPO and GAL-3 prior to reACS in study endpoint cases and endpoint-
free patients. 
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DISCUSSION
We established the detailed temporal trajectories of MPO and GAL-3 in post-ACS pa-
tients by means of frequently serial measurements. MPO was elevated at the time of the 
index-ACS, and decreased and stabilized within 7 days. longitudinal MPO levels were 
not associated with reACS. In particular, no increase in MPO level was observed prior 
to a recurrent event. Similar results were observed with respect to GAL-3: there were 
no differences in longitudinal evolution between reACS cases and event-free patients. 
MPO is a pro-inflammatory biomarker involved in multiple inflammatory processes 
that propagate plaque instability, such as nitric oxide catalysation, leukocyte attrac-
tion, endothelial cell apoptosis and tissue factor activation stimulating thrombosis.2 
GAL-3 is also reckoned a pro-inflammatory biomarker stimulating plaque instability by 
i.e. monocyte attraction, macrophage polarization, foam cell production and vascular 
smooth muscle cell dedifferentiation 1. Because of their inflammatory character, MPO 
and GAL-3 may destabilize plaques susceptible to thrombosis, leading to reACS in 
post-ACS patients.1, 9 A recent meta-analysis showed that higher MPO levels measured 
at baseline, are associated with adverse outcome.9 As for GAL-3, opposite results have 
been found regarding its prognostic value in post-ACS patients.10-12 
BIOMArCS was specifically designed to study the temporal evolution of serum bio-
markers in post-ACS patients, and its highly frequent blood sampling schedule would 
have sufficed to identify meaningful changes in MPO and GAL-3 concentrations, had 
they appeared. However, contrary to our expectations, both biomarkers were not as-
sociated with an increased risk of a recurrent ischemic event during 1-year follow-up. 
Since the median time between the last collected sample in cases and their reACS was 
11 (IQR: 5-20) days, we cannot exclude that just before reACS there might still have 
been biomarker elevations we did not detect. Additionally, we cannot exclude changes 
Table 2. Associations between biomarker trajectories and study endpoints 
- 1 SD Mean + 1 SD unadjusted HR p-value Adjusted HR* p-value
Myeloperoxidase, ng/ml† 15.6 26.2 44.0 0.84 (0.61 - 1.26) 0.32 0.84 (0.56 - 1. 37) 0.44
Galectin 3, ng/ml† 0.10 0.20 0.38 1.41 (0.77 - 2.42) 0.27 1.56 (0.87 - 2.53) 0.12
Sensitivity analysis with post 7 days data       
- 1 SD Mean + 1 SD unadjusted HR p-value Adjusted HR* p-value
Myeloperoxidase, ng/ml‡ 15.7 24.7 38.8 1.00 (0.62 - 1.69) 1.00 1.18 (0.74 – 1.91) 0.52
Galectin 3, ng/ml‡ 0.10 0.20 0.38 1.33 (0.63 - 3.09) 0.47 1.02 (0.48 - 2.15) 0.95
† based on 1478 measurements in 187 patients (median: 8  [IQR: 5-11])
‡ based on 1282 measurements in 174 patients (median: 8  [IQR: 4-10])
*Cox model adjusted for GRACE risk score, mixed model adjusted for GRACE risk score; gender; history of diabe-
tes, coronary artery bypass graft, valvular heart disease, peripheral vessel disease
HR: hazard ratio, ml: microliter, ng: nanogram, SD: standard deviation
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in MPO or GAL-3 levels during long-term follow-up. Nonetheless, it seems that MPO 
and GAL-3 do not advance plaque vulnerability prior to reACS. 
Conclusion
MPO and to a lesser extend GAL-3 were elevated early after, but not before a clinical 
symptomatic ACS. Post-ACS patients who experienced a recurrent event within one 
year were not characterized by elevated levels of these pro-inflammatory biomarkers. 
Also steady or sudden elevations were absent, hence MPO and GAL-3 appear unsuited 
for prognosis monitoring after ACS.
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ABSTRACT
Growth differentiation factor-15 (GDF-15) has appeared as a promising biomarker with 
strong predictive abilities in acute coronary syndrome (ACS). However, studies are 
solely based on single measurements in the acute phase of an ACS event. The way 
GDF-15 patterns in post ACS patients behave on the long term is largely unknown. We 
conducted a nested case-control study within our multicenter, prospective, observa-
tional biomarker study (BIOMArCS) of 844 ACS patients. Following an index ACS event, 
high-frequency blood sampling was performed during 1-year of follow-up. GDF-15 was 
determined batchwise by electrochemiluminescence immunoessays in 37 cases with 
a recurrent event during 1-year follow-up, and in 74 event-free controls. Cases and 
controls had a mean ± standard deviation age of 66.9 ± 11.3 years and 81% were men. 
From 30 days onwards, patients showed stable levels, which were on average 333 
(95% confidence interval 68-647) pg/mL higher in cases than controls (1704 vs. 1371 
pg/mL; p-value 0.013). Additionally, in the post 30-day period, GDF-15 showed low 
within-individual variability in both cases and controls. In conclusion, post ACS patients 
experiencing a recurrent event had stable and systematically higher GDF-15 levels dur-
ing 30-day to 1-year follow-up than their event-free counterparts with otherwise similar 
clinical characteristics. Thus, post-discharge blood sampling might be used throughout 
the course of 1 year to improve prognostication, whereas, in view of the low within-
individual variation, the number of repeated sampling moments might be limited.
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INTRODUCTION
In recent years, circulating growth differentiation factor-15 (GDF-15), a stress-induced 
cytokine, has emerged as a biomarker of interest due to its potential prognostic value 
in patients with cardiovascular disease.1 In particular, elevated levels of GDF-15 are 
associated with an impaired prognosis after acute coronary syndromes (ACS).2-6 
However, the prognostic value of GDF-15 in ACS patients thus far, has been mainly 
based on single measurements in the early, acute phase of an acute ischemic event. 
Therefore, the optimal time point in the stabilized post ACS phase for GDF-15 blood 
sampling to make prognostic implications remains not fully elucidated yet. We used 
our ‘BIOMarker study to identify the Acute risk of a Coronary Syndrome’ (BIOMArCS) 
with high-frequency blood sampling in post ACS patients as a platform to describe the 
temporal evolution of GDF-15 during 1-year follow-up, to evaluate differences between 
patients with and without a recurrent event, and to study the individual variability of 
GDF-15.  
METHODS
We performed a nested case-control analysis within the main BIOMArCS study that was 
approved by the medical ethics committees of all participating hospitals. The rationale 
and design of BIOMArCS are described in detail elsewhere.7 In brief, BIOMArCS is a 
prospective, multicenter, observational study conducted in 18 participating hospitals in 
the Netherlands. A total of 844 patients, admitted for an ACS, including unstable angina 
pectoris, non-ST-elevation myocardial infarction (NSTEMI) and ST-elevation myocar-
dial infarction (STEMI) and with at least one additional cardiovascular risk factor, were 
enrolled between 2008 and 2015. Patients underwent regular blood sampling after the 
initial admission for ACS according to a strict schedule to describe the temporal evolu-
tion of blood biomarkers in the post ACS phase, and to reveal deviations in temporal 
biomarker patterns prior to a recurrent coronary event. Venepuncture was performed at 
admission, at hospital discharge and subsequently every fortnight during the first half 
year, followed by monthly blood sample collection until 1 year. Follow-up blood sampling 
was terminated permanently after coronary artery bypass grafting, hospital admission 
for heart failure, or a detoriation of renal function leading to a glomerular filtration rate of 
< 30 mL/min/1.73m2, since these conditions influence circulating biomarker concentra-
tions. Ultimately, patients had 17 (median) repeated blood samples within 1 year. The 
study was performed in accordance with the criteria described in the declaration of 
Helsinki and all patients provided written informed consent for their participation. 
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The primary study endpoint was a composite of cardiac death, non-fatal myocar-
dial infarction, or unstable angina pectoris, requiring urgent coronary revascularization 
within 1-year follow-up. Study endpoints were adjudicated by a clinical event commit-
tee, blinded for any biomarker data, after the study was completed in 2015. In 2014, 
Roche Diagnostics GmbH offered the opportunity to determine GDF-15 with their pre-
commercial assay in a limited number of BIOMArCS patients. Since no commercial 
GDF-15 assay would have been available within the foreseeable future, we decided 
to accept this one-time offer. We analyzed the blood samples of all patients with an 
investigator-reported endpoint event at that time, as well as 2 matched endpoint-free 
controls for each such event. Matching was based on admission hospital, age (± 5 year 
range), gender, diabetes mellitus, peripheral artery disease and history of coronary 
artery disease (CAD). We kept the results unanalyzed until study completion and event-
adjudication. After study completion, it appeared that 37 of the investigator-reported 
events were confirmed as study endpoint. In the current analysis, these events were 
included as cases, together with their corresponding 74 matched controls. 
Blood samples were initially handled and securely stored on-site. Aliquots were 
frozen at -80 degrees Celsius within two hours after withdrawal. Long-term storage 
and batchwise GDF-15 analysis took place at the department of Clinical Chemistry of 
the Erasmus MC, Rotterdam (the Netherlands). Laboratory personnel were blinded for 
any clinical data, including endpoint data. The plasma GDF-15 concentrations were 
measured using the quantitative sandwich electrochemiluminescence immunoassay 
“ECLIA” (Roche Diagnostics, Mannheim, Germany) on a Cobas e601 immunoassay 
analyzer. The lowest detection limit of GDF-15 analyte concentration was 400 pg/mL. 
No interference was found using in vitro tests to determine interference between 51 
commonly used cardiovascular pharmaceuticals and the assay. 
It is important to discern a fixed amount of individual biomarker variability from clini-
cally relevant changes over time. Therefore certain parameters have been described to 
define individual variability, which are needed to interpret the relevance of changes of 
repeated measurements. The coefficient of variation (CV) of a series of measurements 
is defined as 100% times the standard deviation (
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Since a high II (>1.4) indicates a relatively high within-subject variation and low between-
subjec  variat on, it is more likely that an unusual biom rk r val will lie outside the 
borders of most overlapping values and therefore po ulatio -based referenc  intervals 
are sufficient. Conversely, when the II is low (<0.6), it is agreed that subjects should 
have their own reference values, based on previous samples. The Reference Change 
Value (RCV) reflects the limit of (relative) change in biomarker values in individual 
subjects that can be explained by the combined within-subject and analytical variation. 
For biomarkers with a skewed distribution a log-normal approach has been described, 
and the RCV limits can be determined as follows:
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when the II is low (<0.6), it is agr ed that subj cts should have their own reference values, based on 
previous samples. The Reference Change Value (RCV) reflects the li it of (relative) change in 
biomarker values in individual subjects that can be explained by the combined within-subject and 
analytical variation. For biomarkers with a skewed distribution a log-normal approach has been 
described, and the RCV limits can be determined as follows: 
 RCVdownward = e−Zα 2⁄ ∗√2ln(CVi2+CVa2+1) −  1 RCVupward = eZα 2⁄ ∗√2ln(CVi2+CVa2+1) −  1 
 
We used α = 0.05 (for 95% confidence), thus Z0.025 = 1.96. 
    Since GDF-15 is known to be initially elevated post ACS, all aforementioned variability parameters 
are based on > 30 day blood samples. Although the exact pathophysiological substrate for an initial 
elevation of GDF-15 in the acute phase of ACS is unknown,9 a possible ‘washout’ effect due to an 
acute phase reaction is thereby hampered. After that period, biochemical as well as clinical 
stabilization are expected to be reached for adequately determining GDF-15 variability. Thereafter, 
only patients with at least three available measurements in that time window are included, leaving 20 
cases and 46 controls for variability analysis.  
    Categorical data are presented as numbers and percentages. Continuous variables are presented as 
mean±standard deviation (SD) or as median and interquartile range (IQR), depending on their 
distribution. Normality  of continuous variables was examined by visual inspection of the histogram 
and by normal Q-Q plots. The examined biomarker GDF-15 (outcome) showed a skewed distribution 
and was therefore 2log-transformed  for further analyses. GDF-15 biomarker trajectories were 
examined across different follow-up time intervals after the ACS index event during one year of 
follow-up. Within the first 7 days from admission, each patient’s maximum biomarker value was 
determined. The median values of the patient-level maximum were compared between the cases and 
controls by linear mixed effect (LME) models. Then, the patient-average biomarker trajectories 
between 7 and 30 days from admission and from 30 days onwards were compared between cases 
and controls by LME models with nested random effects. Time from index ACS event until each blood 
sample measurement and a group variable (case / control) were entered as fixed effects in the model, 
paired individuals as random effects and serial GDF-15 measurements as the dependent variable 
(model 1). Subsequently, we fitted multivariable LME models with adjustment for age and gender 
(model 2), and with additional adjustment for admission diagnosis, diabetes mellitus, smoking, 
hypertension, hypercholesterolemia, BMI, history of revascularization, history of myocardial infarction 
and serum creatinine value (which was measured at each sampling moment) (model 3). Values were 
eventually backtransformed to present mean differences (95% confidence intervals (CI)) between 
cases and controls on the linear scale. All data were analyzed with SPSS (version 21) and R statistical 
software (version 3.5.1). All statistical tests were two-tailed and p-values < 0.050 were considered 
statistically significant. 
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analytical variation. For biomarkers with a skewed distribution a log-normal approach has been 
described, and the RCV limits can be determined as follows: 
 RCVdownward = e−Zα 2⁄ ∗√2ln(CVi2+CVa2+1) −  1 RCVupward = eZα 2⁄ ∗√2ln(CVi2+CVa2+1) −  1 
 
  fi Z0.025 = 1.96. 
    Since GDF-15 is known to be initially elevated post ACS, all aforementioned variability parameters 
are based on > 30 day blood samples. Although the exact pathophysiological substrate for an initial 
elevation of GDF-15 in the acute phase of ACS is unknown,9 a possible ‘washout’ effect due to an 
acute phase reaction is thereby hampered. After that period, biochemical as well as clinical 
stabilization are expected to be reached for adequately determining GDF-15 variability. Thereafter, 
only patients with at least three available easurements in that time window are included, leaving 20 
cases and 46 controls for variability analysis.  
    Categorical data are presented as numbers and percentages. Continuous variables are presented as 
mean±standard deviation (SD) or as median and interquartile range (IQR), depending on their 
distribution. Normality  of continuous variables was examined by visual inspection of the histogram 
and by normal Q-Q plots. The examined biomarker GDF-15 (outcome) showed a skewed distribution 
and was therefore 2log-transformed  for further analyses. GDF-15 biomarker trajectories were 
examined across different follow-up time intervals after the ACS index event during one year of 
follow-up. Within the first 7 days from admission, each patient’s axi um biomarker value was 
determined. The median values of the patient-level aximum were compared between the cases and 
controls by linear mixed effect (LME) models. Then, the patient-average biomarker trajectories 
between 7 and 30 days from admission and from 30 days onwards were compared between cases 
and controls by LME models with nested random effects. Time from index ACS event until each blood 
sample easurement and a group variable (case / control) were entered as fixed effects in the model, 
paired individuals as random effects and serial GDF-15 easurements as the dependent variable 
(model 1). Subsequently, we fitted multivariable LME models with adjustment for age and gender 
(model 2), and with additional adjustment for admission diagnosis, diabetes mellitus, smoking, 
hypertension, hypercholesterolemia, BMI, history of revascularization, history of myocardial infarction 
and serum creatinine value (which was measured at each sampling moment) (model 3). Values were 
eventually backtransformed to present mean differences (95% confidence intervals (CI)) between 
cases and controls on the linear scale. All data were analyzed with SPSS (version 21) and R statistical 
software (version 3.5.1). All statistical tests were two-tailed and p-values < 0.050 were considered 
statistically significant. 
 
 
RESULTS 
 
 
Since GDF-15 is known to be initi lly elevated post ACS, all aforementioned variability 
parameters are based on > 30 day blood samples. Although the exact pathophysiologi-
cal substrate for an initial elevation of GDF-15 in the acute phase of ACS is unknown,9 
a possible ‘washout’ effect due to an acute phase reaction is thereby hampered. After 
that period, biochemical as well as clinical stabilization are expected to be reached for 
adequ tely determining GDF-15 vari bility. Thereafter, only patients with at least three 
available measurements in that time window are included, leaving 20 ca es and 46 
controls for variability analysis. 
Categorical data are presented as numbers and percentages. Continuous variables 
are presented as mean±standard deviation (SD) or as median and interquartile range 
(IQR), depending on their distribution. Normality  of continuous variables was examined 
by visual inspection of the histogram and by normal Q-Q plots. The examined bio arker 
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GDF-15 (outcome) showed a skewed distribution and was therefore 2log-transformed 
for further analyses. GDF-15 biomarker trajectories were examined across different 
follow-up time intervals after the ACS index event during one year of follow-up. Within 
the first 7 days from admission, each patient’s maximum biomarker value was deter-
mined. The median values of the patient-level maximum were compared between the 
cases and controls by linear mixed effect (LME) models. Then, the patient-average 
biomarker trajectories between 7 and 30 days from admission and from 30 days on-
wards were compared between cases and controls by LME models with nested random 
effects. Time from index ACS event until each blood sample measurement and a group 
variable (case / control) were entered as fixed effects in the model, paired individuals as 
random effects and serial GDF-15 measurements as the dependent variable (model 1). 
Subsequently, we fitted multivariable LME models with adjustment for age and gender 
(model 2), and with additional adjustment for admission diagnosis, diabetes mellitus, 
smoking, hypertension, hypercholesterolemia, BMI, history of revascularization, his-
tory of myocardial infarction and serum creatinine value (which was measured at each 
sampling moment) (model 3). Values were eventually backtransformed to present mean 
differences (95% confidence intervals (CI)) between cases and controls on the linear 
scale. All data were analyzed with SPSS (version 21) and R statistical software (ver-
sion 3.5.1). All statistical tests were two-tailed and p-values < 0.050 were considered 
statistically significant.
RESULTS
Baseline clinical characteristics are presented in Table 1. The matching procedure ap-
peared successful, as there were no relevant differences between cases and controls, 
except for admission diagnosis of STEMI (p-value <0.001). During the first 7 days after 
the index ACS, GDF-15 levels reached maximum values (median [IQR]) of 2436 [2286 
– 4236] pg/mL in cases and 1804 [1207 – 3749] pg/mL in the controls (p-value 0.22). 
These levels slightly decreased within the first 30 days, and the mean value within the 
7 to 30 day period was 1908 pg/mL and 1590 pg/mL in cases and controls, respectively. 
This mean difference of 318 (95% CI ranging from -215 to 1058) pg/mL was statistically 
non-significant (p-value 0.26). From 30 days after the index ACS onwards until 1-year 
follow-up, cases had systematically higher GDF-15 levels than controls (Table 2, Figure 
1). This difference remained significant after correction for age, gender and multiple 
cardiovascular risk factors (p-value 0.013). These findings are confirmed in strata ac-
cording to gender, diabetes mellitus, smoking, serum creatinine value and admission 
diagnosis (Supplemental Tables 4 - 8). No differences were observed in GDF-15 levels 
across the various subgroups (all p-values for heterogeneity were > 0.05).
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An overview of the different variability parameters, calculated for a selected amount 
of cases and controls, is presented in Table 3. With a CVa of 2%, both groups displayed 
limited within-subject variability (CVi of 16.3 for the cases and 11.5 for the controls), 
whereas the between-subject variability showed larger variation (CVg of 73.1 for the 
cases and 62.0 for the controls). This is also shown by a plot (Figure 2), which illustrates 
low within-subject variability (CVi / (CVi + CVg) = 16-18%) and large between-subject 
Table 1. Baseline clinical characteristics 
 Cases (n = 37) Controls (n = 74) p-value
Age, years 67.9 ± 11.7 66.3 ± 11.2 0.79
Male gender, n (%) 30 (81.1) 60 (81.1) 0.95
Admission diagnosis, n (%)    
STEMI 13 (35.1) 42 (56.8) <0.001
NSTEMI 18 (48.6) 27 (36.5) 0.17
UAP 6 (16.2) 5 (6.8) 0.78
Cardiovascular risk factors, n (%)    
Smoking
Current 13 (35.1) 25 (33.8) 0.91
Former 11 (29.7) 23 (31.1) 0.97
Never 13 (35.1) 26 (35.1) 0.95
Diabetes Mellitus 12 (32.4) 26 (35.1) 0.52
Hypertension 19 (51.4) 40 (54.1) 0.77
Hypercholesterolemia 17 (45.9) 30 (40.5) 0.81
Medical history, n (%)    
Previous myocardial infarction 12 (32.4) 23 (29.7) 0.93
Previous PCI 11 (29.7) 20 (27.0) 0.88
Previous CABG 9 (24.3) 10 (13.5) 0.64
Previous stroke 8 (21.6) 7 (9.5) 0.78
History of peripheral vascular disease 10 (27.0) 13 (17.7) 0.73
Values are mean ± standard deviation or n (%). p-values were obtained by the linear mixed model (continuous vari-
able) or generalized linear mixed model (categorical variable), whichever was appropriate.
CABG: coronary artery bypass grafting, NSTEMI: non-ST-segment elevation myocardial infarction, PCI: percuta-
neous coronary intervention, STEMI: ST-segment elevation myocardial infarction, UAP: unstable angina pectoris
Table 2. Mean GDF-15 (pg/mL) values in cases and controls in the 30 days to 1 year period 
after ACS admission
Cases Controls Mean difference (95% CI) p-value
Model 1* 1780 1414 366 (26, 788) 0.034
Model 2† 1744 1415 329 (2, 732) 0.049
Model 3‡ 1704 1371 333 (68, 647) 0.013
* Unadjusted for patient characteristics 
† Adjusted for age and gender
‡  Adjusted for age, gender, admission diagnosis, diabetes mellitus, smoking, hypertension, hypercholesterolemia, 
BMI, history of revascularization, history of myocardial infarction and serum creatinine value (measured at each 
time-point)
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variability (CVg / (CVi + CVg) 82-84%) with a minimum of 579 pg/mL and a maximum of 
9748 pg/mL. As could be expected from low within-subject variability and high between-
subject variability in both groups, the II was low (below the threshold value of 0.6), 
and thus individual reference values are preferred. Thereby we found that the limits of 
change between subsequent measurements (RCV) are allowed to range from -36% to 
57% in cases and from -28% to 38% in controls.
Unadjusted p-value = 0.034
Adjusted p-value = 0.013
Figure 1. Serial measurements and temporal evolvement of GDF-15 (pg/mL) in cases (red) 
and controls (black). 
The left graph shows the evolvement of GDF-15 since the index event (t=0) until 1-year follow-up. The right graph 
shows the evolvement of GDF-15 before the study endpoint (t=0 in cases), or until the last blood sample moment 
(t=0 in controls). The points represent measurements in individual patients. The lines represent the group average 
values (bold lines) and the 95% confidence intervals (dashed lines), using linear mixed models with nested random 
effects.
Table 3. Parameters describing the biological variability of GDF-15 serial measurements 30 
days after the ACS index event in both cases and controls
 Cases (n = 20) Controls (n = 46)
Average biomarker level (pg/mL), median [IQR] 1423 [1122 – 2594] 1317 [966 - 1705]
Analytical coefficient of variation (CVa) 2% 2%
Intra-individual coefficient of variation (CVi) 16.3 11.5
Inter-individual coefficient of variation (CVg) 73.1 62.0
Index of individuality (II) 0.2 0.2
Reference change value (RCV) 45% 32%
Reference change value, upper limit 57% 38%
Reference change value, lower limit -36% -28%
Parameters describing the biological variability of GDF-15, as calculated by formulas presented in the method 
section. 
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DISCUSSION
This is the first study to describe GDF-15 patterns in post ACS patients in great detail, 
utilizing a high-frequency blood sampling design during 1 year. Four key lessons were 
learned from our analysis. First, in individual patients, after reaching a peak value in 
the first week after admission, GDF-15 concentrations levelled off to levels that remain 
stable throughout 1-year follow-up. Second, importantly, there was no steady or sudden 
change in GDF-15 level prior to a recurrent event. Thus, no significant changes in GDF-
15 values occurred after the initial post ACS phase. Third, patients who experienced a 
recurrent event had on average 26% higher GDF-15 levels than those who remained 
event-free. Although the prognostic value of GDF-15 has already been demonstrated by 
previous studies with one baseline measurement, we additionally proved that repeated 
post-discharge blood sampling of GDF-15 during 1 year might help improve accurate 
prognostication. Fourth, within-patient variability was much smaller than between-
patient variability, meaning that the number of repeated blood samples to obtain a 
patient-specific stable GDF-15 level can be limited. 
Considering the natural course of GDF-15 post ACS in our analysis, peak values are 
present in the first 7 days after an ACS, whereafter it seems that GDF-15 subtly reaches 
a stabilized phase without significant changes, especially prior to a recurrent event. 
By the use of frequent serial measurements, the stability of the marker in individual 
patients on the long term was established. This finding is supported by previous data in 
post ACS patients, demonstrating that GDF-15 concentrations show small alterations 
through the first 72 hours of hospitalization and potentially several months thereafter.3,4 
Patients ranked according to their mean value during follow-up  
R
ep
ea
te
d 
m
ea
su
re
s 
of
 G
D
F-
15
, p
g/
m
L 
(lo
g 
2)
Variationwithin: 18% (cases) and 16% (controls)
Variationbetween: 82% (cases) and 84% (controls) 
Figure 2. Graphical illustration of GDF-15 variability by displaying the distribution of GDF-15 
measurements per patient 30 days after the ACS index event.
The data points represent measurements in individual patients (cases in red; controls in black), ranked according to 
their mean value during post 30 days follow-up in order to display within- and between-individual variation. 
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The fact that GDF-15 concentration levels remain significantly higher in patients who 
experience a recurrent event than in event-free patients over the course of a year in 
our study without any level changes around the event, suggests that GDF-15 is not 
merely a reflection of extent of myocardial damage or infarct size, but rather reflects 
severity of (chronic) atherosclerotic disease burden at any time point. This proposition 
is further supported by findings with cardiovascular magnetic resonance, demonstrating 
that GDF-15 is unrelated to infarct size and myocardial area at risk 2-4 days after the 
index event.9 Furthermore, GDF-15 concentrations on admission seemed to be similar 
between NSTEMI and STEMI patients, of whom more severe myocardial damage can 
be expected.2,3 Thus, in support of our hypothesis, previous studies do not indicate that 
GDF-15 solely mirrors tissue damage.
With regard to prognostication, GDF-15 has been thoroughly investigated in clinical 
studies and shown to be an independent prognostic marker of mortality and cardiovas-
cular events in both healthy individuals and CAD patients, which is in accordance with 
our results.4-6,9-11 Specifically, a recent meta-analysis focused on ACS patients, including 
8 studies and 8903 participants, showed a significant hazard ratio (95% confidence 
interval) of 1.66 (1.47 – 1.87) on the association between GDF-15 and mortality or 
recurrent MI.6 However, most studies performed blood sampling only on admission at 
the onset of an ACS or at discharge during the recovery phase of an ACS. As we have 
demonstrated, initial GDF-15 peak values were largely present in the first 7 days after 
the index ACS, which is likely the expression of an acute phase reaction. Therefore, 
single blood samples timed in the early phase during the course of an ACS event may 
represent a peak level, which does not clarify its prognostic implications on long term 
post ACS. To our knowledge, only two clinical studies have performed a limited number 
of serial GDF-15 measurements in post NSTEMI patients.3,4 Wollert et al3 collected 
blood samples on admission and at 24, 48 and 72 hours in a subgroup of 399 patients, 
whereas Eggers et al4 measured GDF-15 at baseline and after clinical stabilization at 6 
weeks, 3 months, 6 months in 950 patients. Both studies found significant associations 
with respectively 1-year and 5-year mortality at each time point. Along with our data 
with highly frequent blood sampling, we have additionally demonstrated that obtained 
blood samples within a course of 1 year post ACS will provide comparable prognostic 
information.
The biological variability of GDF-15 in ACS patients has not been described so far. 
We found low within-subject variability and high between-subject variability, which cor-
responds with findings from a study on the biovariability of GDF-15 conducted in 41 
patients with stable chronic systolic dysfunction.12 In this study, GDF-15 was measured 
at four blood sampling time points up until 3 months and showed very little biological 
(within-)variation, while there was an elevated between-individual variation (reflected by 
a low II). Altogether, describing biomarker variability is warranted to provide insight into 
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the significance and interpretation of a biomarker in clinical practice. Our results indi-
cate that changes in serial measurements of GDF-15 in an individual who experienced 
an ACS, independently of disease status (case or control), might be more useful than 
population derived reference values.
The unique design and character of this study enabled us to provide novel data 
on the temporal evolution and variability of GDF-15 post ACS. Nevertheless, some 
limitations warrant to be acknowledged. Due to the study design and its observational 
character, this substudy is unable to demonstrate causal inference. Whether GDF-15 
merely reflects CAD pathways, or directly contributes to coronary pathophysiology 
remains unknown. Also, as opposed to previous studies with large cohorts, we could 
not demonstrate significant differences in GDF-15 levels between cases and controls 
within the first 30 days. This is probably due to a lack of power with a limited number 
of measurements < 30 days within a relatively small cohort. In line with this, we are 
aware of the fact that our study comprises a relatively small number of study patients 
and events. Further, by acknowledging previous studies that investigated the prognostic 
value of GDF-15 in large study populations, our study encompassing an exceptional 
blood sampling frequency method should rather be seen as hypothesis-testing with an 
extension to existing knowledge. 
In conclusion, with detailed analysis of the longitudinal GDF-15 pattern post ACS, we 
have demonstrated that GDF-15 concentrations remain stable during follow-up with lim-
ited within-individual variation. In patients who eventually experience a recurrent event, 
GDF-15 is systematically elevated, independently of clinical risk factors and serum 
creatinine. Thus, to enable risk stratification with GDF-15 in post ACS patients, blood 
sampling might be used throughout the course of 1 year for prognostication, whereas 
the number of repeated sampling moments might be limited. Further exploration of the 
exact role of GDF-15 in risk stratifying post ACS patients and deciding on clear cut off 
points is warranted in future studies in order to make accurate prognostications. 
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SUPPLEMENTARY APPENDIX
Table 4. GDF-15 (pg/mL) values of cases and controls in strata according to gender in the 30 
days to 1 year period after index ACS 
Men Women
P for heterogeneity
Cases Controls Mean difference 
(95% CI)
Cases Controls Mean difference 
(95% CI)
Model 1* 1822 1446 377 (-10, 867) 1512 1185 326 (-251, 1262) 0.97
Model 2† 1806 1452 354 (-15, 817) 1505 1227 279 (-281, 1170) 0.96
Model 3‡ 1773 1329 444 (142, 809) 1506 1619 -113 (-596, 598) 0.10
Mean GDF-15 values were based on nested linear mixed effects models with (2log-transformed) GDF-15 as the 
dependent variable, and with gender, time from index ACS event to the blood sample measurement and group 
variable (case / control) as the main independent variables. To obtain the p-value for heterogeneity, an interaction 
term (group variable * gender) was added to the model.   
* Unadjusted for patient characteristics 
† Adjusted for age 
‡  Adjusted for age, admission diagnosis, diabetes mellitus, smoking, hypertension, hypercholesterolemia, body 
mass index, history of revascularization, history of myocardial infarct and serum creatinine value (measured at 
each time-point) 
Table 5. GDF-15 (pg/mL) values of cases and controls in strata according to diabetes mellitus 
in the 30 days to 1 year period after index ACS 
Diabetes Non-diabetes
P for heterogeneity
Cases Controls Mean difference 
(95% CI)
Cases Controls Mean difference 
(95% CI)
Model 1* 2131 1816 315 (-324, 1228) 1605 1208 397 (37, 860) 0.57
Model 2† 2038 1772 266 (-324, 1096) 1607 1236 371 (22, 815) 0.56
Model 3‡ 2175 1760 415 (-169, 1213) 1508 1215 293 (9, 643) 0.98
Mean GDF-15 values were based on nested linear mixed effects models with (2log-transformed) GDF-15 as the 
dependent variable, and with presence of diabetes mellitus, time from index ACS event to the blood sample mea-
surement and group variable (case / control) as the independent variables. To obtain the p-value for heterogeneity, 
an interaction term (group variable * diabetes mellitus) was added to the model.   
* Unadjusted for patient characteristics 
† Adjusted for age and gender
‡  Adjusted for age, gender, admission diagnosis, smoking, hypertension, hypercholesterolemia, body mass index, 
history of revascularization, history of myocardial infarct and serum creatinine value (measured at each time-point)
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Table 6. GDF-15 (pg/mL) values of cases and controls in strata according to smoking in the 30 
days to 1 year period after index ACS
Smoking Non-smoking
P for heterogeneity
Cases Controls Mean difference 
(95% CI)
Cases Controls Mean difference 
(95% CI)
Model 1* 1410 1265 145 (-294, 784) 1997 1458 539 (65, 1158) 0.38
Model 2† 1518 1392 126 (-326, 771) 1889 1411 478 (50, 1411) 0.36
Model 3‡ 1832 1552 280 (-226, 978) 1646 1317 330 (-31, 791) 0.78
Mean GDF-15 values were based on nested linear mixed effects models with (2log-transformed) GDF-15 as the 
dependent variable, and with smoking status, time from index ACS event to the blood sample measurement and 
group variable (case / control) as the independent variables. To obtain the p-value for heterogeneity, an interaction 
term (group variable * smoking status) was added to the model.    
* Unadjusted for patient characteristics 
† Adjusted for age and gender
‡  Adjusted for age, gender, admission diagnosis, diabetes mellitus, hypertension, hypercholesterolemia, body 
mass index, history of revascularization, history of myocardial infarct and serum creatinine value (measured at 
each time-point)
Table 7. GDF-15 (pg/mL) values of cases and controls in strata according to creatinine levels 
(μmol/L) in the 30 days to 1 year period after index ACS
Creatinine ≥ 85 Creatinine < 85
P for heterogeneity
Cases Controls Mean difference 
(95% CI)
Cases Controls Mean difference 
(95% CI)
Model 1* 1952 1532 420 (-79, 1091) 1490 1288 203 (-220, 794) 0.68
Model 2† 1640 1518 122 (-92, 977) 1545 1319 226 (-193, 800) 0.78
Model 3‡ 1817 1460 357 (-25, 841) 1553 1336 217 (-151, 698) 0.71
Mean GDF-15 values were based on nested linear mixed effects models with (2log-transformed) GDF-15 as the 
dependent variable, and with serum creatinine level (dichotomized into equal or above the median and below the 
median), time from index ACS event to the blood sample measurement and group variable (case / control) as the 
independent variables. To obtain the p-value for heterogeneity, an interaction term (group variable * (dichotomous) 
serum creatinine level) was added to the model.    
* Unadjusted for patient characteristics 
† Adjusted for age and gender 
‡  Adjusted for age, gender, admission diagnosis, smoking, diabetes mellitus, hypertension, hypercholesterolemia, 
body mass index, history of revascularization and history of myocardial infarction 
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Table 8. GDF-15 (pg/mL) values of cases and controls in strata according to admission diag-
nosis in the 30 days to 1 year period after index ACS
STEMI NSTEMI
P for heterogeneity
Cases Controls Mean difference 
(95% CI)
Cases Controls Mean difference 
(95% CI)
Model 1* 1535 1223 312 (-119, 911) 1758 1792 -34 (-502, 604) 0.29
Model 2† 1573 1275 299 (-123, 876) 1746 1725 20 (-428, 624) 0.36
Model 3‡ 1670 1337 333 (-68, 862) 1748 1485 264 (-140, 789) 0.76
         
Mean GDF-15 values were based on nested linear mixed effects models with (2log-transformed) GDF-15 as the 
dependent variable, and with admission diagnosis, time from index ACS event to the blood sample measurement 
and group variable (case / control) as the independent variables. To obtain the p-value for heterogeneity, an interac-
tion term (group variable * admission diagnosis) was added to the model.      
* Unadjusted for patient characteristics 
† Adjusted for age and gender 
‡  Adjusted for age, gender, smoking, diabetes mellitus, hypertension, hypercholesterolemia, body mass index, his-
tory of revascularization, history of myocardial infarct and serum creatinine value (measured at each time-point)
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ABSTRACT
Background
The intracellular mitogen-activated protein kinase (MAPK) cascade regulates intracel-
lular processes that modulate cardiovascular disease progression. We explored the 
time-course of serum biomarkers that stimulate the MAPK-cascade in post-acute 
coronary syndrome (ACS) patients, prior to a recurrent coronary event.  
Methods 
BIOMArCS is a high-frequent repeated blood sampling study in post-ACS patients. 
We performed a nested case-control study selecting the 45 patients who experienced 
a recurrent event (cases) and 2 matched event-free controls per case during 1-year 
follow-up. Olink Proteomics ’immunoassay was used to measure 25 serum biomarkers. 
Results are expressed in the arbitrary Normalized Protein eXpression (NPX) unit on 
the 2log-scale. Linear mixed-effects models were applied to examine time-courses and 
differences between cases and controls.
Results 
Mean age was 66±12 years and 80% were men, with no differences between cases 
and controls. Early cases had significantly higher levels of ANG-1 (difference 0.95 NPX 
(95%CI 0.36-1.54), PAR-1 (difference 0.50 NPX (95%CI 0.22-0.77) and BMP-6 (differ-
ence 0.55 NPX (95%CI 0.21-0.90) than controls. No differences in biomarker levels 
were observed between late cases and matching controls. In particular, in cases, no 
increase was observed prior to the moment of the recurrent event.
Conclusion
Patients with an early recurrent coronary event after an index-ACS had higher levels of 
ANG-1, PAR-1 and BMP-6 than patients who remained event-free. 
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INTRODUCTION
Although outcome for patients with cardiovascular disease (CVD) has improved over 
the last decades, hospitalization rates are still increasing.1-3 This increase can partly 
be explained by the increasing population of patients who survived an acute coronary 
syndrome (ACS) and who are at risk of experiencing a recurrent coronary event.1 As 
CVD is dynamic and shows considerable inter-patient variation, to improve secondary 
prevention, insight in the course of CVD in individual subjects is required. Since bio-
marker profiles may serve as a proxy for CVD status and development, the exploration 
of (established and) evolving markers covering relevant pathophysiological processes 
is warranted.
The mitogen-activated protein kinase (MAPK) cascade, is an intracellular cascade of 
proteins that enables extracellular stimuli – blood biomarkers - to modulate several in-
tracellular processes i.e. cell growth, differentiation, proliferation, and apoptosis.4 Basic 
research has shown that the MAPK-cascade plays a pivotal role in cellular processes 
that advance CVD progression.5 First, the MAPK-cascade promotes atherosclerotic 
lesion formation, i.e. by inducing inflammation and cell apoptosis. Secondly, it may 
activate pathological cardiac remodeling after myocardial infarction by constraining 
myocyte mitosis and promoting fibrosis. Thirdly, the cascade might be directly involved 
in the development of in-stent restenosis.5
In view of the pivotal role of the MAPK-cascade in the development and progression 
of CVD, blood biomarkers that regulate the cascade may be useful for the identification 
of patients with CVD who are at higher risk of developing a (recurrent) coronary event. 
However, translational research relating the MAPK-cascade to clinical CVD progression 
is scarce.5
We aimed to explore the course of protein blood biomarkers that stimulate the in-
tracellular MAPK-cascade in post-ACS patients prior to the development of a recurrent 
coronary event during one year of follow-up.
METHODS
Study population
We performed a case-control study that is embedded in The ‘BIOMarker study to iden-
tify the Acute risk of a Coronary Syndrome’ (BIOMArCS).6 BIOMArCS is a multicenter 
observational study with a unique high-frequency sampling design, to study the course 
of blood biomarkers in patients following an ACS in anticipation of a recurrent event. 
The design of BIOMArCS has been described in detail elsewhere.6 In brief, BIOMArCS 
enrolled 844 patients with ACS, aged ≥40 years and who had at least 1 pre-specified 
126
Chapter 9
cardiovascular risk factor. After enrolment, venipuncture was performed at admission, 
discharge, and subsequently every two weeks during the first half-year and every month 
during the second half-year. A median number of 17 repeated blood samples per patient 
were obtained.
BIOMArCS was approved by the Institutional Review Boards of all enrolling hos-
pitals, and all participating patients provided written informed consent. BIOMArCS is 
registered in The Netherlands Trial Register NTR1698 and NTR1106.
Case-control design
The current analysis is based on a case-control approach. A total of 45 patients (cases) 
in BIOMArCS reached the composite study endpoint of cardiac death, non-fatal myo-
cardial infarction (MI), or unstable angina (UA) requiring urgent coronary revasculariza-
tion during one year of follow-up after the index-ACS.  These cases were with two 
controls that are selected from BIOMArCS event-free patients. Cases and controls were 
matched on age, sex and admitted hospital. For reasons of efficiency, for each case, 
the blood sample at hospital admission and the last and second last samples prior to 
the recurrent coronary event have been analyzed. In controls, we selected the blood 
sample at hospital admission and the blood sample that corresponds in time with the 
recurrent event of the matched case.
As a pragmatic choice, separate analyses were performed for cases (and their 
matching controls) that experienced their event in the first 30 days after the index-ACS, 
and for cases (and their matching controls) that experienced their event thereafter. 
Hence, we were able to differentiate between the behavior of biomarkers during the 
acute and post-stabilization phase after the index-ACS.
Biomarker measurements 
Targeted protein biomarker measurements were performed by the Proximity Extension 
Assay (PEA) Technique using Olink Proteomics’ CVD II panel (Olink Proteomics AB, 
Uppsala, Sweden). Details concerning PEA and the CVD II panel are described on 
the website of Olink Proteomics (www.olink.com). In brief, the PEA technique consists 
of a pair of oligonucleotide-labelled antibody probes that pair-wise bind to a targeted 
protein biomarker in a blood sample. This binding induces amplification of the protein 
biomarker by real-time PCR (Fluidigm® BioMark™ HD System).
The PEA technique enables simultaneous analysis of all protein biomarkers of the 
CVD II panel in one blood sample. Olink proteomics’ CVD II panel provides measure-
ments of 25 protein blood biomarkers that are related to the intracellular MAPK-cascade 
(overview of proteins in Table 1). Every measured protein blood biomarker is expressed 
in an arbitrary unit on the log2-scale called Normalized Protein eXpression (NPX). Ac-
cordingly, an increase or decrease of one NPX corresponds with a doubling or halving 
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of a biomarker serum level. NPX values cannot be compared across different proteins. 
For each protein biomarker, general calibrator curves to calculate approximate concen-
trations are available on the website of Olink Proteomics.
Statistical analysis 
Continuous variables are presented as medians with interquartile range (IQR) and cate-
gorical variables as numbers with percentages. Differences between cases and controls 
were compared with Mann-Whitney U and Pearson Chi-square tests, respectively.
As indicated, all biomarkers were analyzed on a log2-transformed scale. We fitted a 
linear mixed-effects model for every biomarker to describe patient-specific longitudinal 
Table 1. Overview of the assessed protein biomarkers 
Abbreviation Full name Synonyms Molecular function
NEMO NF-kappa-B essential modulator IKBKG, FIP3 Binding protein
HB-EGF Proheparin-binding EGF-like growth factor DTR, DTS, HEGFL Growth factor/receptor
SCF Stem cell factor KITLG,MGF Cytokine/growth factor
PDGF subunit 
B
Platelet-derived growth factor subunit 
B PDGFB,PDGF2, SIS
Developmental protein/growth 
factor
GDF-2 Growth/differentiation factor 2 BMP9 Cytokine/growth factor
ANG-1 Angiopoietin-1 ANGPT1 Developmental protein
CCL3 C-C motif chemokine 3 MIP1A, SCYA3, G0S19-1 Chemokine
TIE2 Angiopoietin-1 receptor TEK, VMCM, VMCM1 Receptor
PAR-1 Proteinase-activated receptor 1 F2R, CF2R, TR Receptor
LEP Leptin OB, OBS Hormone/growth factor
REN Renin Hydrolase
TNFRSF11A Tumor necrosis factor receptor superfamily member 11A
RANK, ODFR, CD265, NFKB 
activator Receptor
THPO Thrombopoietin / megakaryocyte colony-stimulating factor MGDF Cytokine/hormone
FGF-21 Fibroblast growth factor 21 Growth factor
GAL-9 Galectin-9 LGALS9 Binding protein 
SRC Proto-oncogene tyrosine-protein kinase SRC SRC1,  C-SRC Kinase
GH Growth hormone GH1, somatotropin Hormone
XCL1 X-C motif chemokine ligand 1 Lymphotactin, LTN, SCYC1, ATAC, SCM-1 Chemokine
FGF-23 Fibroblast growth factor 23 HYPF Growth factor
CCL17 C-C motif chemokine 17 SCYA17, TARC Chemokine
IL-18 Interleukin-18 IGIF, IL1F4 Cytokine
BMP-6 Bone morphogenetic protein 6 VGR1, VGR Cytokine/developmental protein/growth factor
IL-6 Interleukin-6 IFNB2, BSF2, CDF, HGF Cytokine/growth factor 
AMBP alpha-1-microglobulin/bikunin precursor
HCP, ITIL, ITI, Bikunin, EDC1, 
Trypstatin Protease inhibitor
CD40-L CD40 ligand CD40LG, TNFSF5, TRAP, HIGM1, CD154 Cytokine
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biomarker trajectories as a function of time. Likelihood ratio tests and F-tests were used 
for hypothesis testing, whereas residuals were used to examine the model assumptions.
We considered 25 biomarkers. To adjust for inflation of the type I error with multiple 
testing, statistical significance was stated at p=0.003 (two-tailed test), based on the 
matrix spectral decomposition method.7 R statistical software (version 3.4.0) was used 
for analyses, in particular the package nlme (https://cran.r-project.org/web/packages/
nlme/index.html).
RESULTS
Baseline characteristics
Mean age of all patients was 66.0 ±11.9 years and 80.2% were men. Cases and controls 
did not show any significant differences in presentation, initial treatment, cardiovascular 
risk factors and medication at first blood sample, indicating successful matching (Table 2).
Table 2. Baseline clinical characteristics 
 
Cases Controls
n=44 n=87 p-value
Presentation and initial treatment    
Men 35 (79.5) 70 (80.5) 0.90
Age - yr 67.5 (57.3-77.5) 66.7 (57.4-75.5) 0.83
Admission diagnosis 0.38
STEMI 16 (36.4) 42 (48.3)
NSTEMI 22 (50.0) 33 (37.9)
UAP 6 (13.6) 12 (13.8)
CAG performed 39 (88.6) 82 (94.3) 0.25
PCI performed 33 (86.8) 67 (81.7) 0.48
CKmax - U/L 418 (195-1142) 513 (169-1332) 0.94
Cardiovascular risk factors    
Smoking 0.81
Current 17 (38.6) 35 (40.2)
Former 12 (27.3) 27 (31.0)
Never 15 (34.1) 25 (28.7)
Diabetes mellitus 16 (36.4) 32 (36.8) 0.96
Hypertension 21 (47.7) 44 (50.6) 0.76
Hypercholesterolemia 19 (43.2) 46 (52.9) 0.30
Creatinine - µmol/L 88 (73-93) 81 (67-97) 0.15
Cardiovascular history    
Peripheral arterial disease 10 (22.7) 7 (8.0) 0.018
Myocardial infarction 14 (31.8) 33 (37.9) 0.49
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Biomarker trajectories in the first 30 days after the index ACS
15 Cases reached the study endpoint within 30 days after the index ACS. They had 
higher serum levels of ANG-1 (difference of 0.95 NPX, 95% confidence interval [CI] 
0.36-1.54), PAR-1 (difference of 0.50 NPX, 95%CI 0.22-0.77) and BMP-6 (difference 
of 0.55 NPX, 95%CI 0.21-0.90) than the matched controls (Table 3, Figure 1 left-hand 
panel).
Biomarker trajectories after 30 days
30 Cases had the study endpoint in >30 days after the index ACS. Interestingly, in these 
late cases, the biomarker levels during the first 30 days after the index ACS tended to 
be lower than in the early cases (Table 4). In the post-30 day time window, cases and 
matched controls appeared to have similar levels of biomarkers (Table 5). Importantly, 
we found no steady or sudden increase in biomarkers in the days or weeks prior to the 
recurrent event.
Table 2. Baseline clinical characteristics  (continued)
 
Cases Controls
n=44 n=87 p-value
PCI 14 (31.8) 29 (33.3) 0.86
CABG 10 (22.7) 17 (19.5) 0.67
Stroke 9 (20.5) 5 (5.7) 0.010
Valvular heart disease 4 (9.1) 3 (3.4) 0.18
Heart failure 4(9.1) 1 (1.1) 0.025
Medication at first blood sample moment >7 days after the index ACS *
Aspirin 35 (92.1) 76 (92.7) 0.91
P2Y12 inhibitor 36 (94.7) 74 (90.2) 0.41
Vitamin K antagonist 7 (18.4) 8 (9.8) 0.18
Statin 35 (92.1) 79 (96.3) 0.32
Beta-blocker 36 (94.7) 69 (84.1) 0.10
ACE inhibitor or ARB 34 (89.5) 65 (79.3) 0.17
Continuous variables are presented as median (25th-75th percentile). Categorical variables are presented as num-
ber (percentage).
* The first blood sample >7 days was taken at a median (25th-75th percentile) of 24 (16-34) days after the index 
ACS.
ACE: angiotensin converting enzyme, ARB: angiotensin II receptor blocker, CABG: coronary artery bypass grafting, 
CKmax: maximum creatine kinase during the index admission, NSTEMI: non-ST-elevation myocardial infarction, 
PCI: percutaneous coronary intervention, STEMI: ST-elevation myocardial infarction, Troponin ax: maximum tropo-
nin value during the index admission, UAP: unstable angina pectoris, yr: years
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DISCUSSION
Serum levels of ANG-1, PAR-1 and BMP-6 were significantly higher in patients who 
developed a recurrent coronary event within the first 30 days following an ACS than 
in their matching controls. In the time period >30 days after the index-ACS until 1 year 
follow-up, patients with and without a recurrent coronary event had similar patterns of 
MAPK stimulating biomarkers. 
Our study results suggest that during the first 30 days post-ACS, the initial ACS 
induces numerous stimuli that activate the intracellular MAPK-cascade, which, in turn, 
may induce a pro-inflammatory and thrombogenic state, leading to a recurrent event. 
Potentially, other processes play a more important role in the initiation of a new coronary 
event following stabilization after the first 30 days post-ACS
Table 3. Difference in biomarker serum level between cases and controls ≤30 days
 Biomarker (NPX) Coefficient 95%CI p-value 
NEMO 1.16 (0.36-1.95) 0.005
HB-EGF 0.61 (0.11-1.12) 0.018
SCF -0.13 (-0.59-0.32) 0.55
PDGF subunit B 0.92 (0.31-1.54) 0.004
GDF-2 -0.063 (-0.35-0.23) 0.66
ANG-1 0.95 (0.36-1.54) 0.002
CCL3 0.29 (-0.12-0.71) 0.16
TIE2 0.12 (-0.048-0.29) 0.16
PAR-1 0.50 (0.22-0.77) <0.001
LEP 0.35 (-0.31-1.00) 0.29
REN 0.45 (-0.18-1.08) 0.16
TNFRSF11A 0.41 (0.003-0.82) 0.048
THPO 0.22 (-0.018-0.45) 0.069
FGF-21 0.55 (-0.39-1.49) 0.24
GAL-9 0.16 (-0.083-0.41) 0.19
SRC 0.29 (-0.18-0.76) 0.22
GH 0.71 (-0.61-2.02) 0.29
XCL1 0.34 (0.018-0.66) 0.039
FGF-23 0.90 (0.16-1.63) 0.018
CCL17 0.77 (0.089-1.46) 0.028
IL-18 0.19 (-0.15-0.52) 0.27
BMP-6 0.55 (0.21-0.90) 0.002
IL-6 0.95 (0.074-1.82) 0.034
AMBP 0.11 (-0.033-0.25) 0.13
CD40-L 1.32 (0.41-2.22) 0.006
For every biomarker, the difference in biomarker serum level between cases and controls is expressed in a relative 
arbitrary unit on the log 2 scale. Thus, an increase or decrease of one NPX corresponds with a doubling or a halving 
of the protein biomarker serum level. 
ACS: acute coronary syndrome, CI: confidence interval, NPX: Normalized Protein eXpression
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PAR-1 is a receptor expressed by cardiomyocytes, fibroblasts, smooth muscle cells 
and vascular endothelial wall cells.8 Basic scientific research showed that PAR-1 may 
stimulate pathological remodeling after cardiac ischemia/reperfusion injury.8, 9 More-
Figure 2. Time-course of PAR-1, BMP-6 and ANG-1
NPX: Normalized Protein eXpression 
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over, PAR-1 is involved in hemostasis and thrombosis.8, 10, 11 PAR-1 modulates thrombin 
signaling and is expressed on platelets, and may activate platelet secretion and ag-
gregation. Local tissue injury of the vascular endothelial wall might induce endothelial 
responses via PAR-1, like recruitment of leukocytes and platelets, to manage infection 
or damage.11 Accordingly, higher PAR-1 serum levels during the first 30 days following 
an ACS, might play a role in pathological remodeling after an ACS, and may lead to the 
development of (platelet-dependent) arterial thrombosis, and thus the recurrence of a 
coronary event.
BMP-6 is part of the transforming growth factor β family of cytokines. BMP-6 is in-
volved in activation of osteogenic markers in mesenchymal stem cells, and may modu-
late ectopic cartilage and bone matrix formation.12 Bone matrix formation is one of the 
Table 4. Biomarker serum levels in the first 30 days for cases only 
Biomarker (NPX) Early casesa Late casesa p-value
NEMO 6.61±1.08 5.80±1.25 0.062
HB-EGF 5.62±0.89 5.03±0.73 0.049
SCF 8.31±0.87 8.08±0.60 0.40
PDGF subunit B 10.47±0.84 9.49±1.16 0.012
GDF-2 3.16±0.55 2.94±0.37 0.19
ANG-1 9.31±0.91 8.38±1.21 0.022
CCL3 4.04±0.59 3.59±0.36 0.013
TIE2 7.02±0.19 6.86±0.39 0.16
PAR-1 8.66±0.35 8.26±0.48 0.012
LEP 5.26±0.93 4.94±0.51 0.23
REN 8.36±1.34 8.31±1.06 0.91
TNFRSF11A 5.55±0.68 5.15±0.61 0.084
THPO 2.99±0.33 2.87±0.80 0.60
FGF-21 7.01±1.51 6.72±1.12 0.54
Gal-9 7.93±0.39 7.79±0.39 0.34
SRC 7.20±0.37 7.06±0.55 0.40
GH 8.02±2.14 7.27±1.96 0.31
XCL1 4.77±0.52 4.79±0.49 0.92
FGF-23 4.02±1.77 2.84±0.63 0.025
CCL17 8.74±1.14 8.57±1.26 0.70
IL-18 8.59±0.58 8.36±0.46 0.21
BMP-6 5.23±0.60 4.80±0.77 0.091
IL-6 6.00±1.86 4.89±1.37 0.062
AMBP 6.00±0.22 5.90±0.23 0.26
CD40-L 7.28±1.41 6.28±1.44 0.058
Blood samples  ≤30 days after the index ACS were available for 15 early cases and 17 late cases.
* Patient-level mean value ± standard deviation.
NPX: Normalized Protein eXpression
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key processes responsible for vascular calcification.13 Since BMPs are overexpressed 
in (vulnerable) atherosclerotic lesions, it is suggested that BMPs modulate vascular 
calcification.14 Furthermore, it is observed that BMPs contribute to vascular inflamma-
tion.14-16 Lastly, previous research has indicated that oxidative stress may induce BMP-6 
expression and thereby vascular inflammation and calcification.12 Thus, it could be 
hypothesized that post-ACS oxidative stress may induce higher BMP-6 serum levels, 
which – in turn -  might induce vascular inflammation and a recurrent coronary event.
ANG-1 is a widely expressed biomarker and is involved in multiple cellular processes 
that occur following an ACS.17-19 ANG-1 modulates endothelial cell survival, prolifera-
Table 5. Biomarker serum levels in relation to time post index ACS 
 Median maximum value ≤7 days* Patient-level mean value 
≤30 days*
Patient-level mean value 
>30 days†
Biomarker (NPX) Cases Controls Cases Controls Cases Controls
NEMO 6.50 (5.51-7.29) 5.75 (4.70-6.63) 6.18 ±1.22 5.67±1.33 5.44±1.58 5.66±1.50
HB-EGF 5.43 (4.73-5.82) 5.06 (4.48-5.60) 5.31±0.85 5.15±0.88 5.19±0.89 5.32±0.95
SCF 8.18 (7.45-8.88) 8.35 (7.99-8.77) 8.19±0.74 8.40±0.54 8.45±0.55 8.53±0.45
PDGF subunit B 10.66 (9.37-10.87) 10.39 (8.95-10.69) 9.95±1.12 9.72±1.20 9.37±1.45 9.72±1.34
GDF-2 3.33 (3.74-3.59) 3.26 (2.97-3.60) 3.04±0.47 3.28±0.41 3.43±0.48 3.49±0.42
ANG-1 9.51 (7.86-9.78) 8.75 (7.72-9.54) 8.81±1.17 8.52±1.16 8.20±1.25 8.51±1.19
CCL3 3.97 (3.48-4.22) 3.55 (3.21-4.12) 3.80±0.52 3.70±0.68 3.59±0.55 3.62±0.52
TIE2 7.01 (6.89-7.19) 6.88 (6.71-7.17) 6.93±0.32 6.93±0.31 7.01±0.27 6.96±0.32
PAR-1 8.69 (8.27-8.88) 8.36 (7.88-8.59) 8.45±0.47 8.25±0.51 8.40±0.48 8.37±0.51
LEP 5.09 (4.58-5.73) 5.00 (3.96-5.79) 5.09±0.74 4.90±1.22 5.06±0.86 4.96±1.09
REN 8.74 (7.21-9.88) 7.88 (7.05-8.75) 8.34±1.18 8.08±1.06 8.47±1.01 8.24±1.00
TNFRSF11A 5.44 (5.04-6.01) 5.10 (4.60-5.51) 5.34±0.67 5.10±0.69 5.22±0.66 5.09±0.59
THPO 3.01 (2.75-3.42) 2.66 (2.35-2.97) 2.93±0.62 2.72±0.48 2.70±0.65 2.67±0.44
FGF-21 7.33 (6.71-8.36) 6.36 (5.26-7.59) 6.86±1.31 6.60±1.51 7.14±1.21 6.48±1.70
GAL-9 7.94 (7.64-8.10) 7.78 (7.42-8.05) 7.86±0.39 7.79±0.45 7.86±0.37 7.84±0.40
SRC 7.31 (7.21-7.44) 7.34 (7.00-7.61) 7.13±0.47 7.02±0.83 6.77±0.99 6.92±0.93
GH 9.07 (6.46-9.76) 7.15 (5.93-8.92) 7.62±2.05 7.52±2.01 7.32±1.92 7.72±2.05
XCL1 4.72 (4.50-5.21) 4.49 (4.19-4.87) 4.78±0.50 4.53±0.55 4.73±0.57 4.60±0.55
FGF-23 3.32 (2.78-3.89) 2.80 (2.55-3.24) 4.02±1.77 2.93±0.71 3.18±0.81 3.03±0.70
CCL17 8.53 (8.21-9.64) 8.12 (7.57-8.97) 8.74±1.14 8.32±1.39 8.47±1.30 8.46±1.29
IL-18 8.67 (8.07-9.00) 8.50 (7.97-8.76) 8.59±0.58 8.44±0.59 8.37±0.41 8.50±0.56
BMP-6 4.96 (4.65-5.69) 4.61 (4.14-5.11) 5.23±0.60 4.68±0.59 4.77±0.69 4.67±0.62
IL-6 6.56 (4.42-7.18) 5.08 (4.24-5.75) 6.00±1.86 4.63±1.42 3.99±1.04 3.69±0.91
AMBP 5.99 (5.82-6.18) 5.94 (5.68-6.07) 5.99±0.22 5.87±0.24 5.97±0.22 5.89±0.22
CD40-L 7.01 (6.17-8.31) 6.31 (5.40-7.29) 7.28±1.41 6.75±1.49 6.11±1.62 6.37±1.66
Blood samples in the time windows 0-7, 8-30 and 30-365 days after the index ACS were available for 23, 32, 28 
cases and for 44, 67, 70 controls. 
*Median (25th-75th percentile) value of the patient-level maximum.
†Mean ± standard deviation value of the patient-level mean. 
NPX: Normalized Protein eXpression
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tion, migration and reorganization. Furthermore, it promotes angiogenesis and vascular 
quiescence. However, in the absence of vascular endothelial growth factor (VEGF) 
exposure, ANG-1 may promote vessel regression.17 To the contrast of our study, previ-
ous research indicated that ANG-1 positively modulates cardiovascular disease, and 
promotes cardiomyocyte survival and reduces infarct size.20-22 Furthermore, one study 
showed that a lower serum level of ANG-1 on admission date, significantly predicted the 
development of one-year major cardiovascular events in post-ACS patients.22
Despite the complexity of the process, it is of interest to study blood biomarkers that 
stimulate the intracellular MAPK-cascade, since they may serve as novel biomarkers 
for aggravation of CVD. Because of the exploratory character of this study, our study 
results are limited to the examination of divergent biomarker patterns and thus, primar-
ily, are valuable for exploration and identification of (novel) protein blood biomarkers. 
Further research is needed to establish whether the studied protein blood biomarkers 
may actually be used to identify post-ACS patients who are at higher risk of developing 
a recurrent coronary event.
Limitations
Since we chose to use Olinks’Proteomics PEA high throughput analysis to efficiently 
analyze our samples for potential discovery of novel protein blood biomarkers, our 
study results lack generalizability because of the use of arbitrary units. In addition, al-
though Olinks’Proteomics PEA is an assay that gives highly reproducible results.23 PEA 
technique still needs improvements to assure complete reproducibility. Lastly, because 
of the small number of events in our study, differences between cases and controls may 
have been masked.
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Conclusion
In conclusion, the serum levels of ANG-1, PAR-1 and BMP-6, all biomarkers that 
stimulate the MAPK-cascade, were significantly elevated in patients with ACS who 
developed an early recurrent coronary event. These signaling proteins warrant further 
study on their potential use as novel biomarkers to identify high risk post-ACS patients.
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ABSTRACT
Purpose
We assessed the temporal pattern of 29 immune and inflammatory proteins in post-
acute coronary syndrome (ACS) patients, prior to the development of recurrent ACS.
Methods
High-frequency blood sampling was performed in 844 patients admitted for ACS dur-
ing one-year follow-up. We conducted a case-control study on the 45 patients who 
experienced reACS (cases) and two matched event-free patients (controls) per case. 
Olink Proteomics’ immunoassay was used to obtain serum levels of the 29 proteins, 
expressed in an arbitrary unit on the log2-scale (Normalized Protein eXpression[NPX]). 
Linear mixed-effects models were applied to examine the temporal pattern of the pro-
teins, and to illustrate differences between cases and controls.
Results
Mean age was 66±12 years and 80% were men. Cases and controls had similar 
baseline clinical characteristics. During the first 30 days, and after multiple testing cor-
rection, cases had significantly higher serum levels of CXCL1 (difference of 1.00 NPX, 
p=0.002), CD84 (difference of 0.64 NPX, p=0.002) and TNFRSF10A (difference of 0.41 
NPX, p<0.001) than controls. After 30 days, serum levels of all 29 proteins were similar 
in cases and controls. In particular, no increase was observed prior to reACS.
Conclusion
Among 29 immune and inflammatory proteins, CXCL1, CD84 and TNFRSF10A were 
associated with early reACS after initial ACS-admission.
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INTRODUCTION 
In the pathophysiology of atherosclerosis, the lipid metabolism and the immune and 
inflammatory systems are interconnected.1, 2 It is known that both lipids and inflam-
matory biomarkers are affected by LDL lowering treatment, which importantly reduces 
the occurrence of cardiovascular events.  However, despite adequately lowering LDL 
levels, a considerable number of patients with CVD will still develop adverse (coronary) 
events, especially those with a residual inflammatory risk.3 Therefore, more insights in 
the role of the immune- and inflammatory systems are required. 
The research field of proteomics offers a novel way to gain understanding of disease 
processes.4 As the proteome is considered the end product of the genome, and has 
a regulatory role in all kinds of biological processes in the human body, proteins are 
fundamental to determine onset and progression of diseases, including CVD. The 
advantage of research on proteins is the direct information it may offer at tissue level, 
regardless of a patient’s genotype. Novel technologies are emerging to simultaneously 
detect expression patterns of multiple proteins. These technologies offer the opportu-
nity to assess expression patterns of proteins belonging to several pathophysiological 
pathways simultaneously.5 
Studying the temporal behaviour of the proteome in patients with CVD prior to a 
recurrent coronary event may potentially lead to the identification of proteins related to 
progression of atherosclerosis. Therefore, we performed a controlled prospective study 
to assess the temporal pattern of a wide range of proteins involved in the immune- and 
inflammatory systems just prior to the recurrence of a coronary event during one year 
follow-up of patients admitted with an acute coronary syndrome (ACS).
METHODS
Study population
The ‘BIOMarker study to identify the Acute risk of a Coronary Syndrome’ (BIOMArCS) 
is a multicentre observational study with a design characterized by high-frequent blood 
sampling to assess the course over time of blood biomarkers during one-year follow-up 
of patients who have been admitted with an ACS, and to study the temporal pattern of 
these biomarkers just prior to the occurrence of an imminent repeat coronary event.6 
In brief, patients aged ≥40 years, who were admitted with an ACS, and who had  ≥1 
cardiovascular risk factor were eligible. The diagnosis ACS was based on typical isch-
emic chest pain, lasting >10 min in the preceding 24 h, in combination with objective 
evidence of myocardial necrosis, as obtained from the ECG (ST-segment elevation or 
dynamic ST-segment depression) or biochemistry (CKMB or cardiac troponin eleva-
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tion). After enrolment, venepunctures were performed every two weeks during the first 
six months and every four weeks during the second six months of follow-up.
BIOMArCS was approved by the Institutional Review Boards of all 18 enrolling 
hospitals, and all participating patients provided written informed consent. BIOMArCS 
is registered in The Netherlands Trial Register NTR1698 and NTR1106.
Case-control design
For the current study, we applied a nested case-control design for protein measure-
ments and statistical analysis. A total of 45 patients (cases) developed the primary study 
endpoint composed of cardiac death, non-fatal myocardial infarction (MI), or unstable 
angina (UA) requiring urgent coronary revascularization during one year of follow-up 
after the initial ACS. Each case was assigned to two controls matched on age, gender 
and admitted hospital. For reasons of efficiency, for each case, the blood sample at 
hospital admission and the last two samples prior to the recurrent endpoint event were 
selected. For matched controls, the blood sample at hospital admission and the blood 
sample that corresponds in time from enrolment with the timing of the case-event were 
selected.
We were interested in the temporal patterns of the proteins during the acute phase 
after the initial ACS (first 30 days), as well as during the stable phase after the initial 
ACS (30-day to 1-year time period). Thus, separate analyses were conducted for cases 
(and their matching controls) who experienced the event in the first 30 days of follow-up 
after the initial ACS, and for cases (and their matching controls) who experienced their 
event thereafter until one-year follow-up.
Protein measurements
Olink’s high throughput Proximity Extension Assay (PEA) technique (Olink Proteomics 
AB, Uppsala, Sweden) was used to measure 29 immune and inflammatory proteins of 
the cardiovascular II panel (Table 1).5 Detailed information on PEA Technique is avail-
able on Olink’s website (www.olink.com). In brief, PEA technique allows for efficient 
quantification of multiple protein biomarkers simultaneously. Every measured protein 
is expressed in an arbitrary unit on the log2-scale called Normalized Protein eXpres-
sion (NPX). Hence, an increase or decrease of one NPX corresponds to a doubling 
or halving of the protein’s serum level, respectively. To determine approximate serum 
concentrations, general calibrator curves are available on the website of Olink for each 
protein biomarker.
Statistical analysis
Continuous baseline characteristics are presented as medians with 25th and 75th per-
centile, and were compared between cases and controls with the Mann-Whitney U test. 
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Categorical baseline characteristics are presented as numbers with percentages and 
were compared between cases and controls with the Chi-square test.
Linear mixed-effects models were fitted for every protein (dependent). To allow indi-
vidual variation per patient, random intercepts were included in the models. Likelihood 
Table 1. Overview of the immune and inflammatory protein biomarkers
Abbreviation Full name Synonyms Molecular function
ADAM-TS13 A disintegrin and metalloproteinase with thrombospondin motifs 13 C9orf8, vWF-CP Hydrolase 
ADM Adrenomodullin AM Hormone
ACE2  Angiotensin I converting enzyme 2 peptidyl-dipeptidase A Hydrolase/receptor
CXCL1 C-X-C motif chemokine ligand 1 GRO1, GROa, MGSA, FSP, NAP-3
Chemokine/growth 
factor 
CEACAM8 Carcinoembryonic antigenrelated cell adhesion molecule 8 CGM6, CD66b Protein binding 
CTSL1  Cathepsin L1 Hydrolase 
HO-1 Heme oxygenase (decycling) 1 HMOX1 Oxidoreductase
IL-1ra Interleukin-1 receptor antagonist IL1RN, IRAP, ICL-1RA Cytokine 
IL1RL2 Interleukin-1 receptor-like 2 IL1RRP2, IL36R Receptor
IL-17D Interleukin-17D Cytokine
IL-27 Interleukin-27 subunit alpha and beta IL27A, EBI3, IL27B Cytokine
IL-4RA Interleukin-4 receptor subunit alpha IL4R Receptor
LOX-1 Lectin-like oxidized LDL receptor 1 OLR1, CLEC8A Receptor
LPL Lipoprotein lipase LIPD Hydrolase 
IgG Fc receptor 
II-b
Fc Fragment Of IgG, low affinity IIb 
receptor FCGR2B, CD32B Receptor
MARCO Macrophage receptor with collagenous structure SCARA2 Receptor
hOSCAR Osteoclast associated, immunoglobulin-like receptor OSCAR Receptor
PTX3 Pentraxin 3 TSG14,TNFAIP5 Receptor
PIgR  Polymeric immunoglobulin receptor Receptor
IL16 Pro-interleukin-16 LCF Cytokine
PD-L2  Programmed cell death 1 ligand 2 PDCD1LG2, B7DC, CD273 Receptor
RAGE Advanced glycosylation end product-
specific receptor
AGER Receptor
CD84 SLAM family member 5 SLAMF5 Receptor
SPON2 Spondin-2 Mindin, DIL1 Antigen binding
CD4 T-cell surface glycoprotein CD4 Antigen binding
TF Coagulation factor III (tissue factor) F3, thromboplastin Receptor
TRAIL-R2 TNF-related apoptosis-inducing ligand receptor 2 TNFRSF10B,CD262, DR5 Receptor
TNFRSF10A Tumor necrosis factor receptor superfamily member 10A CD261, DR4, TRAILR-1, APO2 Receptor
TNFRSF13B Tumor necrosis factor receptor superfamily member 13B CD267, TACI Receptor
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ratio tests and F tests were used for hypothesis testing, and model assumptions were 
checked by visual examination of the residuals. To account for the 29 proteins tested, 
correction for multiple testing was applied (p=0.003).7 The corrected significance level 
was calculated using the matrix spectral decomposition method, a correction method 
used in ‘omics’ studies to account for the number of independent performed tests.7, 8 
All statistical tests were two-tailed. R statistical software (version 3.4.0) was used for 
statistical analyses, in particular the package nlme (https://cran.r-project.org/web/pack-
ages/nlme/index.html).
RESULTS
Baseline characteristics
Mean age was 66 ±12 years and 80% were men. Presentation, initial treatment, car-
diovascular risk factors and medication at first blood sample (baseline) were similar for 
cases and matched controls (Table 2). Thus, matching was successful.
Biomarker pattern within first 30 days post-ACS
15 Cases experienced a recurrent event within the first 30 days of follow-up. After cor-
rection for multiple testing, the serum level of CXCL1 in the first 30 days was 1.00 NPX 
(95% confidence interval [CI] 0.38-1.61) higher in cases than in their matching controls, 
which corresponds to a doubling of the CXCL1 serum level in cases. The serum levels 
of CD84 and TNFRSF10A were also significantly higher in cases than in their matching 
controls with a difference in these serum levels of 0.64 NPX (95%CI 0.25-1.03) and 0.41 
NPX (95%CI 0.20-0.62), respectively. (Table 3, Figure 1 left-hand panel)
Biomarker pattern after 30 days
29 Cases experienced their recurrent event between 30 days and one year following 
their initial ACS. Prior to the recurrent coronary event in the 30-day to one-year period, 
serum levels of all studied protein biomarkers stabilised in cases and matched controls 
to indistinctive serum levels (Table 4). Hence, we found no significant divergent protein 
biomarker patterns between so-called late cases and matched controls. In particular, no 
(steady) increase was observed prior to the repeat event.
Since we did find significant divergent protein biomarker patterns between early 
cases and matched controls, we compared protein biomarker serum levels of ≤30-day 
cases with those of >30-day cases as a post-hoc analysis in the first 30 days post index-
ACS (Table 5). Overall, most protein biomarker serum levels appeared to be higher in 
early cases.
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Table 2. Baseline clinical characteristics of the patients 
Cases Controls
 n=44 n=87 p-value
Presentation and initial treatment    
Men 35 (79.5) 70 (80.5) 0.90
Age - yr 67.5 (57.3-77.5) 66.7 (57.4-75.5) 0.83
Admission diagnosis 0.38
STEMI 16 (36.4) 42 (48.3)
NSTEMI 22 (50.0) 33 (37.9)
UAP 6 (13.6) 12 (13.8)
CAG performed 39 (88.6) 82 (94.3) 0.25
PCI performed 33 (86.8) 67 (81.7) 0.48
CKmax - U/L 418 (195-1142) 513 (169-1332) 0.94
Cardiovascular risk factors    
Smoking 0.81
Current 17 (38.6) 35 (40.2)
Former 12 (27.3) 27 (31.0)
Never 15 (34.1) 25 (28.7)
Diabetes mellitus 16 (36.4) 32 (36.8) 0.96
Hypertension 21 (47.7) 44 (50.6) 0.76
Hypercholesterolemia 19 (43.2) 46 (52.9) 0.30
Creatinine - µmol/L 88 (73-93) 81 (67-97) 0.15
Cardiovascular history    
Peripheral arterial disease 10 (22.7) 7 (8.0) 0.018
Myocardial infarction 14 (31.8) 33 (37.9) 0.49
PCI 14 (31.8) 29 (33.3) 0.86
CABG 10 (22.7) 17 (19.5) 0.67
Stroke 9 (20.5) 5 (5.7) 0.010
Valvular heart disease 4 (9.1) 3 (3.4) 0.18
Heart failure 4(9.1) 1 (1.1) 0.025
Medication at first blood sample moment >7 days after the index ACS *
Aspirin 35 (92.1) 76 (92.7) 0.91
P2Y12 inhibitor 36 (94.7) 74 (90.2) 0.41
Vitamin K antagonist 7 (18.4) 8 (9.8) 0.18
Statin 35 (92.1) 79 (96.3) 0.32
Beta-blocker 36 (94.7) 69 (84.1) 0.10
ACE inhibitor or ARB 34 (89.5) 65 (79.3) 0.17
Continuous variables are presented as median (25th-75th percentile). Categorical variables are presented as num-
ber (percentage).
* The first blood sample >7 days was taken at a median (25th-75th percentile) of 24 (16-34) days after the index 
ACS.
ACE: angiotensin converting enzyme, ARB: angiotensin II receptor blocker, CABG: coronary artery bypass grafting, 
CKmax: maximum creatine kinase during the index admission, NSTEMI: non-ST-elevation myocardial infarction, 
PCI: percutaneous coronary intervention, STEMI: ST-elevation myocardial infarction, Troponin ax: maximum tropo-
nin value during the index admission, UAP: unstable angina pectoris, yr: years
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Table 3. Difference in protein biomarker serum level between cases and controls ≤30 days
Protein (NPX) Coefficient 95%CI p-value
ADAM-TS13 0.079 (-0.093-0.25) 0.36
ADM 0.36 (0.015-0.70) 0.041
ACE2 0.69 (0.18-1.20) 0.009
CXCL1 1.00 (0.38-1.61) 0.002
CEACAM8 0.38 (-0.070-0.83) 0.096
CTSL1 0.21 (-0.10-0.52) 0.18
HO-1 0.14 (-0.19-0.47) 0.39
IL-1ra 0.11 (-0.49-0.71) 0.72
IL1RL2 0.046 (-0.22-0.31) 0.73
IL-17D 0.23 (0.029-0.43) 0.026
IL-27 0.36 (0.093-0.62) 0.009
IL-4RA 0.48 (0.16-0.80) 0.004
LOX-1 0.16 (-0.23-0.54) 0.42
LPL -0.12 (-0.42-0.17) 0.40
IgG Fc receptor II-b 0.17 (-0.25-0.60) 0.42
MARCO 0.086 (-0.069-0.24) 0.27
hOSCAR 0.15 (-0.040-0.33) 0.12
PTX3 0.34 (-0.13-0.80) 0.15
PIgR 0.040 (-0.032-0.11) 0.27
IL16 0.21 (-0.14-0.56) 0.23
PD-L2 0.21 (-0.010-0.42) 0.061
RAGE 0.40 (0.12-0.67) 0.006
CD84 0.64 (0.25-1.03) 0.002
SPON2 0.14 (0.026-0.25) 0.017
CD4 0.19 (-0.024-0.41) 0.080
TF 0.14 (-0.049-0.33) 0.14
TRAIL-R2 0.29 (-0.041-0.62) 0.084
TNFRSF10A 0.41 (0.20-0.62) 0.0004
TNFRSF13B 0.096 (-0.23-0.43) 0.56
For every protein biomarker, the difference in serum level between cases and controls is expressed in a relative 
arbitrary unit on the log 2 scale. Thus, An increase or decrease of one NPX corresponds with a doubling or a halv-
ing of the protein serum level. 
ACS: acute coronary syndrome, CI: confidence interval, NPX: Normalized Protein eXpression
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Figure 1. The temporal pattern of CD84, TNFRSF10A and CXCL1
NPX: Normalized Protein eXpression
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Table 4. Protein biomarker serum levels in relation to time post index ACS 
 Median maximum value ≤7 days* Patient-level mean value 
≤30 days*
Patient-level mean value 
>30 days†
Protein (NPX) Cases Controls Cases Controls Cases Controls
ADAM-TS13 5.22 (5.02-5.47) 5.19 (4.94-5.31) 5.17±0.32 5.19±0.27 5.20±0.30 5.26±0.31
ADM 7.53 (7.10-8.01) 7.21 (6.75-7.54) 7.36±0.50 7.06±0.55 7.18±0.54 6.99±0.55
ACE2 4.24 (3.95-5.06) 3.95 (3.56-4.29) 4.27±0.92 4.00±0.79 4.21±0.62 4.18±0.86
CXCL1 9.42 (8.76-9.98) 8.68 (7.86-9.22) 8.95±1.07 8.67±1.22 8.46±1.29 8.76±1.22
CEACAM8 3.98 (3.52-4.25) 3.64 (3.09-4.12) 3.76±0.79 3.54±0.65 3.35±0.61 3.30±0.61
CTSL1 5.39 (5.06-5.57) 5.17 (4.85-5.48) 5.30±0.59 5.15±0.49 5.07±0.44 5.02±0.50
HO-1 13.00 (12.63-13.25) 12.79 (12.26-13.20) 12.71±0.50 12.77±0.54 12.55±0.34 12.77±0.52
IL-1ra 7.56 (6.60-8.07) 6.94 (6.44-7.52) 7.11±0.78 7.04±0.92 6.75±0.51 6.81±0.78
IL1RL2 3.13 (2.67-3.47) 3.07 (2.62-3.30) 3.07±0.41 3.07±0.43 3.14±0.34 3.07±0.44
IL-17D 2.49 (2.34-2.71) 2.18 (2.00-2.53) 2.34±0.35 2.22±0.31 2.26±0.22 2.25±0.36
IL-27 3.20 (2.69-3.55) 2.80 (2.51-3.13) 3.05±0.55 2.85±0.42 2.87±0.35 2.79±0.29
IL-4RA 2.21 (1.84-2.91) 1.86 (1.71-2.16) 2.22±0.66 1.88±0.30 1.81±0.26 1.82±0.32
LOX-1 6.33 (5.70-6.96) 5.99 (5.55-6.50) 6.08±0.69 6.03±0.62 5.85±0.49 5.92±0.50
LPL 9.26 (8.67-9.73) 9.09 (8.89-9.67) 9.23±0.50 9.30±0.52 9.40±0.53 9.34±0.49
IgG Fc receptor II-b 3.06 (2.62-3.50) 2.96 (2.43-3.39) 3.01±0.73 2.94±0.70 2.97±0.85 2.88±0.75
MARCO 5.00 (4.79-5.13) 4.93 (4.75-5.19) 4.98±0.22 4.98±0.29 4.99±0.26 5.02±0.29
hOSCAR 10.60 (10.42-10.78) 10.43 (10.19-10.77) 10.58±0.30 10.42±0.35 10.51±0.31 10.40±0.35
PTX3 3.96 (2.96-4.47) 3.38 (2.98-4.06) 3.43±0.82 3.31±0.68 3.03±0.56 2.91±0.51
PIgR 7.25 (7.10-7.33) 7.17 (7.07-7.27) 7.18±0.17 7.17±0.14 7.20±0.18 7.19±0.15
IL16 5.41 (5.18-5.82) 5.23 (4.85-5.54) 5.30±0.48 5.18±0.60 5.33±0.37 5.15±0.52
PD-L2 2.64 (2.30-3.06) 2.44 (2.16-2.74) 2.64±0.44 2.50±0.38 2.65±0.48 2.60±0.37
RAGE 5.57 (5.31-5.92) 5.30 (4.98-5.51) 5.45±0.50 5.14±0.39 5.30±0.51 5.13±0.43
CD84 5.54 (4.86-5.80) 4.93 (4.53-5.33) 5.34±0.62 5.09±0.63 5.17±0.67 5.24±0.65
SPON2 10.28 (10.11-10.43) 10.13 (9.95-10.26) 10.18±0.26 10.09±0.24 10.17±0.21 10.11±0.26
CD4 2.99 (2.48-3.25) 2.74 (2.45-3.02) 2.83±0.38 2.79±0.46 2.87±0.40 2.85±0.46
TF 5.60 (5.48-5.85) 5.55 (5.35-5.78) 5.55±0.31 5.54±0.32 5.59±0.37 5.58±0.36
TRAIL-R2 5.79 (5.48-6.42) 5.65 (5.34-5.93) 5.69±0.60 5.60±1.04 5.61±0.67 5.47±1.03
TNFRSF10A 2.80 (2.50-3.32) 2.48 (2.15-2.78) 2.69±0.44 2.46±0.40 2.50±0.39 2.45±0.36
TNFRSF13B 7.47 (7.33-7.86) 7.55 (7.05-7.85) 7.72±0.88 7.60±0.54 7.89±1.05 7.71±0.59
Blood samples in the time windows 0-7, 8-30 and 30-365 days after the index ACS were available for 23, 32, 28 
cases and for 44, 67, 70 controls. 
*Median (25th-75th percentile) value of the patient-level maximum.
†Mean ± standard deviation value of the patient-level mean. 
NPX: Normalized Protein eXpression
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DISCUSSION
This study assessed the temporal pattern of 29 immune and inflammatory proteins 
in post-ACS patients. Serum levels of CXCL1, CD84 and TNFRSF10A showed to be 
significantly higher In cases than in matched controls prior to their recurrent coronary 
event within 30 days after the index ACS. After the first 30 days of follow-up, none of 
the studied protein biomarkers had detectable divergent serum levels in cases and their 
matched controls. 
Table 5. Protein biomarker serum levels in the first 30 days for cases only 
Protein (NPX) Early cases* Late cases* p-value
ADAM-TS13 5.25±0.30 5.10±0.34 0.20
ADM 7.53±0.50 7.21±0.45 0.067
ACE2 4.64±1.03 3.94±0.70 0.032
CXCL1 9.45±0.69 8.51±1.16 0.010
CEACAM8 3.98±0.72 3.56±0.82 0.13
CTSL1 5.42±0.59 5.20±0.59 0.30
HO-1 12.91±0.49 12.53±0.45 0.028
IL-1ra 7.23±0.84 7.00±0.73 0.42
IL1RL2 2.99±0.43 3.14±0.40 0.33
IL-17D 2.48±0.37 2.22±0.28 0.032
IL-27 3.26±0.59 2.87±0.45 0.045
IL-4RA 2.44±0.75 2.03±0.51 0.079
LOX-1 6.11±0.48 6.06±0.84 0.83
LPL 9.20±0.51 9.25±0.51 0.77
IgG Fc receptor II-b 2.97±0.74 3.05±0.74 0.77
MARCO 5.02±0.21 4.95±0.23 0.36
hOSCAR 10.62±0.23 10.54±0.35 0.48
PTX3 3.64±0.93 3.24±0.68 0.18
PIgR 7.23±0.11 7.14±0.20 0.10
IL16 5.34±0.42 5.27±0.54 0.68
PD-L2 2.70±0.35 2.58±0.51 0.45
RAGE 5.65±0.47 5.28±0.47 0.036
CD84 5.58±0.63 5.13±0.55 0.039
SPON2 10.28±0.21 10.08±0.27 0.031
CD4 2.95±0.33 2.72±0.39 0.079
TF 5.69±0.24 5.43±0.31 0.011
TRAIL-R2 5.88±0.64 5.53±0.53 0.10
TNFRSF10A 2.92±0.41 2.48±0.36 0.003
TNFRSF13B 7.66±0.40 7.78±1.17 0.71
Blood samples  ≤30 days after the index ACS were available for 15 early cases and 17 late cases.
* Patient-level mean value ± standard deviation.
NPX: Normalized Protein eXpression
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CXCL1 is a cytokine that attracts neutrophils by chemotaxis and stimulates monocyte 
arrest.9 Oxidized LDL and wall shear stress on endothelial cells have been shown 
to induce the expression of CXCL1.10, 11 Subsequently, CXCL1 stimulates monocyte 
adhesion to the endothelial wall.12, 13 These monocytes migrate into the endothelial wall 
and stimulate the accumulation of macrophages. Eventually, this process promotes 
atherosclerotic plaque formation and instability and is therefore a key process in patho-
logical atherosclerosis. Since we found higher serum levels of CXCL1 in early cases, 
a possible mechanism may be that CXCL1 is upregulated due to  the index ACS, but 
subsequently also  promotes early recurrent events by inducing atherosclerotic plaque 
instability.  
CD84 is a signalling lymphocyte activation molecule (SLAM) and is expressed on 
platelets. It has been described that during thrombus formation, CD84 is triggered upon 
platelet aggregation and advances thrombus stability.14 Since disproportional throm-
bus formation may cause arterial occlusion, CD84 may be of interest as a biomarker 
for coronary events. However, little research has been conducted on CD84 and its 
association with CVD. One previous study has identified CD84 to be associated with 
adverse outcome in Kawasaki disease coronary arteriopathy.15 In this study, CD84 was 
found to be highly expressed in inflamed endothelium tissue of the coronary arteries 
of patients who developed adverse outcome and was suggested to play an important 
role in the pathogenesis of arterial thrombosis.15 Our study found higher CD84 serum 
levels in post-ACS patients who developed early recurrent events. Potentially, CD84 
upregulation is initiated by the index ACS and, subsequently, promotes disproportional 
thrombus formation causing early recurrent ACS. Further research should establish 
whether CD84 serum levels may be used to identify patients who will develop an early 
recurrent coronary event and who will not. 
TNFRSF10A, a receptor for TNFSF10/TRAIL, is a member of the TNF-receptor 
superfamily and modulates apoptosis and proliferation of vascular smooth muscle 
cells.16, 17 Since these processes may be beneficial as well as disadvantageous for 
atherosclerosis, depending on the stage of an atherosclerotic lesion, there is still an 
ongoing debate as to whether TNFRSF10A and its ligand may be used as a marker for 
progression or regression of atherosclerosis.18 Our study found higher serum levels of 
TNFRSF10A in patients who developed an early recurrent cardiac event. Potentially, 
higher TNFSRF10A serum levels induce excessive proliferation of vascular smooth 
muscle cells after the index ACS which may lead to new coronary stenosis. 19  
Our study shows that CXCL1, CD84 and TNFRSF10A serum levels were elevated 
in post-ACS patients who experienced an early repeat coronary event. Nonetheless, 
we did not find divergent protein biomarker serum levels in post-ACS patients who 
experienced a late repeat coronary event (i.e. in the 30-day to one-year time-window). 
One may argue that differences in serum levels between cases and controls may be 
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smaller in the long-term and our study lacked power to reveal these. We designed the 
current study as an initial analysis and did not quantify all collected blood samples in 
BIOMArCS, since we intended - depending on the first results - to assess more blood 
samples after our first analysis to expand the number of repeated biomarker measure-
ments. However, since we did find associations in early cases, and our study did not 
lack power to reveal these associations, we conclude that the 29 protein biomarkers we 
studied may not be associated with the development of recurrent coronary events in 
late cases. Apparently, the index ACS triggers short-term upregulation of CXCL1, CD84 
and TNFRSF10A, which may play a role in the development of early recurrent coronary 
events.  
For our protein measurements, we used Olink’s PEA technique. This PEA technique 
enables an effective assessment of blood samples with a rapid high-throughput analy-
sis of high sensitivity and specificity. However, although PEA is a promising technique, 
improvements are warranted to assure clinical valid and reproducible measurements. 
In addition to the technical challenges, one should consider that other factors related 
to biobank-sampling, i.e. blood sample collection and repeated freezing and thawing 
of collected blood samples influence the reproducibility of protein measurements. 
Studying the behaviour over time of immune and inflammatory proteins in patients with 
CVD prior to a (recurrent) coronary event may provide new insights on modulators of 
pathological atherosclerosis. However current research remains exploratory. Technical 
improvements are required to assess whether immune and inflammatory proteins can 
be used in clinical practice and may contribute to established clinical tools for disease 
detection and prognosis. Finally, the proposed mechanisms through which the biomark-
ers may be pathophysiologically related to the repeat ACS are hypothesis generating.  
Conclusion
Among 29 immune and inflammatory proteins on the Olink platform, CXCL1, CD84 
and TNFRSF10A were associated with early repeat coronary events in patients who 
experienced an ACS. Further research should assess whether CXCL1, CD84 and 
TNFRSF10A can actually be used to discriminate between patients who will experience 
an early repeat coronary event after an initial ACS admission, and patients who will not. 
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Summary and conclusions
This thesis focused on the identification of patients with cardiovascular disease (CVD), 
especially ischemic heart disease (IHD), who are at higher risk of recurrent CV events.1, 2 
Within the first year after hospital admission for IHD, mortality due to a recurrent CV 
event is 9%. 3 We hypothesized that a more precision-based, personalized approach to 
the course of IHD may improve prognostication, and, ultimately, secondary prevention.
Imaging of coronary atherosclerosis in patients with IHD
We have studied the extent of coronary atherosclerosis and coronary plaque morphol-
ogy, as measured by invasive imaging modalities, including coronary angiography 
(CAG), intravascular ultrasound (IVUS) and near infra-red spectroscopy (NIRS), and 
assessed their relation with adverse clinical outcomes during long-term follow-up in 
patients admitted to the hospital with acute coronary syndrome (ACS) or stable angina 
pectoris (SAP).
The SYNTAX score is an established CAG-based tool to quantify the complexity of 
a patient’s coronary artery disease (CAD), that incorporates luminal stenosis as well 
as other factors reflecting disease severity such as lesion length and disease diffusion. 
The SYNTAX score is limited to coronary luminography and therefore unable to qualify 
plaque morphology and vulnerability in itself. In chapter two, we studied 680 ACS/SAP 
patients, and revealed an association between coronary atherosclerotic complexity as 
measured by the SYNTAX score, based on all three coronary arteries, and coronary 
artery wall pathology as measured by IVUS and NIRS, which was obtained in a single 
non-culprit coronary artery segment.4-6  In particular, SYNTAX score was associated 
with the amount of IVUS-derived fibrous/fibro-fatty tissue and NIRS-derived lipid bur-
den. We found no association between SYNTAX score and the presence of thin-cap 
fibroatheroma (TCFA). As an important secondary finding, our study suggested that 
single-segment imaging might be sufficient to obtain an adequate assessment of a 
patient’s coronary atherosclerotic status.
The SYNTAX score has been applied for prediction of adverse cardiac events up 
to five years after percutaneous intervention (PCI) and coronary artery bypass sur-
gery (CABG).7, 8 However, with regard to NIRS and IVUS, so far only their short-term 
prognostic value had been studied.5, 9 We assessed the association between a range 
of NIRS- and IVUS-derived parameters, as measured by single-segment imaging in a 
non-culprit coronary vessel, and major adverse cardiac events (MACE) in ACS/SAP 
patients during four years of follow-up. In the 275 patients who had NIRS imaging, 
which we described in chapter three, each 100 unit increase of LCBI-derived maximum 
(in a 4 mm section) lipid core burden index (LCBI) was associated with a 19% increase 
in incidence of MACE. In the 581 patients who had IVUS imaging, which we described 
in chapter four, those with a lesion with a minimal luminal area ≤4.0 mm2 had a 49% 
increase in MACE incidence. In addition, each 10 units increase in plaque burden 
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was on its own associated with a 26% increase in MACE incidence. Thus, in line with 
the result of chapter two, the extent and volume of coronary plaques as well as their 
lipid content, and not plaque features, appeared important factors for the prediction of 
adverse CV events. Additionally, we concluded that single-lesion imaging may be used 
for patient prognostication. 
Finally, in chapter five we studied the long-term prognostic value of the SYNTAX 
score II (SSII). SSII incorporates both the original SYNTAX score as well as clinical 
factors, including age, gender, creatinine clearance, left ventricular ejection fraction, 
presence of peripheral vascular disease, chronic obstructive pulmonary disease, and 
unprotected left main CAD. SSII has been validated as a tool for prediction of long-term 
mortality in patients with complex CAD,10-12 but had not yet been studied in a more 
heterogeneous population including less complex CAD. Hence, we examined its prog-
nostic value in 628 ACS/SAP patients with baseline one- or two vessel disease, which 
is more common in routine clinical practice. In our study, each point increase in SSII 
was related with a 10% increase in all-cause mortality during 4.5 year follow-up, and its 
concordance index was 0.77 which can be classified as good performance. Thus, SSII 
may be used for prognostication purposes in CAD patients, irrespective of the extent 
and complexity of disease.
Circulating biomarkers of coronary atherosclerosis in patients with 
IHD
Circulating biomarkers may serve as a proxy for a patient’s CVD progression and are 
therefore an appealing target for prognostic research in patients with IHD.2 Currently, 
various biomarkers have been identified that might be associated with adverse CV 
outcomes in IHD patients. Interestingly, most research conducted on biomarkers uses 
single (baseline) measurements to predict adverse outcome, whereas the development 
of a CV event is a dynamic process. Surprisingly, little is known about the temporal 
evolvement of biomarkers identified in IHD. We postulated that such information is 
needed to successfully apply a biomarker-guided strategy for the identification and 
monitoring of high-risk IHD patients.
Hence, in chapter six, we assessed the temporal patterns of Myeloperoxidase 
and Galectin-3, two known markers of coronary plaque vulnerability, in 187 post-ACS 
patients prior to recurrent nonfatal or fatal ACS during 1 year of follow-up.13, 14 Using 
repeated measurements, we studied the evolvement of both biomarkers early after 
ACS admission, as well as their temporal evolution prior to recurrent ACS. We found 
that Myeloperoxidase showed a peak of 78.3 ng/ml at the time of ACS admission, but 
decreased and stabilised within seven days post ACS admission. Thereafter, Myeloper-
oxidase remained stable throughout follow-up at an average level of 25.6 ng/ml (IQR: 
20.4-32.0) and, notably, no increase in its level prior to recurrent ACS was detected. 
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Galectin-3 showed stable levels during the entire follow-up with an average level of 
230 (167-300) pg/ml. Longitudinal levels of Myeloperoxidase and Galectin-3 were not 
associated with recurrent nonfatal or fatal ACS. 
In chapter seven we studied the temporal pattern of Circulating Growth differentia-
tion Factor-15 (GDF-15) during one year of follow-up in 111 post-ACS patients. GDF-15 
is a stress-reactive inflammatory biomarker and has shown prognostic value in post-
ACS patients.15-17 In our study, GDF-15 level was systematically higher in the post-ACS 
patients who experienced recurrent nonfatal or fatal ACS, than in those who did not. 
After 30 days post the index-ACS, patients showed stable GDF-15 levels, which were 
on average 333 (95%CI 68-647) pg/ml higher in cases than in controls (1704 vs. 1371 
pg/ml).  Between-subject variability of GDF-15 was large (82% in cases and 84% in 
controls), and within-subject variability was low (18% in cases and 16% in controls). 
We concluded that GDF-15 may be used for prognostication in post-ACS patients, and 
individual reference values for GDF-15 would be preferred.
Chapter eight described the temporal pattern of soluble Suppression of Tumori-
genicity-2 (sST2) during one year in 187 post-ACS patients. sST2 is an established 
marker of adverse cardiomyocyte remodelling after myocardial stress, and admission 
levels have shown to associate with adverse outcome in post-ACS patients.18-20 Us-
ing repeated measurements, we found that persistently higher levels of sST2 during 
follow-up are associated with recurrent nonfatal or fatal ACS, as one standard deviation 
increase in sST2 level correlated with a 64% increase in incidence of recurrent CV 
events. Moreover, as we found that the within-patient variability over time in sST2 level 
is low, a limited number of measurements may be sufficient for prognostication. 
In addition to these previously identified biomarkers of adverse outcome in IHD, 
we also studied a broad range of novel protein biomarkers in relation to recurrent CV 
events in post-ACS patients. For this analysis, Olink Proteomics’ immunoassay was 
used to obtain the serum levels of these protein biomarkers, expressed in an arbitrary 
unit on the log2-scale (Normalized Protein eXpression[NPX]).21 In chapter nine we 
described in 131 patients the temporal evolvement of 25 proteins that stimulate the 
mitogen-activated protein kinase (MAPK) cascade. The MAPK cascade is an intracel-
lular cascade through which blood biomarkers modulate cell processes such as cell 
growth, differentiation or apoptosis.22 In CVD development, the MAPK cascade has 
shown to be involved in plaque formation, stress-induced adverse myocardial re-
modelling and restenosis.23 We found that the serum level of angiopoietin-1 (ANG-1), 
proteinase-activated receptor 1 (PAR-1) and bone morphogenetic protein 6 (BMP-6) 
was higher in post-ACS patients who experienced early repeat ACS within 30 days 
after their first ACS-admission. After 30 days, none of the 25 proteins were significantly 
higher in the patients who experienced recurrent ACS within one year. In the same 
patient group, we studied in chapter ten 29 immune and inflammatory proteins and 
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found that serum level of C-X-C motif chemokine 1 (CXCL1), slam-family member 5 
(CD84) and tumor necrosis factor receptor superfamily member 10a (TNFRSF10A) was 
higher in the patients with repeat ACS within 30 days, but not after 30 days. Moreover, 
none of the exploratory proteins described in chapter nine or ten showed a steady or 
sudden increase in serum level prior to recurrent event. 
In chapter eleven we continued to explore novel markers of repeat ACS in 158 post-
ACS patients, studying (lipid) metabolites. For this analysis, high-throughput automated 
proton NMR spectroscopy was applied to simultaneously quantify 151 metabolites per 
serum sample.24 Every standard deviation increase in concentrations of extremely large 
very low density lipoprotein (VLDL), very large VLDL and large VLDL particle concentra-
tion was respectively related to a 60%, 60% and 56% increased incidence of recurrent 
nonfatal or fatal ACS within one year post the index ACS. Notably, in the patients who 
developed recurrent ACS, the longitudinal particle concentrations of extremely large 
VLDL, very large VLDL and large VLDL increased steadily prior to recurrent ACS. 
Hence, repeatedly measuring these concentrations might provide relevant prognostic 
information in patients with IHD.
Lowering LDL cholesterol in patients with IHD effectively reduces their risk for 
recurrent CV events. The American and European guidelines recommend striving for 
LDL levels below 1.8 mmol/l in high-risk patients with CVD.25, 26 However, so far the 
within-subject variability of LDL had been mainly studied in healthy individuals. Results 
of our analyses of within-subject variability in 157 statin-treated post-ACS patients, 
as presented in chapter twelve, showed a reference change value (RCV) for LDL of 
32.7%. This RCV implies that a statin-treated patient with a habitual LDL level of 1.8 
mmol/l may have clinical measurements that range between 1.2 mmol/l and 2.4 mmol/l 
that can be well explained by natural and analytical variation. As these variations may 
lead to inappropriate cholesterol treatment adjustments, the intra-subject variability of 
LDL should be considered while adjusting treatment in clinical practice.  
Finally, in chapter thirteen we systematically assessed the current available lit-
erature on the relationship between serum level of oxidized LDL antibodies and CAD. 
Five out of five cross-sectional studies that studied the association between level of 
immunoglobulin (Ig) M anti-oxidized LDL and degree of CAD as measured in patients 
undergoing clinically indicated CAG, showed that IgM is inversely associated with 
imaged degree of CAD.  In addition, IgM anti-oxidized LDL also appeared inversely as-
sociated with the incidence of long-term CV events in patients without objectified CAD, 
as found in three of the six studies that assessed this association. No associations 
were found in the two studies conducted in patients with objectified CAD. With regard 
to IgG anti-oxidized LDL, inconclusive results were described in the current literature 
and study methods varied greatly. We concluded that IgM anti-oxidized LDL may be of 
interest for identifying high-risk IHD patients.
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Conclusions
Part I of this thesis has showed that, in patients with established IHD, in particular 
coronary atherosclerotic plaque burden carries prognostic value for the incidence of 
recurrent CV events. Noteworthy, we showed that the atherosclerotic burden of one 
single non-culprit coronary artery segment reflects the burden of the complete coronary 
tree, and that IVUS and NIRS imaging of this segment may be used for long-term 
prognostication in IHD patients. Our finding that plaque morphology (i.e. the presence 
of vulnerable plaques at baseline) was unrelated to the incidence of future CV events 
may be (partly) explained by the fact that coronary plaque vulnerability is a dynamic 
progress. Probably, plaque vulnerability aggravates or stabilizes in the presence or 
absence of widespread inflammation. Lastly, we found that SSII may be used for prog-
nostication purposes in CAD patients irrespective of CAD complexity.
In part II of this dissertation, we have found several biomarkers, including ST2, 
GDF15 and the larger VLDL-P’s, that were associated with recurrent CV events in 
IHD patients and we showed that repeated measurements of these markers may carry 
incremental information for prognostication. However, contrary to our expectations we 
have not identified biomarkers that show a sudden increase prior to recurrent CV 
events. Hence, so far, we have not found biomarkers that may be used to monitor IHD 
patients and identify high-risk episodes for CV events. Ultimately, enhancing a more 
precision-based, personalised approach to prognostication in patients with IHD and 
their clinical care still has many challenges. Although the concept of patient monitoring 
using biomarkers appears promising, it remains to be established if this concept may 
actually manifest in clinical practice.
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Onderwerp van dit proefschrift is de identificatie van patiënten met hart- en vaatziekten, 
in het bijzonder patiënten met een ischemische hartziekte, die een verhoogd risico 
hebben op herhaling van een klinisch voorval, zoals bijvoorbeeld een acuut coronair 
syndroom (ACS). Binnen het eerste jaar na een ziekenhuisopname vanwege een 
ischemische hartziekte, is de kans op overlijden ten gevolge van een terugkerende 
cardiovasculaire (CV) voorval 9%. Wij stelden dat een meer precieze, patiëntgebonden 
benadering van het ziekteverloop in deze patiënten het doen van een risicovoorspel-
ling, en waar mogelijk uiteindelijk secundaire preventie, zou kunnen verbeteren.  
Beeldvorming van coronaire atherosclerose bij patiënten met is-
chemische hartziekte 
Aan de hand van invasieve beeldvormingsmodaliteiten zoals coronaire angiografie 
(CAG), intravasculaire echografie (IVUS) en nabij-infrarood spectroscopie (NIRS), 
hebben wij de verdeling van coronaire atherosclerose en de morfologie van coronaire 
laesies bestudeerd en hebben we hun relatie met een ongunstige klinische lange-
termijnprognose onderzocht bij patiënten na een ziekenhuisopname wegens ACS of 
stabiele angina pectoris (SAP). 
De SYNTAX-score is een op CAG-gebaseerde risicoscore ter kwantificatie van de 
complexiteit van coronairlijden, waarin zowel luminale stenoses als andere factoren 
die de ernst van coronairlijden weerspiegelen, zoals laesielengte en –spreiding, wordt 
meegenomen. De SYNTAX-score is beperkt tot coronaire luminografie en kan daarom 
op zichzelf de morfologie van laesies niet kwalificeren. In hoofdstuk twee onderzochten 
we 680 ACS/SAP patiënten en vonden een verband tussen de complexiteit van het co-
ronairlijden van een patiënt, zoals gekwantificeerd met de SYNTAX-score (op basis van 
alle drie de coronairarteriën) en met verschillende laesieparameters gemeten middels 
IVUS en NIRS, verkregen uit een enkel non-culprit coronairsegment. De SYNTAX-score 
correleerde goed, in het bijzonder met IVUS-gemeten fibrous en fibro-fatty weefsel en 
NIRS-gemeten lipid burden. We vonden geen associatie tussen de SYNTAX-score 
en de aanwezigheid van thin-cap fibroatheroma (TCFA). Een belangrijke secundaire 
bevinding was dat beeldvorming van een enkel coronairsegment afdoende zou kunnen 
zijn voor een adequate beoordeling van de ernst van het coronairlijden van een patiënt. 
De SYNTAX-score kan gebruikt worden voor het voorspellen van klinische CV 
voorvallen tot vijf jaar na een percutane interventie (PCI) of bypass operatie (CABG). 
De prognostische waarde van IVUS- en NIRS-gemeten parameters was tot nu toe 
echter alleen bekend tot één jaar na ziekenhuisopname. Derhalve hebben we van 
zowel IVUS- als van NIRS-gemeten parameters, verkregen uit een non-culprit coronair 
segment, de lange termijn prognostische waarde onderzocht. Bij de 275 patiënten die 
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NIRS-beeldvorming ondergingen op baseline, zoals beschreven in hoofdstuk drie, 
was elke toename van 100 eenheden lipid core burden index (in een coronairsegment 
van 4 mm lengte) gerelateerd aan een 19% toename in incidentie van klinische CV 
voorvallen binnen vier jaar. Bij de 581 patiënten die IVUS-beeldvorming ondergingen, 
zoals beschreven in hoofdstuk vier, vonden we dat zij met een laesie van een mini-
maal lumen oppervlak ≤ 4.0 mm2 op baseline, een verhoogde kans op klinische CV 
voorvallen hadden van 49%. Daarbij was elke toename van 10 eenheden in plaque 
burden geassocieerd met een 26% toename in incidentie van klinische CV voorvallen 
binnen vierenhalf jaar. Zoals al gesuggereerd in hoofdstuk twee, bleken dus vooral de 
uitgebreidheid van een coronaire laesie als ook de lipid burden belangrijke voorspel-
lende factoren voor een ongunstige prognose, en in mindere mate de morfologie van 
een laesie. Verder bevestigden we dat beeldvorming van een enkel coronairsegment 
afdoende zou kunnen zijn om uitspraken te doen over de prognose van een ACS/SAP 
patiënt. 
Ten slotte hebben we in hoofdstuk vijf de prognostische waarde van de SYNTAX-
score II (SSII) op de lange termijn bestudeerd. De SSII is een risicoscore die is 
opgebouwd uit zowel de anatomische SYNTAX-score als ook klinische variabelen 
waaronder leeftijd, geslacht, creatinineklaring, linkerventrikelejectiefractie, het hebben 
van perifeer vaatlijden, chronische obstructieve longziekte en hoofdstamlijden. De 
SSII was eerder al gevalideerd voor het voorspellen van mortaliteit in patiënten met 
drievatslijden. Echter, of de SSII ook kon worden toegepast in een meer heterogene 
populatie, zoals bij patiënten met eenvats- of tweevatslijden, was onbekend. Daarom 
onderzochten wij de prognostische waarde van de SS2 in 628 patiënten met één- of 
tweevatslijden die een PCI ondergingen vanwege ACS of SAP. In onze studie vonden 
we dat elke punt toename in SSII correspondeerde met een verhoogd mortaliteitsrisico 
van 10% binnen vierenhalf jaar. De C-index van de SSII was 0.77, wat kan worden 
geclassificeerd als goed. De SSII kan dus worden toegepast voor het voorspellen van 
het risico op overlijden binnen vijf jaar na een PCI, ongeacht de uitgebreidheid van het 
coronairlijden.
De rol van bloedbiomarkers bij patiënten met coronairlijden 
Het meten van biomarkers in het bloed van patiënten met coronairlijden zou een non-
invasieve manier kunnen zijn om het proces van coronairlijden per patiënt nauwkeurig 
te volgen over de tijd. Momenteel zijn er verschillende biomarkers geïdentificeerd 
die mogelijk geassocieerd zijn met de ernst van coronairlijden en met een verhoogd 
risico op het ontwikkelen van klinische CV voorvallen. De bestaande studies richten 
zich echter vooral op de voorspellende waarde van een eenmalige biomarkermeting, 
bijvoorbeeld gemeten tijdens een ziekenhuisopname op baseline. Bij deze studieopzet 
wordt er geen rekening gehouden met het dynamische karakter van coronairlijden en 
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blijft het onbekend hoe een biomarker zich gedraagt gedurende ziektebeloop. Wij stel-
den dat dergelijke informatie nodig is om te onderzoeken of een biomarker, eventueel 
in een multi-marker setting, gebruikt zou kunnen worden voor identificatie en monitoring 
van hoog-risico patiënten met coronairlijden. Daarom bestudeerden we in hoofdstuk 
zes de temporele patronen van Myeloperoxidase en Galectin-3  in 187 patiënten die 
een ACS hebben doorgemaakt voorafgaand aan een tweede klinische CV gebeurtenis 
gedurende een jaar follow-up. Myeloperoxidase en Galectin-3 zijn twee biomarkers 
die eerder zijn geassocieerd met de kwetsbaarheid van coronaire laesies. Met behulp 
van herhaalde bloedmetingen, hebben we de evolutie van beide biomarkers over de 
tijd, zowel vlak na een ACS als in aanloop naar een volgend ACS in kaart kunnen 
brengen. We vonden dat Myeloperoxidase een piek vertoonde van 78.3ng/ml op het 
moment van ziekenhuisopname en vervolgens afnam en stabiliseerde binnen zeven 
dagen na opname. Vervolgens bleef Myeloperoxidase stabiel op een waarde van 25.6 
ng/ml (IQR: 20.4-32,0) gedurende de complete follow-up. Bovendien, werd er geen 
toename in Myeloperoxidase gezien voorafgaand aan een recidiverende klinische CV 
gebeurtenis. Galectin-3 liet gedurende de complete follow-up een stabiele waarde zien 
van gemiddeld 0.23 (0.17-0.30) ng/ml. Ten slotte vonden we dat de longitudinale waar-
des van Myeloperoxidase en Galectin-3 niet geassocieerd waren met recidiverende 
klinische CV gebeurtenissen. 
In hoofdstuk zeven onderzochten we het temporele patroon van Circulating Growth 
differentiation Factor-15 (GDF-15) bij 111 patiënten opgenomen wegens een ACS. GDF-
15 is een inflammatoire biomarker die wordt uitgescheiden in het hart tijdens overbelas-
ting van de hartspier en welke in eerdere studies van prognostische waarde bleek te zijn 
in patiënten na een ACS. GDF-15 was gedurende het jaar follow-up systematisch hoger 
bij patiënten die recidiverende CV gebeurtenissen ontwikkelden (eindpuntpatiënten), 
dan in degenen die dat niet deden. 30 Dagen na de baseline ACS ziekenhuisopname, 
hadden eindpuntpatiënten GDF-15 waardes die gemiddeld 333 (95% CI 68-647) pg/
ml hoger waren dan in controlepatiënten (1704 versus 1371 pg/ml). Er was een grote 
variabiliteit in GDF-15waardes tussen de patiënten (82% in eindpuntpatiënten en 84% 
in controlepatiënten), daarentegen was de variabiliteit in GDF-15 waardes binnen pati-
enten laag (18% in eindpuntpatiënten en 16% in controlepatiënten). Wij concludeerden 
dat GDF-15 gebruikt zou kunnen worden voor risicovoorspellingen bij patiënten die een 
ACS hebben doorgemaakt, waarbij het gebruik van individuele referentiewaardes de 
voorkeur zouden hebben.
Hoofdstuk acht beschreef het temporele patroon van soluble Suppression of Tu-
morigenicity-2 (sST2) gedurende één jaar bij 187 patiënten na opname wegens een 
ACS. sST2 is een biomarker voor toenemende overbelasting van myocyten en eerder 
onderzoek heeft aangetoond dat het hebben van hogere sST2 waardes geassocieerd 
is met een slechte prognose in patiënten met ischemische hartziekte. Door middel van 
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herhaalde metingen vonden wij een verband tussen het langdurig hebben van hogere 
sST2 waardes na een ACS en recidiverende CV gebeurtenissen. Een toename van één 
standaardafwijking in sST2 waarde correleerde in onze studie met een risicotoename 
van 64% op het krijgen van een recidiverende klinische CV gebeurtenis. Verder zagen 
we dat de waardes per patiënt weinig verschilden over de tijd, waaruit we concludeer-
den dat een beperkt aantal metingen per patiënt voldoende zou kunnen zijn voor het 
voorspellen van een prognose. 
Naast bovengenoemde biomarkers die al eerder geïdentificeerd waren als moge-
lijke markers voor CV voorvallen in patiënten met ischemische hartziekte, hebben we 
ook een breed scala aan onbekende eiwit biomarkers geanalyseerd in patiënten die 
opgenomen waren wegens een ACS. De immunoassay van Olink Proteomics werd 
gebruikt om waardes van deze onbekende eiwit biomarkers te verkrijgen, welke werden 
uitgedrukt in een arbitraire eenheid op de log2-schaal (Normalised Protein eXpression 
[NPX]). In hoofdstuk negen beschreven we bij 131 patiënten na ACS opname de 
temporele patronen van 25 eiwitten die de mitogen-activated protein kinase (MAPK) 
cascade stimuleren. De MAPK-cascade is een intracellulaire cascade die gemoduleerd 
kan worden door bloedbiomarkers om intracellulaire processen in gang te zetten, 
zoals celgroei, -differentiatie of -apoptose. Eerdere studies hebben aangetoond dat 
de MAPK-cascade een rol speelt bij vasculaire laesievorming, myocytpathologie door 
overbelasting en herstenose na stenting. Wij vonden dat de serumwaarde van angio-
poietin-1 (ANG-1), proteinase-activated receptor 1 (PAR-1) en bone morphogenetic 
protein 6 (BMP-6) hoger was in de patiënten die binnen 30 dagen na ziekenhuisopname 
wegens ACS een tweede CV voorval doormaakten. Na deze 30 dagen was geen van de 
25 eiwitten significant verhoogd in de eindpuntpatiënten. In deze zelfde patiëntengroep 
van 131 patiënten beschreven we in hoofdstuk tien 29 immunologische en inflamma-
toire eiwitten en vonden dat de serumwaardes van C-X-C motif chemokine 1 (CXCL1), 
slam-family member 5 (CD84) en tumor necrosis factor receptor superfamily member 
10a (TNFRSF10A) ook hoger waren in de patiënten die een recidiverende CV gebeur-
tenis doormaakten binnen 30 dagen na een ziekenhuisopname wegens ACS, maar 
dit was niet het geval na deze 30 dagen. Verder liet geen van de onderzochte eiwitten 
beschreven in hoofdstuk negen of tien een geleidelijke of plotselinge toename in 
serumwaarde zien voorafgaand aan een recidiverend klinisch CV voorval.
Hoofdstuk elf focuste wederom op het verkennen van nieuwe markers, echter dit-
maal door het herhaald meten van (lipide) metabolieten in 158 patiënten na ziekenhuis-
opname wegens ACS. Voor deze analyses maakten we gebruik van geautomatiseerde 
proton NMR-spectroscopie om per serummonster tegelijkertijd 151 metabolieten te 
kwantificeren. Elke toename in standaardafwijking in de partikelconcentraties van 
extremely large very low density lipoprotein (VLDL), very large VLDL and large VLDL 
was respectievelijk gerelateerd aan een 60%, 60% en 56% verhoogde incidentie in 
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recidiverende CV gebeurtenissen binnen een jaar na ziekenhuisopname wegens ACS. 
Bovendien zagen we dat in de eindpuntpatiënten de partikelconcentraties van extre-
mely large VLDL, very large VLDL en large VLDL geleidelijk toenamen voorafgaand aan 
een CV gebeurtenis. Het herhaaldelijk meten van deze VLDL partikelconcentraties in 
patiënten na een opname wegens ACS zou dus relevante informatie kunnen opleveren 
voor risicovoorspellingen in deze patiënten.
Het verlagen van LDL-cholesterol in patiënten met ischemische hartziekte vermin-
dert het risico op recidiverende klinische CV voorvallen. Amerikaanse en Europese 
richtlijnen raden aan om LDL-waardes in hoogrisicopatiënten met hart- en vaatziekten 
onder de 1.8 mmol/L te houden. Tot nu toe hebben eerdere studies alleen de variabiliteit 
in LDL waardes bestudeerd in gezonde patiënten. De resultaten van onze analyse 
uitgevoerd bij 157 patiënten die na een ACS behandeld werden met statines, zoals 
beschreven in hoofdstuk twaalf, toonden een reference change value (RCV) voor 
LDL van 32.7%. Deze RCV impliceert dat een patiënt met een LDL waarde van 1.8 
mmol/l tijdens klinische metingen kan variëren tussen 1.2 mmol/l en 2.4 mmol/l door 
natuurlijke en analytische variatie. Omdat deze variatie, indien onbekend, zou kunnen 
leiden tot het onjuist aanpassen van de cholesterolbehandeling van een patiënt, moet 
de intra-individuele variabiliteit in LDL in acht worden genomen bij het doorvoeren van 
veranderingen in de cholesterolbehandeling van een patiënt die behandeld wordt met 
statines.
Tot slot hebben we in hoofdstuk dertien systematisch de huidige beschikbare litera-
tuur in kaart gebracht wat betreft de relatie tussen serumwaardes van geoxideerde 
LDL-antilichamen en coronairlijden. Vijf van de vijf cross-sectionele studies die de 
associatie tussen het niveau van immunoglobuline (Ig) M-anti-geoxideerd LDL en 
de mate van coronairlijden onderzochten in patiënten die een klinische CAG onder-
gingen, vonden dat IgM omgekeerd evenredig geassocieerd was met de ernst van 
coronairlijden zoals gekwantificeerd tijdens CAG. Hiernaast leek IgM-anti-geoxideerd 
LDL ook omgekeerd evenredig geassocieerd te zijn met de incidentie van klinische CV 
gebeurtenissen in patiënten zonder CV voorgeschiedenis, zoals beschreven werd in 
drie van de zes studies die deze associatie onderzochten. In de twee studies die deze 
associatie bestudeerden in patiënten met reeds bestaande ischemische hartziekte wer-
den geen associaties gevonden. Wat betreft IgG-anti-geoxideerd LDL zijn er tot dusver 
tegenstrijdige bevindingen beschreven in de literatuur waarbij er ook een sterke variatie 
werd gezien in de gebruikte studiemethoden. We concludeerden dan ook dat alleen 
IgM-anti-geoxideerd LDL geschikt zou kunnen zijn voor het identificeren van patiënten 
met een verhoogd risico op een toekomstig CV gebeurtenis. 
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Conclusies 
Deel I van dit proefschrift toonde aan dat in patiënten met ischemische hartziekte voor-
namelijk de coronaire plaque burden belangrijk is voor het voorspellen van toekomstige 
klinische CV gebeurtenissen. Daarnaast hebben we aangetoond dat de plaque burden 
van een enkel non-culprit coronairsegment afdoende zou kunnen zijn om de ernst van 
het totale coronairlijden van een patiënt in te schatten. IVUS- en NIRS-beeldvorming 
van dit segment kan gebruikt worden voor het doen van lange termijn risicovoorspellin-
gen in patiënten met ischemische hartziekte. Onze bevinding dat laesiemorfologie (dat 
wil zeggen de aanwezigheid van kwetsbare laesies tijdens een ACS) niet gerelateerd 
is aan de incidentie van toekomstige klinische CV gebeurtenissen kan (gedeeltelijk) 
worden verklaard door het feit dat kwetsbare laesies dynamisch van aard zijn en kun-
nen stabiliseren over de tijd. Waarschijnlijk neemt de kwetsbaarheid van laesies toe of 
stabiliseren deze juist in de aan- of afwezigheid van algehele (cardiale) inflammatie. 
Ten slotte hebben we geconstateerd dat SSII kan worden gebruikt voor prognosedoel-
einden in patiënten met coronairlijden, ongeacht een- twee- of drievatslijden. 
In deel II van dit proefschrift hebben we verschillende biomarkers onderzocht, 
waaronder ST2, GDF15 en de grotere VLDL partikels, die geassocieerd zijn met re-
cidiverende klinische CV voorvallen in patiënten na een ACS opname. We toonden 
aan dat het herhaald meten van deze biomarkers mogelijk van toegevoegde waarde 
kan zijn voor het doen van risicovoorspellingen. In tegenstelling tot onze verwachting, 
hebben we geen (nieuwe) biomarkers gevonden die een plotselinge stijging lieten zien 
voorafgaand aan een recidiverende CV gebeurtenis. Met ons huidige onderzoek heb-
ben we nog geen biomarkers kunnen identificeren die geschikt zouden kunnen zijn 
voor het monitoren van patiënten na een ACS opname en die gebruikt zouden kunnen 
worden voor het herkennen van risicovollere periodes. Uiteindelijk kent het ontwikkelen 
van een meer precieze, patiëntgebonden prognose als ook de behandeling van deze 
patiëntengroep door middel van biomarkers nog steeds vele uitdagingen. Hoewel het 
concept van biomarkergeleide monitoring van patiënten veelbelovend klinkt, zal nog 
moeten blijken of dit concept zich daadwerkelijk kan realiseren in de klinische praktijk.
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jaren ontzettend leerzaam geweest, waarvoor dank!
Dr. K.M. Akkerhuis en dr. I. Kardys, mijn co-promotoren. Beste Martijn, ik weet nog 
goed hoe jij mij in ons eerste gesprek aan de koffietafel enthousiasmeerde voor het 
SYNTAX-project. Naast jouw klinische inzicht, zijn jouw oog voor detail en gevoel voor 
taal van grote betekenis geweest voor het tot stand komen van de hoofdstukken in 
dit proefschrift. Beste Isabella, als tweede co-promotor was je altijd bereid om mee te 
denken over vraagstukken wanneer dit nodig was. Jouw kritische blik op manuscripten 
is absoluut van toegevoegde waarde geweest. Ik dank jullie beiden voor alle inbreng 
en fijne samenwerking!
Uiteraard wil ik ook prof.dr. Jaap W. Deckers, prof.dr. Steven A.J. Chamuleau, dr. 
Maryam Kavousi, prof.dr. Jolien W. Roos-Wesselink, prof.dr. Gert-Jan Kleinrensink en 
dr. Jolanda J. Wentzel bedanken voor hun bereidheid om  zitting te nemen in mijn 
kleine en grote commissie en voor de tijd die zij hebben genomen om mijn proefschrift 
te beoordelen.
Verder wil ik alle co-auteurs bedanken voor hun bijdrage. In het bijzonder bedank ik 
Jurgen Ligthart die mij op weg heeft geholpen met de SYNTAX score en dr. Rohit 
Oemrawsingh voor het meedenken bij verschillende projecten.  
Hiernaast bedank ik natuurlijk alle onderzoekscollega’s die de afgelopen jaren heb-
ben gezorgd voor een leerzame en vooral ook leuke onderzoekstijd. Graag begin ik 
met de KLEP-groep: Victor, ondanks alle verhuizingen was je van begin tot eind mijn 
kamergenoot. Bedankt voor de fijne samenwerking en je vriendschap. Ik zal nu echt 
proberen te onthouden dat ‘al…dan’ geen bestaande zinsconstructie is in het Ned-
erlands... Anne-Sophie, door jou heb ik de muziek uit de 80s (her)ontdekt, het was 
de ideale achtergrondmuziek voor dit proefschrift! Je bent nu net begonnen aan je 
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geneeskundeavontuur in Groningen, ik wens je veel succes. Milos, it was such an hon-
our to be your paranymph together with Elke. I am sure you are going to achieve your 
American goals. Basically, bedankt en tot ziens! Nermina, bedankt voor de spontane 
vocale intermezzo’s achter de computer! Ik wens je alle goeds in Denemarken. Sara, 
jij weet echt alles, zowel op onderzoeksgebied als daarbuiten. Mocht ik ooit meedoen 
aan een spelshow, dan weet ik je te vinden! Jan-Kees, de man van de Cox-regressie, 
naast de nodige humor was jouw nuchterheid altijd verfrissend. Cordula, je was bijna 
klaar toen ik begon, maar zeker niet minder aanwezig bij de KLEP-activiteiten. Bedankt 
voor de gezelligheid! Sharda, jij zorgde ervoor dat we in het z-gebouw nooit verlegen 
zaten om koffie! Laurie, ik beloofde je een hele alinea in mijn dankwoord, maar tot mijn 
spijt paste deze net niet in de finale versie. Echt zonde, het was een prachtige alinea… 
Marie, Marlou, Michelle, Muhammed en Nathalie jullie mogen nog even! Heel veel suc-
ces de komende tijd.  Ook noem ik alle andere onderzoekcollega’s van de cardiologie 
die voor gezelligheid zorgden op congressen, skireizen, borrels en barbecues: Allard, 
Carlijn, Fay, Jaap, Lennart, Lucia, Lida, Lidia, Nikki, Rafi, Ro, Savine, Vivan en iedereen 
die ik nu nog vergeet: bedankt! 
Alle studievrienden waarmee ik vele niet-onbelangrijke koffiepauzes heb gehouden 
tijdens het onderzoeken, ik kijk uit naar jullie promoties! 
Jaarclub Vief, Huyze Gusto en mijn hockeyteam, ook jullie waren onmisbaar in het 
proces. Ik heb jullie interesse en gezelligheid ontzettend gewaardeerd, jullie waren en 
zijn altijd een fantastische afleiding!
Davine, bedankt voor het ontwerpen van de cover van mijn boekje. Ik vond het geweldig 
dat ik jou als oud-huisgenootje kon betrekken bij dit project. 
Anna, vanaf de eerste dag in Rotterdam was je erbij: samen roeiend bij Skadi, in de 
collegebanken, als clubgenoot bij Laurentius en als teamgenoot bij Leonidas. Ik lijk 
maar niet van je af te komen... Super dat je nu als paranimf naast me staat!
Elke, ook mijn paranimf, halverwege mijn onderzoekstijd voegde jij je bij de KLEP-groep 
en je was al snel niet meer weg te denken. Ik ken oprecht niemand die zo georganiseerd 
is als jij. Ik verdenk je ervan zelfs je post-its te archiveren... Je was er zowel om mee te 
sparren als om mee te lachen! 
Jinne, volgens mij sta ik bij je in het krijt... Ik lees jouw eerstvolgende paar motivati-
ebrieven wel na, oké?   
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Bibi en Fleur, mijn oudste en jongste zus, jullie inbreng is niet onder woorden te bren-
gen. Dank dat jullie er altijd zijn!
Pap, mam, opa en oma, het is af! Heel veel dank voor jullie interesse en de bemoedi-
gende woorden de afgelopen jaren. 
 
 
 
 
 
 
 
 
 
 
 
 
